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Abstract 
 
HER2 protein overexpression in breast cancer patients is a predictor of poor prognosis and 
resistance to therapies. Despite significant advances in the development of targeted therapies 
and improvements in the 5-year survival rate of metastatic HER2 positive breast cancer 
patients, new approaches are needed to better understand the disease at an early stage in 
order to identify means to inhibit its progression.  An inducible breast cancer transformation 
system allows examination of early molecular changes at high temporal resolution. Here, we 
show that HER2 overexpression to similar levels as those observed in a subtype of HER2 breast 
cancer patients is sufficient to induce transformation of MCF10A cells. We found that HER2 
activation generated gross morphological changes in 3D cell culture, increased anchorage-
independent growth of cells and altered the transcriptional programme of various genes 
associated with oncogenic transformation. Global phosphoproteomic analysis during early 
transformation uncovered numerous signalling changes associated with cancer upon HER2 
overexpression. Candidate pathways included chromatin regulators, in addition to known 
cascades such as MAPK, focal adhesion, mTOR, and HER signalling pathways. To understand 
the effect of kinase signalling on chromatin accessibility landscape, we performed ATAC-seq on 
acini isolated from 3D cell culture. This enables elucidation of HER2 induced signalling effects 
on chromatin architecture and its contribution to transformation at temporal resolution. 
Uniquely, we identify that HER2 overexpression promotes reprogramming-associated 
heterogeneity, with a subset of cells acquiring a stem-like phenotype, expressing breast stem 
and cancer stem cell markers, making them likely targets for malignant transformation. Our 
preliminary data show that this population of cells, which counterintuitively enriches for 
relatively low HER2 protein abundance, possesses transformational drive, resulting in 
increased anchorage-independent growth in vitro compared to cells not enriching for stem 
markers. Our data provide a discovery platform for signalling to chromatin pathways in HER2-
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driven cancers, offering an opportunity for biomarker discovery and identification of novel 
drug targets. 
  
6 
 
List of Figures 
 
Figure 1.1: A simplified outline of HER signalling network. 
Figure 1.2: Schematic of EMT programme. 
Figure 1.3: HER2 protein over expression in various malignancies.  
Figure 1.4: Kaplan-Meier curves depicting disease-free survival (DFS) 
Figure 1.5: Schematic of tetracycline (ON) inducible system. 
Figure 1.6: Simplified model of chromatin states. 
Figure 1.7: Cancer metastasis and Intra-tumoural heterogeneity. 
Figure 2.1: Plasmid construction 
Figure 3.1: Schematic of third generation lentiviral transduction. 
Figure 3.2: Generating a HER2 inducible MCF10A cell line using lentiviral transduction. 
Figure 3.3: Doxycycline induces HER2 over expression. 
Figure 3.4: HER2 over expression disrupts normal MCF10A morphology. 
Figure 3.5: Inhibition of HER2 and its signalling. 
Figure 3.6: HER2-associated migration and invasion. 
Figure 3.7: HER2 induces MCF10A cell anchorage-independent growth. 
Figure 4.1: Detection ERK and AKT activation upon HER2 protein over expression. 
Figure 4.2: Transcriptional effects of HER2 over expression. 
Figure 4.3: Schematic of experimental outline and phospho-proteome dataset overview. 
Figure 4.4: Quantification of protein phosphorylation. 
7 
 
Figure 4.5: An internal quality control (QC) for phospho-proteomic analysis. 
Figure 4.6: Volcano plot of showing the phospho-proteome of HER2 induced changes in 
MCF10A cells at 0.5 hours. 
Figure 4.7: Volcano plot of showing the phospho-proteome of HER2 induced changes in 
MCF10A cells at 4 hours. 
Figure 4.8: Volcano plot of showing the phospho-proteome of HER2 induced changes in 
MCF10A cells at 7 hours. 
Figure 4.9: Phospho-proteome identification. 
Figure 4.10: Signalling and biological function analysis of the early immediate changes in 
transformation. 
Figure 4.11. Time dependent phosphorylation events. 
Figure 4.12: Identification of transcription factors and chromatin regulators. 
Figure 4.13: Potential mechanism of HER2 induced transformation in MCF10A cells. 
Figure 5.1: ATAC-seq library profiles. 
Figure 5.2: Fragment size and evaluation of reproducibility. 
Figure 5.3: ATAC-seq quality metrics. 
Figure 5.4: Quantification of accessible chromatin. 
Figure 5.5: Visualising the peaks and associated genes. 
Figure 5.6: Profiling of chromatin accessibility at early time points upon HER2 over expression. 
Figure 6.1: Investigating the acquisition of stem-like phenotypic features. 
Figure 6.2: Determining the expression of stem markers. 
8 
 
Figure 6.3: Relative abundance of MUC1 protein expression. 
Figure 6.4: Relative abundance of EpCAM protein expression. 
Figure 6.5: Outline of flow cytometry strategy of identifying the MUC1/EpCAM/CD24 co-
expression in DOX +ve and DOX -ve cells. 
Figure 6.6: Identification of stemness based on HER2 biomarker heterogeneity. 
Figure 6.7: Enrichment of stem markers based on “intermediate” expression of HER2. 
Figure 6.8: Determining enrichment of stem cell markers in subpopulations of HER2 positive 
cells. 
Figure 6.9. Anchorage-independent growth of cells based on stem-like phenotype. 
Figure 6.10: Measuring transformational potential of cells based on stem-like phenotype. 
Figure 6.11: Investigating oncogene-induced senescence. 
Figure 6.12: ERK phosphorylation in cells expressing differential levels of HER2 protein. 
Figure 6.13: Morphology observed for the labelled cell populations grown in matrigel/collagen. 
  
9 
 
List of tables 
 
Table 2.1: Antibody list with name, dilution and source. 
Table 2.2: List of antibodies used for flow cytometry or flow sorting with source and dilutions. 
Table 2.3: Reagents and volume of the cDNA master mix to convert RNA to cDNA.  
Table 2.4: PCR conditions required cDNA synthesis. 
Table 2.5: List of forward and reverse primers used for RT-PCR. 
 
 
 
  
10 
 
Contents 
 
Statement of originality ................................................................................................................ 2 
Acknowledgments ......................................................................................................................... 3 
Abstract ......................................................................................................................................... 4 
List of Figures ................................................................................................................................ 6 
List of tables .................................................................................................................................. 9 
Acronyms .................................................................................................................................... 13 
Chapter 1 ..................................................................................................................................... 15 
1. Introduction .................................................................................................................... 15 
1.1 Neoplastic transformation ...................................................................................... 15 
1.2 HER2 in cancer ........................................................................................................ 25 
1.3 Chromatin and transcriptional regulation .................................................................... 32 
1.4 Tumour heterogeneity .................................................................................................. 39 
1.18 Reprogramming-associated heterogeneity in transformation ................................... 44 
1.19 Aims and Objectives: ................................................................................................... 46 
Chapter 2 ..................................................................................................................................... 47 
2. Materials and Methods ................................................................................................... 47 
2.1 Monolayer cell culture .................................................................................................. 47 
2.2 Lentiviral transduction and generation of HER2 inducible cell line .............................. 50 
2.3 Preparation of protein lysates ...................................................................................... 52 
2.4 BCA (Bicinchoninic Acid) Protein Assay......................................................................... 53 
2.5 SDS-PAGE ...................................................................................................................... 53 
2.6 Protein transfer and antibody incubation .................................................................... 54 
2.7 Detection of proteins .................................................................................................... 55 
2.9 Immunofluorescence .................................................................................................... 57 
2.9 Immunofluorescence of acini in 3D cell culture ........................................................... 57 
2.10 Transwell migration/invasion assay ............................................................................ 58 
2.11 Sample preparation for flow cytometry and flow sorting .......................................... 58 
2.12 qRT PCR ....................................................................................................................... 60 
2.13 ATAC-seq library preparation...................................................................................... 63 
2.14 Phosphoproteomic sample preparation ..................................................................... 65 
2.15 Image J quantification ................................................................................................. 67 
2.16 Bioinformatics analysis ............................................................................................... 68 
2.17 Statistics ...................................................................................................................... 70 
11 
 
Chapter 3 ..................................................................................................................................... 71 
Establishment and characterisation of HER2 inducible transformation model ..................... 71 
3.1 Introduction .................................................................................................................. 71 
3.2 Generation of HER2-MCF10A cell line using tetracycline inducible system ................. 71 
3.3 Dose and time dependent HER2 expression ................................................................. 75 
3.5 Effects of lapatinib and dox absence on HER2 expressing cells .................................... 81 
3.6 HER2 induces invasion of cells and activates associated pathway ............................... 84 
Chapter 4 ..................................................................................................................................... 92 
Investigating the dynamics of early signalling changes upon HER2 over expression ............. 92 
4.1 Introduction .................................................................................................................. 92 
4.2 Detection of downstream signalling events upon HER2 induction .............................. 93 
4.3 HER2 over expression increases expression of genes related to angiogenesis and 
adhesion mediators ............................................................................................................ 95 
4.4 Phospho-proteomic analysis of HER2 activation – an overview of experimental design
 ............................................................................................................................................ 97 
4.5 Overview of the phosphorylation changes upon HER2 activation ............................... 99 
4.6 HER2 induced time-dependent differentially regulated phosphorylation events ...... 101 
4.7 Multisite protein phosphorylation .............................................................................. 109 
4.8 Quantitative phospho-proteomic analysis of HER2 induced changes ........................ 112 
4.9 Time dependent changes upon HER2 over expression .............................................. 115 
4.10 Activation of chromatin regulators and transcription factors .................................. 117 
4.11 Discussion .................................................................................................................. 121 
Chapter 5 ................................................................................................................................... 124 
Assessing global chromatin accessibility alterations in HER2 induced transformation ....... 124 
5.1 Introduction ................................................................................................................ 124 
5.2 ATAC-seq library preparation – attacking the chromatin ........................................... 125 
5.3 Quality metrics and validation .................................................................................... 126 
5.4 Overview of chromatin accessibility landscape .......................................................... 131 
5.5 Discussion .................................................................................................................... 137 
Chapter 6 ................................................................................................................................... 140 
Investigating HER2 induced reprogramming associated heterogeneity .............................. 140 
6.1 Introduction ................................................................................................................ 140 
6.2 Identification of stem cell markers upon HER2 protein induction ................................. 141 
6.3 Characterising HER2 induced MCF10A cells for stemness .......................................... 146 
6.4 Cells enriched for breast stem cell markers are associated with increased colony 
formation in vitro .............................................................................................................. 159 
12 
 
6.5 Investigating oncogene-induced senescence ............................................................. 162 
6.6 Discussion .................................................................................................................... 168 
Chapter 7 ................................................................................................................................... 171 
Discussion.............................................................................................................................. 171 
7.1 MCF10A cells – controversial model for breast cancer progression .......................... 171 
7.2 Conditional oncogene expression – taking advantage of inducibility ........................ 172 
7.3 HER2 induced phenotypic alterations ......................................................................... 174 
7.4 The signalling dynamics – taking a global approach ................................................... 177 
7.5 Multiple layers of heterogeneity in breast cancer ...................................................... 181 
7.6 HER2 over expression – what does it mean in the context of patients? .................... 183 
References ................................................................................................................................ 186 
 
  
13 
 
Acronyms 
 
AKT/PKB  Protein kinase B 
ATAC-seq  Assay for transposase-accessible chromatin using sequencing 
BMP6   Bone Morphogenetic Protein 6 
BMPR2   Bone Morphogenetic Protein Receptor Type 2 
ECL   Enhanced chemiluminescence 
cDNA   Complementary DNA 
CRE   Cyclisation recombination 
DAPI   4′,6-diamidino-2-phenylindole 
DAVID   Functional Annotation Bioinformatics Microarray Analysis 
DCIS   Ductal carcinoma in-situ 
DMEM   Dulbecco's Modified Eagle Medium 
Dox   Doxycycline hyclate 
EMT   Epithelial to mesenchymal 
EF1α   Elongation factor 1-alpha promoter 
EGF   Epidermal growth factor  
EGFR/HER1  Epidermal growth factor receptor/ Human epidermal receptor 1 
ELK1   ETS Like-1 protein 
ERK   extracellular signal-regulated kinase 
FACS   Fluorescence-activated cell sorting 
FDR   False discovery rate 
FISH   Fluorescence in-situ hybridisation 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
GFP   Green fluorescent protein 
HER2   Human epidermal receptor 2 
14 
 
HRG   Heregulin 
IDC   Invasive ductal carcinoma 
IGV    Integrative Genomics Viewer 
IF   Immunofluorescence analysis 
IHC   Immunohistochemistry 
ILK   Integrin-linked kinase 
LOX   Lysyl oxidase 
LOXL2   Lysyl Oxidase Homolog 2 
MCF10A   Human normal immortalised mammary epithelial cell line 
NFkB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NRG   Neuregulin 
pINDUCER21  Inducible vector 
RT-PCR   Real-time polymerase chain reaction 
rtTA   Reverse transcription transactivator 
Tet-On   Tetracycline On system 
TGFα   Transforming growth factor alpha 
TiO₂   Titanium dioxide 
Tn5   Hyperactive transposase enzyme 
TRE   Tetracycline response element 
VEGFC   Vascular endothelial growth factor C 
3D   3-dimensational 
 
 
  
15 
 
Chapter 1 
1. Introduction 
 
1.1 Neoplastic transformation 
 
1.1.1 The process of transformation 
 
Transformation takes place when cells acquire the key hallmarks of cancer (1). These include; 
morphological changes, increased migration and invasion potential, anchorage-independent 
growth, foci formation, as well as differences in the genetic and epigenetic landscape between 
normal and transformed cells (2-4). One of the methods to achieve neoplastic transformation 
of cells is the introduction of cancer associated oncogenic lesion(s). Transformation of normal 
human cells has been achieved by a step wise process of immortalisation and then conversion 
of the immortalised cells to metastatic transformation (5). Studies have shown that 
transformation of normal rodent cells can be achieved by the activation of a single oncogene in 
immortalised rodent cell lines, as they have already undergone genetic and/or epigenetic 
changes (6, 7). However, primary rodent cells are transformed by the co-expression of two 
distinct co-operating oncogenes or in combination with mutation or inactivation of a tumour 
suppressor gene (8).  
Similar strategies have been used to convert normal primary human cells to tumourigenic 
state. It is suggested that three distinct oncogenic “hits” may be required, which lead to 
growth-regulating alterations to transform primary human cells (9). The foreskin fibroblasts 
(BJ), human mammary epithelial cells (HMECs) and human embryonic kidney cells (HEK) were 
transformed by genomic versions of H-Ras, hTERT and SV-40 LT genes (9-11). This suggests that 
there are fundamental differences for transformation in rodent versus human cells. An 
explanation has emerged that may elucidate such differences. The primary rodent cells are 
16 
 
easier to immortalise compared to the primary human cells (12). The latter rarely undergo 
spontaneous, immortalisation, whereas the rodent cells can be spontaneously immortalised, 
which indicates that the control of cellular lifespan between the two different cells is very 
different (13, 14). This change could partially be attributed to telomere biology. Unlike rodent 
cells, the human cells lack detectable telomerase activity and have relatively shorter 
telomeres, which erodes and triggers cellular senescence (15, 16). Interestingly, both inbred 
and wild type mice have telomerase activity, with wild type mice having shorter telomere 
length as similarly observed in humans, however, the growth characteristics between wild type 
and inbred animals are similar (17). However, it could be that inbred mice have a more 
“permissive” genetics, which make them more prone to immortalisation.  
The vast majority of the in vivo and in vitro transformation models have been able to study the 
events occurring between normal and already transformed cells. This has made it impossible 
to track the early aberrant events taking place during the process of transformation upon an 
oncogene induction. Many experimental models both in vivo and in vitro have implicated a 
variety of mechanisms involved in oncogene-mediated transformation, but a unified 
mechanistic system cannot yet be proposed, in part due the lack of understanding of the early 
events in oncogene mediated tumourigenesis. To overcome the challenge in characterising the 
earliest changes, such as those in the signalling network and chromatin dynamics during 
transformation upon oncogene induction, an inducible model could be utilised.  
1.1.2 Signalling by HER proteins 
 
The human epidermal receptor (HER) family of proteins belong to the type I transmembrane 
growth factor receptors that function to activate a rich network of intracellular signalling 
pathways in response to extracellular signals (18, 19). The HER family has four members that 
are structurally and functionally very similar; HER1 (EGFR, or ErbB1), HER2 (ErbB2 or neu), 
HER3 (ErbB3), and HER4 (ErbB4). Their structure consists of an extracellular ligand-binding 
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domain, a transmembrane domain and an intracellular tyrosine kinase domain. This group of 
receptors have individual features which include the ligand-deprived HER2 receptor and a 
kinase-inactive HER3 receptor (20). In mammalian cells, at least 12 ligands are known to induce 
dimerisation, with each ligand favouring a specific combination of receptor dimerisation in a 
specific hierarchical order. However, there is a marked preference of HER2 as a dimerising 
partner of the three other partners (21, 22). The HER2 heterodimer with HER3 generates the 
most potent intracellular signal compared to those originating from other combinations, 
because HER2 contains the strongest catalytic kinase activity (23). In addition, HER2 
heterodimers have slow ligand dissociation, prolonged firing, rapid recycling, slow endocytosis, 
slow ligand dissociation and internalisation (24). The HER proteins are normally widely 
expressed in numerous non-haematopoietic cells and are functionally important (25). The 
receptors are essential in tissue growth and development and knock out models have shown 
that they are critical for the development of organs such as lung, brain, gastrointestinal tract 
and skin (26-28).  
The extracellular binding domain of the receptors except HER2 can be in active (open) or 
inactive (closed) conformation. Upon ligand binding, the extracellular binding domain of the 
HER protein undergoes structural change to an active conformation, which promotes 
dimerisation of the receptors. This leads to auto-phosphorylation of the intracellular tyrosine 
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kinase domain, which initiates a plethora of downstream signalling pathways and cross talks 
with other signalling proteins, leading to the regulation of numerous cellular activities (29, 30).  
 
 
Figure 1.1: A simplified outline of HER signalling network. For simplicity only 5 ligands are shown out of 
the 12 that have been identified in mammalian cells. Number in each receptor circle or semi-circle 
indicate the respective receptor of the HER family. HER2 does not bind to any ligand hence a closed 
(circular) conformation, other HER receptors have an open conformation and the green blocks indicate 
the respective ligand that induces the dimerisation. HER3 has an inactive catalytic intracellular tyrosine 
kinase domain indicated by a cross. HER2-HER3 heterodimer is coloured in red because they generate 
the most potent signals. Signalling is transmitted to the adaptor proteins and enzymes, which activate a 
large network of signalling cascades of which only some of them are shown here. Signalling pathways 
19 
 
activate various transcription factors but at present time, their translation to a specific type of output is 
not fully understood.   
HER2 does not require a specific ligand as its extracellular binding domain is always in a 
constitutively open (active) conformation, unlike its family members (Figure 1.1). In normal 
cells with endogenous levels of HER2 expression, the activation of pathways carefully regulates 
normal cell growth, adhesion, survival, and differentiation and other biological processes as 
the dimerisation of receptors and the ensuing activation are temporary and spatially 
controlled. Furthermore, in normal cells the excess signalling induces apoptosis due to the 
presence of a wild type p53 and other tumour suppressor genes (31). Expectedly, p53 
inactivation is associated with HER2 induced tumours (32).  
1.1.3 Transformation potential of HER2 
 
The data supporting the ability of HER2 to transform human cells is compelling. HER2 protein 
over expression or gene amplification in breast epithelial cells has been shown to cause 
morphological alterations in the mammary acini and induce proliferation (33). HER2 over 
expression alone in NIH-3T3 cells is sufficient to transform cells in vitro and its over expression 
in invasive breast cancer cell line (MCF-7) is known to enhance tumourigenicity (34, 35).  The 
evidence showing the transformation potential of neu (nomenclature of HER2 for rodent 
counterparts) in rodents is also robust and rodent cells are simpler to transform compared to 
the human cells (36). Transgenic mice with active neu developed mammary adenocarcinomas 
in a step-wise progression and neu was sufficient to induce transformation (37). Wild type 
(WT) neu over expression in the basal layer of mouse epidermis allowed for proliferation and 
tumour formation as early as six weeks (38). Numerous other studies have shown the potent 
transforming potential of neu inducing malignant transformation in a variety of organs and 
model systems (39-45).  
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1.1.4 Transformation of MCF10A cell line 
 
To study the transformational events upon oncogene expression, the focus has historically 
been on the immortalised yet non-tumourigenic cell lines as a starting model. MCF10A cell 
line, the human mammary epithelial cells have been extensively used for this purpose. Forced 
ectopic over expression of constitutively active and inducible oncogenes such as Ha-Ras (46), 
HER1 (47), B-Raf (48), MYC (BHLH Transcription Factor) (49) NCT (Nicastrin) (50), RANK 
(Receptor activator of nuclear factor κ B) (51) and HER2 (3, 52) in the mammary epithelial cells 
produced many transformation associated phenotypic and transcriptional changes. These 
alterations include the morphological disruption in 3-dimensaional (3D) cell cultures and 
transcriptomic differences between the oncogene induced transformation relative to control 
cells (3). 
Furthermore, HER2 gene in breast cancer appears to hold the transformational potential 
through its amplification alone. Therefore, to investigate the effects of HER2 over expression in 
tumourigenesis, a cell line that contains either “low” or endogenous levels of HER2 would be 
an ideal starting model to appropriately quantify the impact of HER2 and changes that occur 
consequently. MCF10A cell line is thought to have very low levels of endogenous HER2. 
Moreover, since HER receptors work closely with each other the expression of HER2 family 
members are also of importance in breast cancer. MCF10A cells express “normal” levels of 
EGFR and very low endogenous levels of HER3 (53, 54). This is essential to understand the first 
steps of HER2 over expression to dissect its effects and to reliably attribute the changes to the 
HER2 levels alone without ambiguity from other factors.  
MCF10A cells expresses markers associated with basal/myoepithelial and luminal phenotype 
as is seen in the normal breast (55). When grown in 3D cell culture of matrigel and collagen 
mixture, MCF10A cells form a lumen as a result of apoptotic (e.g. anoikis) conditions in the 
centre of the acini (56, 57). This resembles the acini of the normal breast tissue with clustered 
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lobules, connecting the interlobular ductules with each other (58). This shows that overall 
MCF10A is a good initial model to study the transformational changes in the context of human 
mammary breast cancer, and analysis from this model could be further extended. 
1.1.5 Epithelial to mesenchymal transition in transformation 
 
Epithelial to mesenchymal transition (EMT) is a reversible cellular process that is known to 
have important roles in morphogenesis, wound healing, embryogenesis, development, tumour 
invasiveness and malignant transformation (59-61). During the EMT process, epithelial cells 
progressively lose their phenotype, which involves remodelling of the cell-extracellular matrix 
and cell-cell interactions. This results in the detachment of the epithelial cells from each other 
and the underlying base membrane, resulting in the activation of a new transcriptional 
programme that encourages the mesenchymal state (62). A widely studied phenotype of cells 
that have undergone EMT is the transformation of their normal compact – epithelial-cell-like 
morphology to a more elongated, spindle-like - mesenchymal morphology (63-65). Since EMT 
is a reversible process, mesenchymal cells can revert back to epithelial cells, known as the 
mesenchymal to epithelial transition (MET). 
Moreover, normal epithelial cells are held together by tight junctions, gap junctions, 
desmosomes and adherens junctions, which consist of cell surface epithelial cadherin (E-
cadherin) genes. This structure is critical for the integrity of epithelial cells. Upon EMT 
induction, the E-cadherins are downregulated alongside the repression and activation of other 
markers, leading to the arising of mesenchymal cells. This involves the breakdown of normal 
morphology of cells and acquisition of a more fibroblastic mesenchymal phenotype (60).  The 
malignant transformation of many different tumours is dependent on EMT activation (66, 67). 
In transformation, the consequences of EMT activation are the degradation of the underlying 
22 
 
basement membrane, disruption to cell-cell interactions and cell polarity, as well as the 
abnormal reorganisation of the extracellular matrix (68) (Figure 1.2).  
 
 
Figure 1.2: Schematic of EMT programme. Epithelial cells are held together by adherens junction, tight 
junctions, and are linked to the basement membrane by hemi-desmosomes. These cells express genes 
that are associated with the epithelial state and sustain polarity of cells (list of genes in light yellow box). 
The epithelial state has downregulation of molecules associated with mesenchymal state. EMT induction 
results in the expression of genes associated with mesenchymal state (listed in the orange box) and the 
concomitant down regulation of the epithelial genes. The alterations in gene expression in epithelial 
state leads to disruption of tight junctions, adherens junctions and the disassembly of cell-cell and cell-
basement membrane attachments. Epithelial cells progressively lose their features by the acquisition of 
intermediate stage and associated gene expression. In certain circumstances, full EMT features occur 
but cells rarely advance to complete mesenchymal state. EMT is a reversible programme, and cells can 
revert back by undergoing MET.   
In addition, prominent genes that are associated with the epithelial state, such as cytokeratin 
and E-cadherin are repressed, whilst at the same time, expression of genes that are linked to 
the mesenchymal state are activated. These include fibronectin, N-cadherin and vimentin (69).  
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Furthermore, in clinical setting, the protein markers that are associated with EMT activation 
could be used as specific indicators of high grade malignant transformation by pathologists 
(70). However, the transition from epithelial to mesenchymal state does not work as a binary 
switch and cancer cells do not always execute the complete EMT reprogramming to drive cells 
to an unequivocal mesenchymal state. The process appears to be more dynamic, and that is 
crucial for driving tumourigenesis, which contributes to full malignant transformation (62, 71).  
Likewise, in cancer progression it has been widely known that during early carcinomas, cells 
are in the epithelial-cell-like state, and as the transformation progresses, cells gradually gain 
more mesenchymal features. The EMT activation in cancer cells has been associated with 
higher resistance to several therapies (68). Additionally, in breast cancer cells, the EMT 
programme is known to associate with more cancer stem-like phenotype, which in turn has a 
higher transformational potential (72). 
1.1.6 Breast cancer progression – the role of HER2 over expression 
 
It has been documented that upregulated levels of HER2 expression can be detected in 
mammary tissues that show features of partial transformation, but are not yet completely 
transformed. Generally, HER2 is expressed at low levels or is absent in benign breast lesions 
(73, 74). For example, HER2 is almost undetectable in terminal ductal lobular units (TDLUs), 
and has been detected at very low levels (0-9%) in atypical ductal hyperplasia (ADH) (75).  In 
contrast, HER2 protein over expression and gene amplification are readily detected in the pre-
invasive stage, in ductal carcinoma in situ (DCIS), with approximately 70% of patients exhibiting 
HER2 over expression (76-78). The progression from low HER2 expression levels – or its 
absence – in the benign breast biopsies to high incidence of HER2 over expression in the pre-
invasive stage of the disease suggests that HER2 over expression is an early lesion in breast 
tumourigenesis. However, not all of the DCIS cases possess the ability to invade and 
metastasise, since about 20%-30% of the invasive breast cancers have HER2 over 
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expression/amplification. Thus, this points to the possibility of there being underlying 
differences causing some of the pre-invasive breast disease to either remain stable or progress 
to an invasive stage. It has been known that minor aberrations in HER2 over expressions cases 
are sufficient to induce transformation (79). Additional alterations alongside HER2 over 
expression may also play an important role in the progression of HER2 positive breast cancers 
from benign to invasive disease, such as associated abnormalities in p53 and E-cadherin genes 
(80, 81).    
On the other hand, there is evidence to suggest that HER2 over expression does not change 
between primary tumours and those that metastasise. For instance, there was no drastic 
change in HER2 expression between primary tumours and lymph node metastatic cases, as 
HER2 over expression was found in 55% of primary disease, but also in metastatic cases at the 
same incidence rate (82). Indeed, there are many studies that have shown very little to no 
difference in HER2 over expression status between primary tumours and the corresponding 
metastatic breast cancer stage (83-87). 
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1.2 HER2 in cancer 
 
1.2.1 HER2 over expression in cancer 
 
The data from the experimental models is well supported by a significant body of clinical data 
from patients. HER2 is over expressed in approximately 20-30% of breast and ovarian cancers 
and is correlated with worse prognosis (88, 89). In addition, over expression of HER2 is 
observed in lung, head and neck, endometrial, oesophageal and kidney cancers and is also 
associated with worse prognosis (90) (Figure 1.3). HER2 over expression is a significant and 
early event in breast tumourigenesis and its expression is sustained through the different 
stages of breast cancer, from early detection, to invasive disease, to node and finally distal 
metastasis (91, 92). However, despite HER2 being maintained throughout disease progression, 
its over expression in early stage defines a sub type of breast cancer (HER2 positive), 
notwithstanding its expression at later stages (92-95). 
 
Figure 1.3: HER2 protein over expression in various malignancies. HER2 gene amplification and protein 
over expression has been identified in many cancer types. Only a few different types of cancers are 
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selected here out of the many other HER2 over expressing cancers. HER2 over expression shown here is 
determined by IHC and/or FISH. 
Different studies have reported that within the same cancer type there is a wide range of 
variation/heterogeneity in the pattern of HER2 over expression, despite the same standardised 
fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) analysis being used 
for detection (96). The source(s) of variation in HER2 expression is not yet elucidated, it could 
however be the intra-laboratory techniques, or that this subtype of breast cancer is extremely 
heterogeneous. The effect of HER2 over expression in breast cancer is well characterised. 
However, the clinical behaviour of HER2 in patients displaying varying levels of heterogeneity 
require much additional study. The intra-heterogeneity of HER2 expression within the same 
patient requires additional investigation to dissect if different levels of HER2 expression have 
different transformation potential. 
1.2.2 HER2 positive breast cancer 
 
HER2 over expression is the result of HER2 gene amplification and/or increased transcription. 
The extent of HER2 over expression can be evaluated at mRNA level by Real-Time PCR (RT-PCR) 
and FISH, or by IHC to quantify the protein levels. Currently, breast cancer patients undergo 
testing to check for HER2 positivity but the ideal way to evaluate the HER2 positive status 
remains unclear and controversial, because there is no standardised criteria for assessing HER2 
as a prognostic marker (97). However, the guidelines have been updated in 2013 and more 
recently focused updated in 2018 by the American Society of Clinical Oncology (ASCO)/College 
of American Pathologists (CAP) (98, 99). The guidelines are based on HER2 gene and/or HER2 
protein assessment and recommend the use of FISH and IHC assays to inform diagnoses of 
HER2 positivity in breast cancer. The utility of RT-PCR to diagnose or serve as a substitute for 
either FISH or IHC remains unclear because of high rates of false negative results and 
insufficient evidence to support its use as it is not fully validated in diagnostic settings (100).  
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The extent of HER2 protein over expression is firstly diagnosed by IHC to grade the tumour. If 
the protein staining results in unequivocal 0 or 1+ grade, the cancer is considered HER2 
negative. If the results are unequivocal 3+ grade, the cancer is considered HER2 positive. If it is 
graded equivocal 2+, subsequent FISH analysis is used to determine the positivity of HER2 gene 
amplification (101). 
In a phase III clinical trial (CLEOPATRA), women who have higher HER2 mRNA or protein over 
expression corresponds to a higher magnitude of benefit from Trastuzumab (Herceptin) (102). 
However, this is not true in all clinical cases as Trastuzumab treatments of lower HER2 
expressing tumours are still associated with clinical benefit (103). This might account for the 
spatial heterogeneity and variation of HER2 expression which under appreciates the bona fide 
percentage of HER2 positivity in cells. 
1.2.3 Clinical evidence of anti-HER2 therapies 
 
Over the past 20 years, there have been significant advances in the therapeutic strategies 
employed for the treatment of HER2 positive breast cancer. The commonly recommended 
anti-HER2 therapies include trastuzumab, lapatinib, ado-trastuzumab emtansine (T-DM1), and 
pertuzumab (104). Trastuzumab was approved as a first-line treatment alongside paclitaxel for 
metastatic HER2 positive breast cancer after it was approved in 1998 (105). The benefit of 
trastuzumab in treating patients with metastatic disease has been well documented in clinical 
trials led by the North Central Cancer Treatment Group (NCCTG) and the National Surgical 
Adjuvant Breast and Bowel Project (NSABP). The results of the trials compared chemotherapy 
with or without trastuzumab. They found, after a follow up of two years, that there were 133 
events in the trastuzumab group compared to 261 events in the chemotherapy treated 
patients without trastuzumab. The percentages of patients alive in the trastuzumab treated 
group were 87.1% compared to 75.4% in the control group in the medial follow-up of two 
years. At four years, the percentage of patients alive with trastuzumab were 85.3%, compared 
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to 67.1% in the control group (106). Therefore, trastuzumab in combination with paclitaxel in 
adjuvant setting significantly improved patients’ disease-free survival (DFS) and overall survival 
(OS).  
Furthermore, lapatinib – which is known to target the intracellular tyrosine kinase domain of 
the HER2 receptor (107) – was shown to be effective in treating HER2 positive breast cancer 
tumours that were resistant to trastuzumab (108, 109). Several clinical trials have shown that 
the combination of lapatinib with trastuzumab had significantly better progression-free 
survival (PFS) than lapatinib treatment alone (110). The median survival for the combination 
treatment was 12 weeks compared to 8.1 weeks with lapatinib alone (111).  
 
Figure 1.4: Kaplan-Meier curves depicting disease-free survival (DFS) (A) and overall survival (OS) (B) of 
patient treated with chemotherapy alone (control) vs Trastuzumab and chemotherapy.  
1.2.4 Inducible transformation models in cancer 
 
To achieve dose-dependent, reversible and uniform temporal control of a gene of interest, an 
inducible system has obvious advantages in many experimental settings. Numerous inducible 
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systems have been developed to understand the function of specific lesions in different 
diseases. For instance, a mouse embryonic cell line called C3H/10T1/2 with ras oncogene 
under the transcriptional control of the inducible mouse metallothionein-I promoter induced 
by heavy meal (zinc) ions induced conditional and reversible transformation (112). In addition, 
it has been shown that mutations in the DNA methyltransferase (DNMT3a) using Cre-inducible 
(cyclisation recombination) system and nucleophosmin (NMP1) enhanced clonogenic potential 
and eventually induced transformation in experimental mice (113). Furthermore, a doxycycline 
(dox) inducible H-RAS V12G mutation induced in the melanocytes of mice resulted in them 
developing spontaneous melanomas that eventually regressed upon withdrawal of doxycycline 
(114). Inducible HER2 over expression in primary human mammary cells induced various 
tumourigenic alterations to the ductal bilayer observed in early breast tumorigenesis (115).  
The inducible models mentioned above and others provide advantages over conventional non-
inducible systems. Firstly, in some cases the expression of constitutively active gene could be 
toxic to the cells, therefore the ability to control the timing and levels of ectopically expressed 
transgenes is extremely valuable. Secondly, inducibility grants the ability to track and 
characterise the very early molecular changes that occur upon gene induction, which would be 
impossible to capture otherwise. Thirdly, the reversibility of gene expression and phenotype 
upon withdrawal of the inducing agent can be useful to investigate because once the stimulus 
is removed, an inducible gene returns to inactive, basal level.  
The inducible systems in published works have been valuable to show the combination of 
oncogenes required for transformation. However, in many cases they do not reflect the 
endogenous expression of oncogenes or the inactivation of tumour suppressor genes as 
presented clinically in patients. They are based on the forced ectopic expression of genes that 
are not normally seen in tumours. Therefore, there is a need for an inducible in vitro system to 
model transformation in a way that better reflects the early progression of HER2 breast 
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cancer, with endogenous levels of expression of oncogene(s) comparable to those observed in 
physiological conditions.   
1.2.5 Inducible transformational vectors 
 
1.2.5.1 Tetracycline inducible system 
 
Conditional gene expression tools that can control the induction and reversibility of a gene are 
essential tools in research with broad applications. The tetracycline inducible vector is a 
responsive and tightly regulated system that produces robust expression of a gene of interest 
in the target cells (116). There are two subtypes of tetracycline inducible system.  
Firstly the Tet-On, which is based on the reverse tetracycline controlled transactivator (rtTA). 
The rtTA consists of VP16 transactivation domain and the TetR repressor. The tetracycline 
response element (TRE), which is the inducible element (promoter) contains the Tet operator 
(TetO) sequence can bind the rtTA in the TRE of the target transgene in the presence of 
doxycycline (dox). Thus, the addition of dox regulates the expression of the gene of interest 
quantitatively and temporally (Figure 1.4). The Tet-Off system functions in the opposite 
manner, in the presence of dox, expression from the TRE is reduced, resulting in blocking of 
transcription (116, 117). 
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Figure 1.5: Schematic of tetracycline (ON) inducible system. In the presence of an inducing agent (dox), 
rtTA is bound by it, which binds to the TRE and induces the expression of HER2. Withdrawal of dox 
leaves the rtTA empty and therefore, transcription of HER2 is blocked.   
1.2.5.2 Cre-Lox Inducible technology 
 
Cre-Lox inducible model derived from the P1 bacteriophage is a specific and potent system for 
conditional control of gene expression. The inactivation of the allele is maintained by an 
inhibitory cassette called the lox-STOP-lox or LSL. The cre recombinase enzyme recognises the 
loxP sites (34bp recognition site), which results in the recombination reaction and the removal 
of one loxP site and the STOP cassette making the LSL cassette dysfunctional and thus permits 
the activation of a target gene (6, 118). 
These two inducible systems are the most widely used and reported in the literature out of the 
many other inducible models that exists. In our study, we have used the Tet-On system 
because it offers tight control of gene expression and is reversible upon dox withdrawal and as 
we require the activation of gene occasionally upon dox treatment, using the Tet-On system is 
the most appropriate model.  
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1.3 Chromatin and transcriptional regulation 
   
1.3.1 Mechanisms of transcriptional regulation 
 
1.3.1.1 The structure of chromatin 
 
In eukaryotic cells, the genomic DNA is not found naked but is bound by proteins which is 
tightly and efficiently packaged. The combination of the compacted proteins and DNA is 
known as chromatin. The canonical nucleosome, which is the repeating unit of chromatin, is 
formed by wrapping approximately 145-147 base pairs of DNA around the histone octamer 
(H2A, H2B, H3, H4  - two molecules of each histone) (119, 120). Nucleosomes are connected to 
each other by linker DNA to form nucleosomal arrays, also known as the beads-on-a-string 
structure (10 nm fibre), where each nucleosome is linearly and individually organised. Fibre-
fibre interactions can contribute to higher order conformations and cause chromatin to 
become condensed (121). This generates the secondary chromatin structure (a 30 nm fibre) 
and eventually produces the high-order chromatin known as the tertiary structure, which can 
compact the original DNA by an extraordinary 10,000-fold of its original length (122). 
The chromatin structure is dependent on environmental cues and stimuli, which can make 
chromatin highly accessible or inaccessible. Therefore, chromatin structure has a significant 
impact on transcriptional regulation. Chromatin is classified into two states: heterochromatin 
and euchromatin. Heterochromatin is highly compact and condensed (“inactive”) chromatin 
and covers approximately 96% of the mammalian genome. Euchromatin refers to 
decondensed or open (“active”) chromatin and comprises approximately 2-3% of the entire 
DNA sequence but captures over 90% of transcription factors (TFs) bound to it (123) (Figure 
1.5). There are ever increasing numbers of post-translational modifications (PTMs) that are 
being identified, alongside nucleosome-binding proteins, architectural chromatin proteins 
(ACPs) and ATP-hydrolysis dependent chromatin re-modellers (such as the SN1/SWF family re-
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modellers) impacting the conformation, and essentially the active and inactive states of 
chromatin at all levels. 
 
Figure 1.6: Simplified model of chromatin states. Majority of DNA is packaged into inactive (closed) 
chromatin marked by the repressive histone modifications and methylated CpG islands. Permissive 
chromatin is sufficiently dynamic to be modified by active histone modifications, which mediate 
remodelling and establishes an open chromatin state. The topological organisation of nucleosomes 
regulate chromatin accessibility through various distinct mechanisms such as altering the transcription 
factor binding to the DNA. The graph shows closed chromatin (blue) indicated by a lower peak, lower 
accessibility. Permissive chromatin (yellow), which is an intermediate stage has open chromatin with the 
nucleosomes arranged linearly and individually, shows an increase in chromatin accessibility. The open 
chromatin (green), is below sub-nucleosomal level and has a higher peak indicating chromatin is open 
and accessible.     
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1.3.2 Transcription by epigenetic regulation 
 
DNA methylation, catalysed by one of the DNA methyltransferases (DNMTs), is an epigenetic 
modification and has been associated with both activation and repression of genes (124). In 
cancer cells, some CpG islands in promoter sequences become highly methylated, resulting in 
transcriptional repression of tumour suppressor genes. The gene bodies are generally 
methylated in normal cells, and this pattern is reversed in cancer cells (125). Histone 
methyltransferases (HMTs) are specific enzymes catalysing the methylation of histone tails. 
The lysine methylation marks are both linked to activation and inactivation. For example, 
HEK9me3 and H3K27me3 are both repressive methylation marks (126). The H3K79me, 
K3K4me3 and HEK36me3 are associated with active transcription (127).  
Acetylation of histone residues is generally associated with transcriptional activation. The 
histone acetyl-transferases (HATs) are recruited to the histone tails to catalyse the addition of 
an acetyl group, which promotes transcription. The histone de-acetyl-transferases (HDACs) are 
repressors and reverse this modification (128). Several activatory acetylation marks include 
H4K16ac and H3K14ac (129, 130).  
Furthermore, the activity of kinases associated with intracellular signalling pathways have 
been linked to changes in gene expression. For instance, MAPK, c-Jun, and PKC can directly 
catalyse the phosphorylation of various histones and have been correlated with gene 
activation (131).  
1.3.2.1 Chromatin accessibility in cancer 
 
Recent technological developments have dramatically improved our ability to measure 
chromatin accessibility by decreasing the amount of biological material required to levels that 
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are clinically achievable. This has made it possible to catalogue chromatin architectural 
changes between normal and transformed cells (132, 133). The phenotypic changes observed 
in tumour progression would most likely require transcriptional and/or epigenetic changes 
that drive migration, invasion, and metastasis (134). At present time, it appears that there is 
no universal signature of chromatin accessibility of normal versus cancer cells. 
However, it has been shown that the over expression of a transcription factor known as Nfib 
(nuclear factor I B) is sufficient to globally alter the chromatin state (135). Nfib was shown to 
transform cells in vivo and induce widespread increase in the chromatin accessibility. In 
addition, there was a dramatic increase in the chromatin accessibility between primary 
tumours and metastatic cancer (135). Furthermore, SETD2 mutation was found to alter the 
chromatin organisation in primary human kidney tumours (97). It has been found that there 
was widespread decompaction of heterochromatin in actively transcribed genes of cancer cells 
compared to normal cells. These chromatin accessibility changes were associated with defects 
in RNA processing (136).  
Additionally, it is known that, as cells progress from an embryonic stem cell state to a more 
differentiated state, the proportion of accessible chromatin regions is reduced. In transformed 
cells, the accessible chromatin landscape, which is normally repressed in the developmental 
programme is re-activated. It has been shown that, whilst the chromatin accessible landscape 
of normal cells is clearly distinct, cancer chromatin accessible regions resemble those found in 
embryonic stem cells (132). Accessible regions in pancreatic, prostate and lung 
adenocarcinoma cells coincide with endodermal stage of development, whereas malignant 
melanoma and mammary ductal carcinoma open chromatin loci converge with ectodermal 
stage of development. Overall, the majority (88-97%) of the accessible chromatin regions 
found in tumourigenesis of 21 different cancer cell lines were also found in normal foetal and 
adult cells or tissues (132). Furthermore, ATAC-seq (Assay for Transposase-Accessible 
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Chromatin using sequencing) analysis of cutaneous T cell lymphoma (CTCL) displayed distinct 
open chromatin signatures as patient samples aligned very well with H3K27ac (active histone 
modification mark), showing that the detected regions of the DNA are accessible and open. 
They found that the sites that were highly accessible in normal cells were less accessible in 
cancer cells, indicating disease-specific signatures between normal and cancer cells (137).  
Interestingly, the acidosis-adapted colorectal cancer cell line (SW60-AA), showing enhanced 
invasion and metastasis in vivo, had 12,010 fewer ATAC-peaks, indicating a reduction in the 
overall accessibility compared to non-acidosis-adapted SW60 cell line (138). Furthermore, 
knockdown of ARID1A and ARID1B in colorectal carcinoma cells resulted in decreased ATAC-
chromatin accessibility at 112,623 sites (12.5%) but showed increase in chromatin accessibility 
at 5264 sites (5.2%). The effect of decreased accessibility by ARID1B was only possible when 
ARID1A was not present, as ARID1B knock down had no effect (139). Moreover, over 
expression of nuclear auto-antigenic sperm protein (NASP) induces in vitro transformation in 
hepatocellular carcinoma and forms tumours in vivo. NASP over expression is also known to 
decrease chromatin accessibility, as its knock down leads to enhanced chromatin accessibility 
and transcription (140).  
1.3.3 Signalling to chromatin 
 
Accessibility of DNA within chromatin is an important feature that impacts DNA-dependent 
functions such as replication, transcription and repair. The structure of chromatin can be 
locally and globally altered by interactions with architectural proteins such as High-Mobility 
Group (HMG) proteins that influences chromatin accessibility (141). The activation of MAPK 
signalling pathway by the addition of a stimulus such as EGF, propagates signalling from the 
cellular membrane through to the nucleus, resulting in histone tail modification and induction 
of transcription (142). The induction of MAPK pathway leads to the activation of nuclear 
kinases such MSK1 and MSK2 that phosphorylate histone H3 on serine 10 and serine 28. These 
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phosphorylation events are rapid, occurring within minutes of stimulation with factors such as 
UV irradiation, Anisomycin, and EGF. This leads to the activation of immediate-early genes (e.g. 
junB, c-myc, c-fos, junD, fosB) regulating chromatin accessibility (143).  
Furthermore, the phosphorylation and mutations in transcription factors such STAT5 and 
STAT3 can activate the JAK-STAT pathway. It is known that STAT3 acetylation by histone 
acetyltransferases can promote transcriptional activation as a result of chromatin remodelling 
(144). The silencing of the JAK-STAT pathway can globally affect the heterochromatin through 
the disruption of HP1 binding. This is especially important in differentiation, as the formation 
of heterochromatin leads to silencing of genes whose inactivation is required during 
differentiation (145, 146).     
1.3.4 Cellular hierarchy in the breast tissue 
 
Breast cancer is extremely heterogeneous and has been categorised into at least five different 
subclasses (147-149). These are luminal A, luminal B, basal, normal-like, and HER2 over 
expressing breast cancers. It has been widely recognised that the mammary compartment is 
made up of the inner luminal cells, which is covered by the outer layer of myoepithelial cells. 
Nevertheless, there is growing evidence which suggests that the mammary epithelium 
compartment exists as a cellular hierarchy spanning from stem cells, to biprogenitor cells, to 
the fully differentiated cells (150-152).  The mammary stem cells, also known as MaSCs, have 
the self-renewal ability and organise the development of the breast gland during embryonic 
development.  In the stem cell hierarchy model, stem and progenitor cells are of great interest, 
as they are possible targets for initial transformational events and cancer cells are generated 
from the stem cell population (153, 154).  
Evidence has shown the existence of breast cancer stem cells that express surface stem 
proteins, such as CD44 +ve and CD24 -ve phenotype, exhibit increased tumour formation 
ability compared to other breast cancer tumours (155). The markers of cancer stem cells in the 
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human mammary gland are inferred from in vitro assays, flow cytometry and 
xenotransplantation. Generally, existing data has shown that the MaSCs are enriched for CD44 
+ve, ALDH1 +ve, CD49F +ve, EpCAM -ve, and MUC1 -ve, with a more basal-like phenotype in 
the mammary compartment (154-156). The second most abundant cell type in the mammary 
epithelial hierarchy are the bipotent progenitors that have MUC1 -ve, EpCAM -ve and CD49F 
+ve phenotype, which are characterised as being more luminal-like. These cells can diverge 
into ductal epithelial cells or ductal myoepithelial cells, which enrich for the CD49 +ve or 
EpCAM -ve phenotype. 
It appears that there is no universal breast cancer stem cell set of markers, since combinations 
of different stem markers have been associated with different breast tumours. For example, 
the CD44 +ve, EpCAM +ve, CD24 -ve phenotype was found in more than 80% of tumours 
analysed in a study (155). Furthermore, mammospheres generated from CD44 +ve and CD24 -
ve cells resulted in tumours in immunodeficient mice (157). In other cases, the expression of 
ALDH1 protein is a predictor of poor outcome in patients, and its expression alongside CD44 
+ve and CD24 -ve phenotype is associated with heightened tumourigenicity (158, 159). 
  
39 
 
1.4 Tumour heterogeneity 
 
1.4.1 Intra- and inter- tumoural heterogeneity in cancer 
 
Intra-tumoural heterogeneity, which has long been recognised, refers to the existence of 
distinct cellular populations with specific phenotypic features/markers within a tumour (160, 
161). This phenomenon has been well-characterised in many different types of cancers 
including breast cancer (162), colorectal cancer (163), ovarian cancer (164, 165), brain cancer 
(166), and kidney cancer (167). Within cancers, variations can occur by multiple biological 
processes. These could be alterations in the genetic code or in the epigenome between single 
cells, or macroscopic heterogeneity involving changes in the morphology between regions of 
the same tumour. There is significant evidence of intra-tumoural heterogeneity shown in the 
early breast cancer, in ductal carcinoma in-situ (DCIS) stage of the disease (168). The evidence 
for heterogeneity is provided by traditional histopathology, biomarker expression (169), 
genetic signature (170) and non-genomic lesions such epigenomics (171), metabolomics (172, 
173), and transcriptomics (174, 175). The histopathological intra-tumoural heterogeneity in 
DCIS include mitotic features, chromatin rearrangements, nuclear size and nucleolar 
prominence (176-178). About 50% of DCIS cases exhibit multiple architectural characteristics 
such as concurrent cribriform and solid and micro-papillary features, concurrent cribriform and 
micro-papillary features, and concurrent cribriform and solid features and so on (179-182). 
Furthermore, most cases of DCIS present some degree of heterogeneity when evaluated for 
biomarker expression. Approximately 70% of DCIS cases are oestrogen receptor (ER) positive  
(183). Similarly, HER2 over expression is observed heterogeneously in DCIS, with clusters of 
spatially intense regions to adjacent unamplified regions (184). Other markers such as p16, 
COX-2, p53, and ki67 also exhibit heterogeneous expression (185-187).  
One of the mechanism for generating intra-tumoural heterogeneity is the presence of stem-
like phenotype in tumours (“stemness”) (188). It is known that a subset of stem cells within a 
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tumour can self-renew and differentiate into many other types of cells, each type having its 
own capabilities and phenotypes (189-191). As the process of differentiation takes place, 
tumours are organised into a hierarchy of distinct cell types, including tumourigenic cancer 
stem cells, which can give rise to intermediate progenitors and differentiated cells (189). 
Therefore, these cancer stem cells are a source of intra- and inter- heterogeneity as well as 
being drivers of tumour initiation (190).  
Other types of heterogeneity have also been described in cancer biology. The most well-known 
is inter-patient heterogeneity, which suggests that any two patients carrying the same sub-
type of tumour are not the same and will have distinct clinical behaviour before and/or after 
treatment. This could be due to a variety of factors such as differences in the epigenome, 
mutations that arise within the tumour of individual patients, germline alterations and the 
tumour microenvironment (192). The resulting metastasis from primary tumours can give rise 
to distinct cellular populations, which consequently gives rise to heterogeneity in metastases 
from the same subtype of tumour, known as inter-metastatic heterogeneity (192). Moreover, 
each heterogeneous metastatic cancer can independently evolve and acquire different genetic 
mutations and/or epigenetic changes, which results in intra-metastatic heterogeneity (192). 
The intertumour heterogeneity in early breast carcinoma is illustrated by disease stage based 
on imaging and physical examinations.  
1.4.2 How cancer heterogeneity arises 
 
Tumour heterogeneity can be the consequence of genetic and non-genetic sources. The latter 
include epigenetic alterations or concerted or stochastic biological and biochemical processes 
within each cell and heterogeneous cancer cell microenvironment (193, 194). The epigenetic 
factors can include upregulation of polycomb group proteins of transcriptional repressors such 
as EZH2 and BMI-1, which are associated with normal stem cell self-renewal. These can have 
heterogeneous expression levels in tumours and contribute to tumourigenesis (195). The 
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genetic causes include cancers that spontaneously arise through clonal evolution and acquire 
“driver” mutations, which impact the cancer cell survival and proliferation, alongside 
“passenger” events that are believed to be phenotypically repressed and do not grant the 
tumour a selective fitness advantage (196).  
One model for clonal evolution in cancer is that most cancers arise from a single previously 
normal cell, which gives it a sequential selective advantage over the adjacent normal cell 
triggering many other clonal expansions and the acquisition of driver aberrations, which will 
eventually outgrow and outcompete the normal cell in a typical Darwinian-like clonal 
evolution. This model does not suggest that a single mutation cannot affect other cells in the 
tissue, but suggests that the tumour results in linear steps and that the developing tumour 
evolves from the progeny of a single cell (197).  Nevertheless, evidence is increasingly showing 
that cancer populations have multiple separate subpopulations that have distinct genetic 
make-up, at different locations that co-exist within the same tumour, rather than being the 
consequence of a series of gradual intermediates (198) (Figure 1.6).  
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Figure 1.7: Cancer metastasis and Intra-tumoural heterogeneity. Primary cancers comprises many 
distinct types of sub clones which may be subjected to a variety of selection pressures such as 
chemotherapy. Under such type of selection pressures, sub clones (green) that are sensitive to therapies 
are diminished as a result of therapy. Sub clones (red) with de novo resistance outgrow and dominate 
the tumour mass, contributing to cancer progression. Other sub clones (yellow) may also emerge as the 
tumour acquires secondary mutations, which could potentially lead to cancer metastasis.   
 
1.4.3 Evidence of heterogeneity in HER2 positive breast cancer 
 
HER2 positive breast cancers exhibit cell to cell, temporal, and spatial heterogeneity both at 
inter- and intra-tumoural levels, as has been acknowledged for some time. The heterogeneous 
nature of this cancer might explain why it remains a challenging task to treat it, despite having 
well established treatments such as Trastuzumab and Lapatinib. The HER2 protein staining and 
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gene amplification can be highly heterogeneous (199, 200), and can ultimately impact disease-
free survival (DFS) (201). Some cases of HER2 positive cancers can have gene amplifications by 
FISH without protein over expression, or protein over expression by IHC without gene 
amplification, or substantial intra-tumoural heterogeneity (202). The amplification of HER2 
gene in a single location of a tumour is sufficient to categorise a tumour as HER2 amplified. 
This maximises patient eligibility for personalised medicine without consideration of clinical 
implications of intra-tumoural heterogeneity (203). Heterogeneous expression of other 
markers in HER2 positive cancer has been noted and these include HER1 (EGFR)  (204), c-myc 
(205), p53 (199), PCNA (Proliferating cell nuclear antigen) (206), and cyclin D1 amongst other 
proteins (205). Epigenetic silencing of RASSF1A (Ras Association Domain Family Member 1) 
(207) and p16 (208) has also been recorded. 
Interestingly, the borderline equivocal (2+) cases of HER2 positive cancers tend to have a 
higher HER2 biomarker heterogeneity than the unequivocal (3+ or 0/1+) cases, which tend to 
have a more homogenous HER2 expression. This is clinically relevant to Trastuzumab response, 
as the unequivocal cases respond better to Trastuzumab therapy compared to the borderline 
cases, indicating challenges to overcome HER2 biomarker variations (209). 
Various stem cell markers have been proposed to identify cancer stem cells in HER2 positive 
breast cancer patients. Breast cancer stem cells express cell surface markers in vitro such as 
high levels of CD44, ALDH1, and low levels of CD24 (210, 211). High expression of CD44 and 
low expression of CD24 are also associated with EMT. The expression of stem like markers is a 
possible mechanism of Trastuzumab resistance (212). HER2 interaction with other signalling 
pathways is involved in the regulation of cancer stem cells through the Wnt, PI3 kinase, and 
AKT signalling pathways (213). For example, in HER2 positive breast cancers, HER2 has been 
shown to interact with CXCR1, and the blockade of CXCR1 leads to apoptosis of CSCs via the 
FAK/AKT/FOXO3A axis (214, 215). 
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1.18 Reprogramming-associated heterogeneity in transformation 
 
The acquisition of stem like phenotype has been associated with human neoplastic 
transformation. It has been shown that DU145 prostate cancer cells were activated by 
heregulin growth factor (HGF) through Notch signalling, which induces a molecular signature 
associated with stem cells. This consists of upregulation of CD49f, CD49b, SOX9, and CD44 and 
downregulation of CD24 (216). Furthermore, loss of the transcription factor ETS is known to 
determine EMT and transformation in prostate epithelial cells. The knockdown of ETS also 
increased several genes associated with stem-like phenotype, which include NANOG, POU5F1, 
STAT3, and BMI-1 (217). In U251 glioma cells, tumour-like characteristics such as migration, 
invasion and proliferation were enhanced by exosome induction. This was also associated with 
the upregulation of markers associated with “stemness” such as Nestin and CD133 (218). 
Moreover, Scaffidi et al have shown that fibroblasts transformed by stable ectopic expression 
of H-Ras-V12, h-TERT, and SV40 LT and Small ST antigens exhibited differential expression of a 
stem marker known as stage-specific embryonic antigen (SSEA-1) in approximately 1% of 
transformed cells, but which was absent in the control cells (219).  
During oncogene-induced transformation, cells reprogramme from a differentiated state to a 
more primitive, stem-like state that has high degree of plasticity, which gives the cells the 
ability to self-renew and differentiate into multiple lineages. It is interesting to note that 
various genes implicated in normal reprogramming from stem cell stage to differentiation are 
also involved in transformation, such as SOX2 in breast cancer (220), and the expression of 
KLF4 in human gastrointestinal cancer (221). This indicates that normal reprogramming and 
transformation occur through similar pathways/processes. 
Furthermore, cancer by and large arises due the combination of genetic aberrations and 
epigenetic lesions that induces growth advantage in afflicted cells (222). It has been shown 
that histone modifications, DNA methylation, and chromatin remodelling can have a profound 
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influence in cellular transformation (223). Chromatin becomes condensed as differentiation 
proceeds, this process is reversed by cellular reprogramming. Cellular reprogramming involves 
local and genome-wide changes to the chromatin architecture as cells enter into a state of 
plasticity during reprograming. The chromatin of embryonic stem cells (ESCs) is open and 
accessible, which is reflected in the elevated activity of transcriptional programme as it is 
associated with enrichment of active histone marks such as H3K14ac, H3K9ac, H3K36me, 
H3K4me3, and H3K36me2 (224). Pioneering work by Yamanaka showed that differentiated 
cells can be reprogrammed back to more primitive or ‘induced’ pluripotent cells (iPS) by the 
addition of four transcription factors; SOX2, KLF4, OCT4, and c-Myc (225). During the transition 
to iPS, transcription factor mediated chromatin activation and associated transcriptional 
dynamics occur rapidly and early as is shown by the increase levels of euchromatin mark, 
H3K4me2 (226). Transformation gives rise to distinct cell types establishing subclones with 
heterogeneous genetic profile that has an epigenetic hierarchy, which may include aberrant 
chromatin state and DNA methylation changes (227). Cellular reprogramming involves the 
acquisition of epigenetic changes similar to those observed in cellular transformation such as 
promoter-specific DNA hyper-methylation and the inactivation of DNA methyltransferase 
enzymes (227).   
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1.19 Aims and Objectives: 
 
Cancer cells display profound rearrangements of the signalling and epigenetic landscape but 
how such changes unfold is not fully understood. A limited number of studies have focused on 
the very early transformational events in transition from normal to cancer cells but rarely in 
the context of the chromatin. More specifically, how re-wiring of the signalling events can 
impact the epigenetic landscape, which can pave the way to fully transformed cells is not yet 
elucidated. To understand this, we used a relatively simple experimental in vitro system to 
characterise the events that enable emergence of transformed cells. The aims of the project 
were to: 
• Establish and characterise the HER2 inducible transformation in breast epithelial cells 
(MCF10A cell line). 
• Investigate the dynamics of global early signalling changes upon HER2 over expression. 
• Assess the genome-wide chromatin accessibility alterations in HER2 induced 
transformation. 
• Investigate HER2 induced reprogramming-associated heterogeneity. 
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Chapter 2 
 
2. Materials and Methods 
 
2.1 Monolayer cell culture 
 
MCF10A cells were examined using a light microscope at 4X or 10X magnifications, and were 
passaged before they could reach 70% confluency. These cells were plated in either a 6-well 
plate, T25 cm², or a T75 cm² flask depending on the experimental setting. To split the cells, 
medium was aspirated, and cells were washed using phosphate-buffered saline (PBS) (1X) 
(GIBCO #14190-094). Cells were then incubated for 15 minutes with Trypsin-
ethylenediaminetetraacetic acid (EDTA) (GIBCO #R-001-100) at 37 °C. Flask or plates were then 
gently tapped to detach adhering cells attached to the plastic, and trypsin was immediately 
inactivated using full growth medium. Cell suspension was gently pipetted upon and down to 
create single cell suspension and remove any formed clumps and directly added to a 15 mL 
falcon tubes. Cells were then centrifuged at 1200 RMP for 3 minutes at room temperature. The 
supernatants were discarded and cells were resuspended in fresh growth medium. Cells were 
then seeded into an appropriate new flask depending on the experimental requirements. The 
flask/plate was gently swirled in a figure of 8 to distribute the cell content evenly in the plate. 
MCF10A cell medium consists of Dulbecco’s Modified Eagle’s Medium (DMEM/F12) (SIGMA 
#D8347) supplemented with 5% Horse Serum (SIGMA #H1138), 0.5 µg/mL Hydrocortisone 
(SIGMA #H0888), 20 ng/mL Epidermal Growth Factor (EGF) (SIGMA #E4127), 100 ng/mL 
Cholera Toxin (SIGMA #C8052), 10 µg/mL Insulin (SIGMA #i9278) and 1X Pen/Strep. To induce 
the overexpression of HER2, 1 µg/mL of Doxycycline (SIGMA #DN891) was added to the media.  
HEK293T cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (SIGMA#D5796) 
in 10% foetal bovine serum (FBS) with 1X Pen/Strep. Cells were cultured in appropriate sized 
48 
 
sterile cell culture flask/plate depending on the experimental requirements. To detach cells from 
the flask/plate, cells were flashed with full growth media to remove any adherent cells attached 
to the plastic. 
2.1.1 Freezing 
 
Cells were cultured as above (see section 2.1) and centrifuged to obtain a cell pellet. The cell 
pellet was resuspended in full fresh growth medium containing 10% dimethyl sulfoxide (DMSO) 
(FISHER CHEMICAL #D/412/PB08), and aliquoted in 1 mL in cryovials and transferred to a Mr. 
Frosty freezing containers and stored in a -80 °C freezer for 24 hours. Cells were then transferred 
to liquid nitrogen for long term storage. 
2.1.2 Thawing 
 
Cells were retrieved from the liquid nitrogen in dry ice to prevent defrosting prematurely. The 
cryovial containing cells were placed in the 37 °C water bath for approximately 2-3 minutes. Cells 
were immediately transferred to a 15ml falcon tube containing 5ml full growth medium and 
resuspended. Cells were centrifuged at 1200 RPM for 3 minutes at room temperature. The 
supernatants were removed and cells were resuspended in 1ml of full growth medium, and 
plated in an appropriate cell culture dish. 
2.1.3 Cell counting 
 
To count a specific number of cells, a haemocytometer (BRIGHT LINE #520188) or automated 
cell counting device such as the Luna cell counter (LOGOBIO #L20001). For counting with 
haemocytometer 10 µL cells were resuspended in 90 µL of 0.4% trypan blue solution (GIBCO 
#15250-061) in a 96-well plate and added to the counting chamber to be counted under a light 
microscope (LIFE TECHNOLOGIES, EVOS XL CORE) using 10X magnification. For the Luna cell 
counter, 10 µL of cells were mixed with 10 µL of trypan blue and added to the counting slide 
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(LUNA #10182907) and inserted into the instrument, to quantify cell number. Readings were 
generally taken twice and averaged to get the correct number of cells. 
2.1.4 3D cell culture 
 
Matrigel (CORNING #356230) was thawed on ice at 4 °C overnight and aliquoted into 2 mL 
eppendorf tubes followed by freezing at -20 °C until required. Pipette tips were kept in -20 °C 
for 30 minutes and then used to prevent matrigel from solidifying whilst pipetting. To neutralise 
the acidic pH of collagen type I (CORNING #11563550) , it was required to add 62.5 µL of 10X 
PBS (THERMOFISHER # 70011044) and 62.5 µL of 0.1M NaOH (SIGMA ALDRICH #43617) to 500 
µL of collagen. This helped neutralise the pH and allow cells to proliferate in the medium. To 
prepare one 8-well chamber slide 300 µL of matrigel and 200 µL of collagen mixture is required. 
They are both mixed whilst on ice to prevent it from solidifying and is pipetted up and down 
gently until a homogenous mixture is formed. 42 µL of this mixture is added to the centre of the 
well and a 10 µL pipette tip is used to spread the mixture evenly to create a layer of the mixture 
covering the entire well, without overspreading to the edges. The chamber is then placed in the 
incubator for 30-45 minutes to solidify. Meanwhile, cells are trypsinised and counted using a 
haemocytometer (see section 2.1.3). Cell mixture is resuspended thoroughly to avoid cell 
clamping and to make a single cell suspension before plating on to the wells.  A cell suspension 
of 10,000 cells per mL was made and in each well 400 µL cell suspension containing 4000 cells 
was plated. 2% of matrigel mixture is added to the 400 µL cell suspension and carefully added 
to the wells by pipetting evenly into the well. Cells are re-fed with the 2% matrigel containing 
medium the next day and then medium is replaced as normal thereafter, until experimental 
endpoint.  
  
50 
 
2.2 Lentiviral transduction and generation of HER2 inducible cell line 
 
HEK293T cells were used for the production of lentiviral particles due to their high transfectibilty. 
HEK293T cells were plated in a 6-well plate in full growth media until they were approximately 
90% confluent the next day. For transfections, jetPRIME transfection reagent (POLYPLUS #114-
15). The following plasmids were prepared: 5 µg of the HER2 (ADDGENE #23888) plasmid, which 
was sub-cloned into pINDUCER21 (ADDGENE #46948) plasmid as described in (116), 1.75µg 
pMD2.G (ADDGENE #12259) [envelope plasmid], and 3.25µg of pCMV delta R8.2 (ADDGENE 
#12263) [packaging plasmid]. The appropriate amount of jetPRIME buffer was added to the 
plasmid DNA and a ratio of 1:2 of DNA to jetPRIME reagent was used, briefly vortexed and 
incubated for 10 minutes at room temperature. The transfection mix was then added to the cells 
in a 6-well plate and incubated for 24 hours at 37 °C. The next day, lentiviral particles were 
harvested from HEK293T cells by collecting the media from cells and transferring it to a 15 mL 
falcon tube and centrifuging it for 1 hour, at 1500 RPM at 4 °C. The freshly produced lentiviral 
particles were added to the MCF10A cells to infect them, which were approximately 30% 
confluent, for an additional 48 hours. 
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2.2.1 Plasmid maps 
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Figure 2.1. Plasmid construction. (A) The HER2 plasmid containing WT human HER2 sequence was 
cloned into the (B) inducible vector (pINDUCER21) plasmid to construct an inducible HER2 plasmid. The 
inducible plasmid map shows GFP gene which was used to select for HER2 positive cells. (C) plasmid 
map for the non-inducible GFP vector. 
 
2.3 Preparation of protein lysates 
 
Cells were seeded in a 6-well plate in full growth medium before protein analysis. For 
identification of phosphoproteins cells were seeded in serum starved medium (without horse 
serum and EGF) overnight. The following day, medium was removed and cells were stimulated 
with full medium for a desired time point depending on the experimental requirement. For the 
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analysis of total proteins, medium was removed and cells were washed with PBS. Cell lysis 
buffer, 200µl of either NP40 (ABCAM #142227) or RIPA buffer (THERMOFISHER #89900) 
containing complete cocktail of the protease inhibitors (SIGMA #P38340) or phosphatase 
inhibitors (SIGMA #P8340) when probing for phosphorylated proteins were added onto the cells. 
Cells were scraped off using a cell scraper and added to a 1 mL labelled eppendorf tubes on ice, 
for 30 minutes, with occasional vortexing for 5 seconds every 10 minutes in between. The 
suspension was then centrifuged at 4 °C, for 10 minutes at 10,000 g. The supernatant containing 
the protein was transferred to newly labelled eppendorf tubes and kept on ice until BCA assay 
(THERMOFISHER #23225). 
2.4 BCA (Bicinchoninic Acid) Protein Assay 
 
A BCA assay was used to determine the protein concentration of samples. In a 96-well plate, 200 
µL of BCA reagent A and BCA reagent B (ratio 50:1) was added followed by the BCA protein 
standards and each sample in duplicates. The absorbance of each well was quantified using a 
plate reader (DYNEX TECHNOLOGIES OPSYS MR #CG34328) at an excitation of 562 nm. The plate 
reader automatically generates a standard curve and an equation using linear regression, whilst 
also giving us the concentrations of proteins in µg/µL. The required, but equal amount of protein 
(in concentration and in volume – equalised by adding some lysis buffer) was added to new 1 
mL eppendorf tubes with the sample buffer (INVTROGEN #2020067) to a final concentration 1X 
and proteins denatured by placing the samples in a heat block (EPPENDORF THERMOSTAT PLUS) 
at 95 °C for 5 minutes. 
2.5 SDS-PAGE 
 
Proteins samples were resolved using 4-10% Bis-Tris mini gels (THERMOFISHER #NP0301). The 
tank was filled with 1X MOPS running buffer (THERMOFISHER # NP000102), and equal amounts 
of protein were loaded in wells ,alongside a colour pre-stained protein ladder (NEW ENGLAND 
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BIO-LABS #P7712). The gel was run at 70V for the first 20 minutes and then at 150V for another 
50-60 minutes making sure the proteins have resolved to a sufficient degree, or until the blue 
down has reached the bottom of the running tank. 
 
2.6 Protein transfer and antibody incubation 
 
After successful running of the gel, proteins were transferred to a PVDF membrane (IMMOBILON 
#IPVH15150) by either wet transfer or semi-dry transfer (TRANSFER STACKS #AB401002) using 
i-Blot. For the wet transfer, 1 litre of 1X transfer buffer (THERMOFISHER #NP0006) containing 
20% methanol and milli-Q water. The gel was removed from the tank and a transfer ‘sandwich’ 
was made. This was done by placing a sponge, followed by filter paper, and the gel. The PVDF 
membrane was activated by placing it in methanol for 1 minute and placed on top of the gel. 
This was followed by placing another filter paper and a sponge, the cassette was closed and 
placed in the chamber, in the transfer tank. A cold pack was placed in the side of the tank and 
the tank was filled to the top with the transfer buffer. The tank was placed at 4 °C overnight and 
20V was applied to allow the negatively charged proteins to transfer to the membrane.  
For the semi-dry transfer, gels were carefully removed from the plastic cassette and placed onto 
the “bottom” transfer stack so that the gel is facing the PVDF membrane.  A filtered paper was 
paced on the back of the gel following by placing the “top” transfer stack. For smaller proteins 
ranging from 20-50 kDa, the transfer time was set up to 6 minutes, for larger proteins 
(approximately 180 kDa), transfer time was increased to 11 minutes.  
This was followed by incubation of the PVDF membrane in 5% semi-skimmed milk (SIGMA 
ALDRICH 70166) for blocking to avoid non-specific antibody binding, for 1 hour at room 
temperature. Membranes were cut to size and appropriate antibody (see table 2.1) was added 
in 5 mL of BSA solution and incubated overnight at 4 °C, with gentle rocking or rolling in a 50 mL 
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falcon tube. Membranes were washed 3 times, 15 minutes each in 0.5% PBS-Tween (SIGMA 
ALDRICH P1379) followed by the incubation of the appropriate, species-specific secondary (see 
table 2.1) antibody diluted in 5 mL of BSA solution for 1 hour, at room temperature, gently rolling 
in a 50 mL falcon tube.  
2.7 Detection of proteins 
 
A 1:1 mixture of SuperSignal™ West Pico PLUS Chemiluminescent Substrate (THERMOFISHER 
#34580) was added to a 15 mL falcon tube and briefly vortexed. An appropriate volume (usually 
1 mL) of the mixture was added to the membrane making sure that the entire membrane is 
covered and incubated at room temperature for 3-5 minutes. ECL was removed and the 
membrane was placed in a clear plastic film and exposed using Chemidoc (AMERSHAM IMAGER 
600 #56930330) for an appropriate length of time. 
Protein Antibody Source Dilution 
HER2 HER2/ERBB2 Rabbit mAb CELLSIGNALLING #2165 1:5000 
pAKT Phospho-AKT (Ser473) CELLSIGNALLING #9271 1:5000 
tAKT total AKT CELLSIGNALLING #9272 1:5000 
GAPDH GAPDH CELLSIGNALLING #2118 1:2500 
Alpha-Tubulin Anti-alpha tubulin 
antibody (DM1A) 
ABCAM #7291 1:5000 
p53 p53 (7F5) Rabbit mAb 
#2527 
CELLSIGNALLING #2527 1:1000 
Anti-rabbit 
secondary 
GE HEALTH CARE LIFE 
SCIENCES  
Amersham ECL Rabbit IgG, 
HRP-linked whole Ab #NA934 
1:5000 
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p21 p21 Waf1/Cip1 (12D1) 
Rabbit mAb 
CELLSIGNALLING #2947 1:1000 
p27 p27 Kip1 (D69C12) XP® 
Rabbit mAb 
CELLSIGNALLING #3836 1:1000 
ACTIN (dye) Rhodamine Phalloidin THERMOFISHER # R415 1:200 to 
1:500 
Table 2.1: Antibody list with name, dilution and source. 
 2.8 Soft agar colony formation assay 
The ultra-pure culture grade agarose (THERMOFISHER #16500500) were first diluted down to 
1% in PBS and placed in a microwave to melt the agarose and then autoclaved. Soft agar assays 
were performed in either 12 well tissue culture plates or 24 well plates. Firstly, 0.8% of ultra-
pure agarose layer (mixed with an appropriate medium) was made at the base of the wells and 
allowed to settle for 30 minutes at room temperature. Secondly, 10,000 cells for 12-well plates 
or 5000 cells for 24-well plates were mixed with 0.3% agarose and plated evenly, drop-wise, on 
top of the base layer and incubated for 21 days, with medium changed every 2 days. This was 
performed with three technical triplicates. After 21 days, medium was aspirated and cells 
washed with PBS. Colonies were fixed using 4% formaldehyde (PFA) at room temperature for 
20-30 minutes. PFA was removed and colonies were washed with PBS and permeabalised by 
adding 100% methanol for 2 minutes at room temperature. Methanol was removed and 
colonies were washed by PBS. Colonies were stained by adding 0.05% of crystal violet dye 
diluted in PBS for 1 hour at room temperature. Crystal violet was removed and added to a 15 
mL falcon tube to be used again. Colonies were washed with PBS, 3 times to make sure no dye 
remains. Images were taken of nearly the entire well using a dissecting microscope. Images 
were then quantified using imageJ. 
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2.9 Immunofluorescence 
 
Autoclaved glass coverslips were placed in a 12-well tissue culture plates and appropriate 
number of cells seeded on the coverslips one day before immunofluorescence assay. The 
following day, media was removed and cells were washed with PBS 3 times, and an immuno-
pen was used to draw a barrier around the glass cover to prevent spill over of buffers and 
antibodies. Cells were fixed by 4% PFA at room temperature, for 15 minutes and then washed 
in PBS 3 times. Cells were blocked in blocking solution (2% FBS/PBS) for 1 hour at room 
temperature. The blocking solution was removed, and appropriate antibodies were added 
onto the cells for 1 hour at room temperature. The antibodies were removed, and coverslips 
washed by PBS 3 times, 5 minutes each. The appropriate secondary antibodies were added to 
the cells for 1 hour at room temperature in the dark. Cells were washed 3 times in PBS 5 
minutes each. A drop of mounting media either Glass anti-fade reagent (INVITROGEN 
#B36982) was added to the coverslips and were inverted into the glass sides and allowed to 
settle in dark for 30 minutes at room temperature. Excess mounting media was removed using 
tissue and a nail varnish was used to draw around coverslips to make sure they stay unmoved. 
Cells were imaged using the fluorescence microscope.  
2.9 Immunofluorescence of acini in 3D cell culture  
 
Media was aspirated from each well of the chamber and wells are washed with PBS carefully 
not to detach the layer of matrigel from the wells. Acini were fixed with 4% PFA for 30 minutes 
at room temperature. PFA was removed and acini washed with PBS 1 time.  Acini were 
permeabalised with 0.5% Triton-X for 10 minutes at room temperature. Acini are then blocked 
in 10% goat serum in PBS-Tween, for 1 hour at room temperature. Acini are stained with 
Phalloidin dye over night at 4°C. Phalloidin dye was removed and acini washed with PBS 3 
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times, 10 minutes each at room temperature. At this point, the detachable chambers are 
removed and acini mounted in mounting media reagent and allowed to dry in the dark at room 
temperature for 4 hours. Once dried, slides are visualised using a confocal or a fluorescence 
microscope.  
2.10 Transwell migration/invasion assay 
 
Matrigel or collagen was diluted 1:5 with chilled growth factor reduced medium and pipetted 
up and down slowly to generate a homogenous mixture. 90µl of chilled diluted matrigel or 
collagen mixture was directly pipetted on the centre of an 8 µm pore size transwell inserts 
(MILLICELL #MCEP12H48) that was placed onto a 12-well plate. No matrix was placed onto the 
transwell insert if migration was measured. The 12-well plate was placed into an incubator for 
30 minutes to allow the matrix and collagen to solidify. Meanwhile, 500µl of full medium 
containing growth factors (chemoattractant) was added to the wells in the 12-well plate. Cells 
were detached by trypsinisation and 150,000 cells were added in 200µl reduced growth factor 
medium, which were pipetted onto the transwell insert either coated with a matrix or the 
uncoated inserts. Plates were placed in the incubator for 16 hours. Highly invasive cells had 
invaded towards the chemoattractant, which were then stained with 0.05% of crystal violet 
dye. Images of random regions are taken using a standard light microscope and quantified 
using imageJ. 
2.11 Sample preparation for flow cytometry and flow sorting 
 
Cells were trypsinised and 500,000 cells were added to 1 mL of 2% horse serum/PBS in a 
polystyrene round bottomed tubes. Cells were centrifuged 5 minutes, 1200 RPM, at room 
temperature. Whilst cells were centrifuging, the lights in the cell culture hood were turned off 
and the antibody master mix was prepared in 1.5 mL eppendorf tubes. Cells were retained 
from the centrifuge and supernatants discarded. Antibodies were added to the polystyrene 
59 
 
tubes containing cells and thoroughly resuspended. Cells with antibodies were incubated for 
20 minutes at room temperature, covered with kitchen foil in the dark. After 20 minutes, cells 
were resuspended in 2% horse serum/PBS and centrifuged for 5 minutes, 1200 RPM, at room 
temperature. Whilst centrifuging, DAPI suspension was made in 2% horse serum/PBS in 1:2000 
dilution. Cells were retained from the centrifuge, and supernatants were discarded. Cells were 
washed again in 1 mL 2% horse serum/PBS by centrifugation for 5 minutes. DAPI suspension 
was added to the cells or just the staining buffer for unstained controls. 
Fluorescence minus-one-controls (FMOs) were made for appropriate interpretation of the flow 
cytometry data, to make sure that the gating is based on the context of data spread in a panel 
with multiple fluorochromes. To do this, the FMO control contains all the antibodies except 
one in the designed panel with the same dilutions as shown in table 2.2. 
For compensation, AbC™ Total Antibody Compensation Bead Kit (INVITOGEN #A10513) was 
used. The total compensation capture beads (component A) and negative beads (component 
B) were vortexed for 10 seconds before use. Flow cytometry tubes were labelled with the 
respective antibody name and 1 drop of component A was added to each tube. Pre-titrated 
amount of each antibody was directly added to the bead suspension and mixed well and 
incubated for 15 minutes at room temperature, protected from light. The beads/antibody 
mixture were washed by adding 3 mL of PBS by centrifugation at 250 x g, for 5 minutes. 
Supernatants were removed and the bead pellet was resuspended by adding 500 µL of PBS to 
the tubes. 1 drop of component B was added to the tubes and mixed well. The samples and 
bead pellets were kept on ice, protected from light and proceeded to flow cytometry analysis.  
For flow sorting, same protocol as above was employed. Additionally, the required number of 
15 mL falcon tubes or polystyrene tubes containing the appropriate medium was taken to 
obtain the sorted cells for further propagation in cell culture. 
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Protein Antibody Source Dilution 
HER2 BV650 Mouse Anti-Human Her2/Neu  
Clone  NEU 24.7   (RUO) 
BD Biosciences 1:100 
EpCAM APC Mouse Anti-Human EpCAM  
Clone  EBA-1   (RUO (GMP) 
BD Biosciences 2:100 
MUC1 BV786 Mouse Anti-Human MUC1 (CD227)  
Clone  HMPV   (RUO) 
BD Biosciences 2:100 
CD44 PE Mouse Anti-Human CD44  
Clone  515   (RUO) 
BD Biosciences 1:100 
CD24 Brilliant Violet 711™ anti-human CD24 Antibody BD Biosciences 2:100 
CD49F  BV650 Rat Anti-Human CD49f  
Clone  GoH3   (RUO) 
BD Biosciences 1:100 
Table 2.2: List of antibodies used for flow cytometry or flow sorting with source and dilutions. 
2.12 qRT PCR  
 
Cells were grown and passaged in 6-well plates as previously described and resuspended in 1 
mL of medium. The cell suspension was transferred to a 1.5 mL eppendorf tubes and 
centrifuged at 250 g for 5 minutes to obtain a cell pellet. The supernatants were discarded and 
cells were lysed in an appropriate volume (for 1 million cells use 300 µL) of TRI reagent (ZYMO 
(R2050-1-200) (kept in 4 °C) by pipetting up and down thoroughly. An equal volume (to the TRI 
reagent) of 100% ethanol and was added and mixed. RNA extraction was performed using 
Zymo kit (#R2050). The mixture was transferred to a Zymo-Spin Column placed in a collection 
tube and centrifuged at 10,000 g for 30 seconds. The column was transferred to a new 
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collection tube and the flow through was discarded. Next, 400 µL of Direct-zol RNA PreWash 
was added to the column and centrifuged at 10,000 g for 30 seconds. Flow through was 
discarded and this step was repeated again. 700 µL of RNA wash Buffer was added to the 
column and 10,000 g for 2 minutes. The column was carefully transferred into a labelled 
RNase-free tube. RNA was eluted by adding 50 µL of DNA/RNase-free water directly onto the 
column matrix and centrifuged at 10,000 g for 30 seconds. The extracted RNA was then 
subjected to DNase treatment using DNA-free kit (INVITROGEN #AM1906). This reaction was 
performed in 10 µL. Firstly, 0.1 volume (e.g. 1 µL in a 10 µL reaction) 10X DNase I buffer and 1 
µL rDNase I was added to the RNA and gently mixed. This was incubated at 37 °C for 20-30 
minutes. Then the resuspended DNase Inactivation Reagent (0.1 volume) was added to the 
mixture and mixed well by pipetting up and down. Tubes were incubated at room temperature 
for 2 minutes. Samples were centrifuged at 10,000 g for 90 seconds and RNA transferred to a 
clean 1.5 mL labelled eppendorf tubes. RNA was diluted in RNase free water to a concentration 
of 200 ng/µl.  
RNA was reverse transcribed into a cDNA using the high capacity cDNA reverse transcription 
kit (APPLIED BIOSYSTEMS #4368814).The master mix consisted of the following components: 
Component Volume/Reaction 
10 RT Buffer 2 µL 
25X dNTP Mix (100 mM) 0.8 µL 
10X RT Random Primers 2 µL 
MultiScribe Reverse Transcriptase 1 µL 
Nuclease-free water 4.2 µL 
Total per reaction 10 µL 
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Table 2.3: Reagents and volume of the cDNA master mix to convert RNA to cDNA.  
The master mix was placed on ice and gently mixed. Per each reaction, 10 µL of RNA was 
mixed added to 10 µL RT (reverse transcriptase) master mix in PCR tubes. Tubes were briefly 
centrifuged to spin down the contents and eliminate any existing air bubbles. Tubes were then 
placed into a thermal cyclers under the following conditions: 
 Step 1 Step 2 Step 3 Step 4 
Temperature 25 °C 37 °C 85 °C 4 °C 
Time 10 minutes 120 minutes 5 minutes - 
Table 2.4: PCR conditions required cDNA synthesis. 
After the reaction was completed, cDNA was then analysed by qRT PCR in three technical 
replicates using SsoAdvanced™ Universal SYBR® Green Supermix, (#1725274). 1 µL of cDNA 
was added per 10 µL reaction. The master mix contained 0.275 µL forward and reverse 
primers, 5.5 µL SYBR probe (Bio-Rad kit), and 3.95 µL nuclease-free water). 
At the endpoint of qPCR Ct values are generated, which were used to analyse expression levels 
using the (2-ΔΔCt) [delta-delta Ct) method. 18S was used as a house keep gene. The primers 
used for qPCR are listen in the table below: 
Gene Forward Primer Reverse primer 
HER2 TGACACCTAGCGGAGCGA GGGGATGTGTTTTCCCTCAA 
BMP6 ACATGGTCATGAGCTTTGTGA ACTCTTTGTGGTGTCGCTGA 
BMPR2 GCCCAGGGGAGGAAGATA TGGTGCCATATATCTGATAGTGC 
LOX GGGAATGGCACAGTTGTCA ACTTGCTTTGTGGCCTTCAG 
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VEGFC TGCCAGCAACACTACCACAG GTGATTATTCCACATGTAATTGGTG 
 
ILK AACACGGAGAACGACCTCAA 
 
CATCTCAACCACAGCAGAGC 
 
18S AAACGGCTACCACATCCAAG CCTCCAATGGATCCTCGTTA 
Table 2.5: List of forward and reverse primers used for RT-PCR. 
2.13 ATAC-seq library preparation  
 
300,000 cells per condition were grown in chamber wells as per the 3D cell culture overlay 
method described in section 2.1.4. Cells were isolated from the matrigel/collagen mixture 
using the cell recovery solution (Corning™ Cell Recovery Solution #354253). The cell recovery 
was done by removing the medium from the cells and washing cells with cold PBS. The 
removable chambers were detached from the slides and 2 mL of recovery solution was added. 
The matrix (matrigel/collagen mixture) was gently scraped using a sterile cell scraper onto an 
ice cold 15 mL falcon tube. The slides were rinsed again with 1mL of recovery solution onto the 
falcon tube to make sure all of the matrix and cells are recovered. The falcon tube is inverted a 
few times and placed on ice for 30 minutes until the matrix has been completely dissolved. The 
falcon tube is flicked with the finger tips back and forth to speed up the procedure. After about 
15 minutes, cells begin to settle at the bottom of the falcon tube, indicating that the 
matrigel/collagen is dissolving. After 30 minutes, the matrix would have completely dissolved 
and cells are then pelleted to the bottom of the falcon tube by centrifugation at 200-300 g, for 
5 minutes at 4 °C. The supernatants are discarded and cells were washed with PBS and 
centrifuged again for 5 minutes at 4 °C. Finally, cells were resuspended in 1 mL PBS for 
counting.  
Cells were counted using the Luna counting device. 50,000 cells were used from each 
condition and time point to perform ATAC seq library preparation. In this experiment, we have 
used the OMNI-ATAC protocol with some optimisations (228). 50µl of cold ATAC-Resuspension 
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Buffer (RSB) containing 0.1% NP40, 0.1% Tween-20 AND 0.01% Digitonin was added to the cell 
pellet (in 1.5 mL eppendorf tube) and pipetted up and down 3 times. Cell pellet was incubated 
on ice for 3 minutes. The lysis was washed with 1 mL of cold ATAC-RSB containing 0.1% Tween-
20 but no digitonin or NP40 and the eppendorf tube was inverted 3 times to mix. Nuclei were 
pelleted at 500 RCF for 10 minutes, at 4 °C. The tubes were retained and supernatants 
discarded using two separate pipetting steps, to be careful not to touch the almost visible cell 
pellet. To do this, remove 900 µL of the supernatant first with a p1000 pipette and use a p200 
pipette to aspirate the remaining 100 µL supernatants. The cell pellet was then resuspended in 
50 µL of the transposition mixture by pipetting up and down 6 times. The transposition 
mixture consisted of: 25 µL 2x TD buffer, 2.5 µL transposase (100 nM final), 16.5 µL PBS, 0.5 µL 
digitonin, 0.5 µL of 10% Tween-20, and 5 µL of water. The reaction was incubated at 37 °C for 
30 minutes in a thermomixer with 1000 RMP mixing. 
The reaction was cleaned up with a Zymo DNA Clean and Concentrator-5 kit (ZYMO #D4014). 
To do this, 250 µL of the DNA binding buffer was added to the DNA samples and DNA was 
transferred to a Zymo-Spin columns in a collection tubes. The column was centrifuged at 1000 
g, for 30 seconds and flow through was discarded. 200 µL of DNA wash buffer was added to 
the columns, centrifuged for 30 seconds. This step was repeated 1 more time. Finally, DNA was 
eluted in 21 µL sterile water.  
The ultra-pure DNA was now subjected to amplification by PCR. For amplification conditions 
see table below: 
Lastly, the PCR samples were cleaned up using the Zymo DNA Clean and Concentrator-5 kit 
(ZYMO # D4014) as described above. 
The DNA library profile was viewed using the automated electrophoresis tool, the Agilent 
TatpeStation System (serial number DEDAA01244). All the reagents were equilibrated to room 
temperature for 30 minutes. 1 µl of DNA sample was mixed with 1 µ1 of high sensitivity 
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(D1000) sample buffer (AGILENT #5067-5585) in strips (AGILENT #401428) and closed with 
caps (AGILENT #401425). Samples were vortexed for 60 seconds and span down and were 
analysed by the TapeSation.  
 
2.14 Phosphoproteomic sample preparation 
 
Cell medium was aspirated from cells in 6-well plates and 1 mL of ice cold PBS containing 
phosphatase and protease inhibitors (Add 20 µL NaF and 100 µL Na3VO4 to 10 mL of PBS) 
were added onto the wells whilst keeping the flask on ice. PBS was aspirated and this step was 
repeated again. 500 µL of lysis buffer was added to each well, cells were scraped off and 
transferred to a 1.5 mL eppendorf tubes.  The cell suspension were sonicated at 50% intensity 
for 15 seconds, then rested for 10 seconds. This step was repeat two further times. Cell 
suspension was centrifuged at 20,000 g for 10 minutes, at 4 °C. Supernatant were recovered to 
a 1.5 mL eppendorf protein Lo-bind tube.  
2.14.1 In Solution Tryptic digestion 
 
Protein quantification was performed by BCA assay as described in 2.1.7. All samples were 
normalised to 250 µg concentration of total protein in a final volume of 300 µL. An appropriate 
volume of 1 M DTT to a final concentration of 10 mM (e.g. 3 µL in 300 µL) was added and 
incubated at room temperature, for 30 minutes with agitation (in the dark). Then, 415 mM 
iodoacetamide (IAM) was added to a final concentration of 16.6 mM (e.g. 12 uL in 300 µL). This 
was incubated at room temperature for 30 minutes with agitation (in the dark). Tubes are 
retained and 0.04 µL beads/µL of lysate containing 250 µg protein is added for the digest (e.g.  
0.02 µl beads/ µg of protein). Appropriate volume of beads from stock beads container and 
aliquoted into a 1.5 mL Lo-bind Eppendorf tubes and centrifuged at 2,000 g for 5 min; 4 °C. 
HEPES buffer was added in equal volume to that of the beads (i.e. 1:1) and centrifuged at 
2,000 g for 5 min at 4 °C. Supernatants was removed and replaced with fresh HEPES buffer 
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(1:1). The last two steps were repeated two further times. Samples were diluted 4X with HEPES 
buffer after the IAM incubation (e.g. 900 µL HEPES buffer to 300 µL lysate; 1200 µL total). The 
appropriate amount of conditioned beads (48 µL of beads for a 1200 µL digest containing 250 
µg of protein) and incubated overnight at 37 °C with agitation. The next day, samples were 
transferred onto ice and centrifuged at 2,000 g for 5 min at 4 °C. Supernatants were 
transferred to a Lo-bind protein eppendorf tubes on ice. Meanwhile, vacuum manifold was 
setup to ~5 inHg. Samples were equilibrated at room temperature and loaded onto the 
vacuum manifold using the lowest flow rate possible. Samples were washed with 1 mL 
desalting loading buffer. Samples were retained and eluted with 0.5 mL Elution buffer A.  
2.14.2 Phosphopeptide enrichment 
 
An appropriate amount of TiO₂ beads from stock vial (50 µg beads/1 µg protein) were re-
suspended in 1% TFA and vortexed. This was kept at 4 °C, when not in use. All the OASIS eluted 
fraction(s) volumes were adjusted to 500 µL with 1 M Glycolic acid in 80% ACN/ 5% TFA. 25 µL 
(i.e. 12.5 mg) of re-suspended TiO₂ beads were added to the OASIS eluted fraction(s) and 
vortexed. The TiO₂ beads were resuspended between samples before adding them, this is to 
ensure the same quantity of TiO₂ beads is added. Samples were incubated for 5 minutes with 
rotation/agitation. For spintips equilibration: the spintip(s) were placed in normal 2 mL 
eppendorfs and 200 µL 100% ACN applied to spintip(s), followed by centrifugation for 3 min at 
1,500  g and flow through was discarded. Samples were incubated with TiO₂ for 5 minutes and 
then span down for 30 seconds, at 1500 g. The supernatants were transferred to protein Lo-
bind 1.5 mL eppendorf tubes on ice. The TiO₂ beads were resuspended in the remaining 100 µL 
of solution and vortexed. 100 µL of re-suspended samples were applied to the empty spintip(s) 
and centrifuged for 2 min at 1,500 g. 100 µL 1 M Glycolic acid in 80% ACN/ 5% TFA was added 
to the sample tubes and the remaining TiO₂ beads were resuspended. Vortexed and span for 
10 seconds. The remaining TiO₂ beads were applied to the spintip(s) and centrifuged for 2 min 
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at 1,500 g. Flow through was discarded. The 400 µL remaining aliquots was removed from ice 
to equilibrate at room temperature. The 400 µL of remaining sample was applied to the TiO₂-
filled spintip(s); 2 x 200 µL batches – centrifuged for 3 min at 1,500 g. Flow through was 
discarded. 100 µL 1M Glycolic acid in 80% ACN/ 5% TFA was applied to the spintip(s). 
Centrifuged for 2 minutes at 1,500 g. Flow through was discarded to remove non-
phosphorylated peptides. 100 µL 100 mM Ammonium Acetate (25% ACN) was applied to the 
spintip(s). Centrifuged for 2 minutes at 1,500 g. Flow through was discarded to remove acidic 
non-phosphorylated peptides. 100 µL 90/10 H₂O/CAN was applied to spintip(s). Centrifuged 
for 2 min at 1,500 g. Flow through was discarded. The last step was repeated twice to remove 
any salts and HILIC-mode bound non-phosphorylated peptides from the TiO₂ layer before the 
elution step. The spintip(s) were transferred to fresh 2 mL protein Lo-bind eppendorf tubes. 50 
µL 5% NH4OH (10% ACN) was applied to the spintip(s) and centrifuged for 2 min at 1,500 g. 
The flow-through(s) were kept and pooled to elute phosphopeptides from the TiO₂ layer. This 
step was repeated 3 more times. Samples were snap-frozen and placed in speed-vac to dry 
overnight. Samples were then subjected to mass spectrometry analysis.  
2.15 Image J quantification 
 
Image J software was used to perform densitometry analysis on the western blots. A 
rectangular area around the first band was drawn using the “rectangular select” tool. 
Sequentially, a rectangle is drawn and selected for all of the bands of interest. Additionally, to 
compensate for the background noise, five random representative regions of the same size as 
the bands of interest were also selected. Once all the bands were selected, CTRL 3 was pressed 
and another image with histograms appear for each selected region. To obtain the results, we 
selected the “magic wand” button and clicked in each histogram. The average of five different 
random regions were subtracted from the band of interest to compensate for the background 
and results were plotted using prism as shown by bar graphs. 
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2.16 Bioinformatics analysis  
The ATAC-seq data was provided as FASTQ files. The initial quality control checks were 
performed on each sample using the FastQC tool. The adapter sequences were removed with 
cutadapt using: 
Cutadapt -a CTGTCTCTTATACACATCT -A CTGTCTCTTATACACATCT -o out.1.fastq -p out.2.fastq 
infastqfile1 infastqfile2 
 Samples were aligned to the human genome, Genome Reference Consortium Human Build 38 
patch release 13 (GRCh38.p13), using bowtie2, and a SAM file was obtained. 
bowtie2 index -1 trimmed FASTQ file -2 trimmed FASTQ file –S 1.sam 
SAM files were converted to BAM files (binary files) using the following command: 
Samtools view –Sb in.samfile > out.bamfile 
Bam files were sorted using: 
Samtools sort in.bamfile -o out.bamfile 
The sorted files were then indexed using: 
Samtools index in.bamfile 
The ATAC-seq files can have a large number of reads (40-60%) that align to the mitochondrial 
DNA which should be removed using: 
Samtools view –h in.bamfile | removeChrom - - chrM | Samtools view - b - > out.bamfile  
PCR duplicates were removed from the files using Picard tools: 
Java -jar picard.jar MarkDuplicates  I=in.bamfile  O= out.bamfile M=dups.txt 
REMOVE_DUPLICATES=true VALIDATION_STRIGENCY=LENIENT 
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Samples were downsampled to 25 million reads by working out the ratio (which was done by 
dividing 25 million by the total number of reads were in that specific file. The reason for down 
sampling/normalising all reads in each sample to 25 million was because there were drastically 
uneven number of reads (ranging from 27-55 million reads) obtained from our ATAC-seq data. 
To make sure we account for the differences in sequencing depth between the different 
samples, all samples were trimmed to 25 million reads prior to analysis to bring different 
samples onto a common scale. The logic behind down sampling to the lowest number of 
sequences produced from any sample is generally unreported, but presumably it is to 
compromise between data set balance and information loss. This down sampling is only 
performed when visualising and checking the quality of the data. The differential analysis 
would be performed by the raw BAM files, and programmes such as DiffBind would have an 
internal control to compensate for the differences in coverage. 
samtools view -b -s 0.5 in.bam > out.Downsampled.bam 
Peaks were called using the MACS2 tool for each bam file separately using: 
MACS2 callpeak -t inbamfile -f BAMPE -n in.bamfile -g ce –keep-dup all 
The two biological replicates were intersected using bedtools with the following script: 
Bedtools intersect -a peakfile.1 -b peakfile.2 -f 0.50 -r > out.bedfile 
To report unique entries we used: 
Bedtools intersect -a bed.file -b bedfile.2 -v > 1.bed 
To report overlap entries we used: 
Bedtools intersect -a bed.file -b bed.file2 -u > 1.bed 
To create a matrix to then generate a heatmap, we first converted the bam files to bigwif files 
using:  
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bamCoverage -b in.bam -o coverage.bw 
computeMatrix reference-point –referencePoint center –S in.bigwigfile.1 bigwigfile.2 –R 
bedfile.1 –a 1000 –b 1000 –o matrix.1 
To plot a heatmap: 
plotHeatmap –m marix.1 –o Heatmap.png 
To plot correlation we first produced a multiBamSummary and and multibigWigSummary 
using: 
multiBamSummary bins --bamfiles file1.bam file2.bam -o results.npz 
multiBigwigSummary bins -b file1.bw file2.bw -o results.npz 
Then the correlation were plotted using: 
plotCorrelation –n result.npz – corMethod Pearson –skipZeros – plotTitle “Pearson 
Correlation” --whatToPlot heatmap --colorMap RdYlBu--plotNumbers--o heatmappearson.png 
To plot profile we used the following script: 
plotProfile -m matrix.mat.gz --perGroup --kmeans 2  -plotType heatmap   -
outExampleProfile1.png 
Number of peaks were counted using: 
samtools view -c in.bam 
2.17 Statistics  
The appropriate statistics were performed using either GraphPad Prism 5.4 or Microsoft Excel 
2013. For each experiment see accompanying figure legend.  
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Chapter 3 
 
Establishment and characterisation of HER2 inducible 
transformation model 
 
3.1 Introduction 
 
To overcome significant challenges in delineating early transformational events of normal cells 
progressing towards cancer, we took advantage of the tetracycline (Tet-On) inducible system. 
HER2 over expression is observed in up to 30% of breast cancers and have been found to 
promote tumourigenesis. However, the early changes occurring upon HER2 over expression, 
particularly those regarding intracellular signalling, chromatin architecture and cell physiology 
need further investigation. The main advantage of this model lies in the ability to control the 
levels and timing of expression of the gene of interest. Furthermore, it provides us with a 
platform to investigate the events leading to oncogenic transformation in a reproducible 
experimental setting, which to date have not been fully exploited. The over expression of HER2 
using Tet-On system in human mammary epithelial (MCF10A) cells represents a simple, yet 
versatile model for the study of early changes in the process of transformation. This system 
post establishment and characterisation will provide novel insights into the effects of HER2 
over expression on signalling and chromatin conformation changes.  
3.2 Generation of HER2-MCF10A cell line using tetracycline inducible 
system 
 
To generate a stable inducible HER2 over expressing cell line we used a third generation stable 
lentiviral transduction system. We transiently co-transfected the human embryonic kidney 
epithelial (HEK) 293T cell line with pCMV delta R8.2 (packaging vector), pMD2.G (envelope 
vector) and the Tet-On inducible pINDUCER21 HER2 construct containing a surrogate marker, a 
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constitutively active GFP (green fluorescent protein) gene for tracking and selection purposes 
(Figure 3.1). This plasmid has been generated in a series of inducible vectors for inducible 
control of gene function (116). It has been previously used to investigate the relationship 
between myoepithelial-luminal cells in progression of breast cancer (115). In parallel, as a 
control for our subsequent experiments, 293T cells were co-transfected with an empty 
constitutively expressed pLV-eGFP vector along with the same packaging and envelope 
vectors. Lentiviral particles were harvested 24 hours post transfection and MCF10A cells were 
infected with the viral particles for an additional 48 hours.  
 
Figure 3.1: Schematic of third generation lentiviral transduction. pINDUCER21 vector containing 
wildtype HER2 insert was co-transfected with the packaging (pCMV delta R8.2) and envelope (pMD2.G) 
vectors in HEK293T cells. Viral particles were purified with centrifugation 24 hours after transient 
transfection by the labelled vectors. MCF10A cells were infected with the freshly produced virus for 48 
hours.  
 
In control cells, expression of GFP, which is under the control of the constitutively active 
cytomegalovirus immediate-early (CMV) promoter, was readily detected using the 
fluorescence imaging microscope in the HEK293T cells and subsequently in the infected control 
GFP-MCF10A cells (Figure 3.2A.). However, barely detectable levels of GFP were observed in 
HEK293T and MCF10A cells transduced with the inducible pINDUCER21 HER2 construct. GFP in 
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the pINDUCER21 HER2 construct is expressed from a weak constitutively active human 
elongation factor 1α (EF1α) promoter. Therefore, to adequately quantify the percentage and 
relative intensity of the GFP positive cells, flow cytometry was performed. It showed that GFP 
expression is notably lower in the pINDUCER21 HER2 transduced cells, with a 2.27% 
transduction efficiency. This is in comparison to GFP-MCF10A cells, which exhibited a 35.6% 
transduction efficiency (Figure 3.2B). The successfully transduced cells were flow sorted at high 
purity (approximately 90%) based on GFP expression from the non-transduced background 
population. The purity check is routinely performed directly after FACS sorting has been 
completed and we found that the GFP positive cells were purified at 90%. Subsequently, from 
the pINDUCER21 HER2 transduced cells, the GFP positive cells were separated into two 
populations for propagation with either doxycycline hyclate (dox), to induce HER2 expression 
(DOX +ve cells), or without dox as a parental control (DOX -ve cells).  
Furthermore, to investigate if GFP efficiency remains stable over time. We passaged cells for 
an additional 6 times and 8 times respectively and measured the GFP expression of cells by 
flow cytometry. We found that that there was a decrease in GFP expression from the original 
90% of pure GFP population to approximately 65% GFP expression (Figure 3.2C). 
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Figure 3.2: Generating a HER2 inducible MCF10A cell line using lentiviral transduction. (A) 
Fluorescence images of HEK293T cells transfected with pINDUCER21 HER2 and control empty GFP 
plasmids 24 hours post transfection. MCF10A cells were infected with the virus for 48 hours resulting in 
fluorescence in GFP transduced cells but not in the pINDUCER21 HER2 transduced cells (B) Scatter plots 
of flow cytometric analysis of MCF10A cells transduced with pINDUCER21 HER2 and control GFP 
expressing virus to check for transduction efficiency. (C) Flow cytometry analysis of cells cultured for 6 
and 8 passages after the initial transduction and GFP expression measured by flow cytometry. 
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3.3 Dose and time dependent HER2 expression 
 
To investigate inducibility of HER2 expression at the protein level, we selected five different 
concentrations of dox and cultured cells for 24 hours. Some of these concentrations selected 
here have been previously used to induce the expression of gene of interest (115, 229). HER2 
over expression was readily and efficiently induced in the infected MCF10A cells upon 
exposure of cells to dox. Typically, HER2 expression was induced by dox in a dose-dependent 
manner. It also shows that protein expression is tightly regulated, as there is no “leaky” 
expression of HER2 in the DOX -ve cells (Figure 3.3A). We wished to examine whether this 
model could be used to express similar levels of HER2 protein as seen in a subset of HER2 over 
expressing breast cancer patients, with the aim to generate a more physiologically relevant 
human context (230). Using Real-Time Polymerase Chain Reaction (RT-PCR), we verified the 
increase in HER2 expression at gene expression level with increasing concentration of dox. In 
addition, we determined that there is approximately 18-fold more HER2 mRNA transcripts in 
the DOX +ve cells when cells are exposed to 1 µg/ml of dox relative to normal MCF10A cells 
(Figure 3.3B). We found that the HER2 gene expression is relatively similar to levels observed 
in the 2+ grade tumours in some HER2 positive breast cancer patients (231, 232) 
Immunofluorescence (IF) staining was performed to confirm the cellular localisation of HER2 
protein in DOX +ve cells, after cells were cultured in 1 µg/ml of dox for 24 hours. As a cell 
surface receptor, HER2 localised around the plasma membrane as expected, whereas in 
normal MCF10A cells, HER2 levels were negative or below the detection threshold of IF (Figure 
3.3C). Additionally, we noted that HER2 was expressed heterogeneously, with some cells 
appearing brighter than others and a fraction of cells not exhibiting any fluorescence. Next, we 
sought to quantify the levels of HER2 in DOX +ve cells in a time-dependent manner. We 
selected 12 different time points, ranging from 0 hours to 17 hours, with samples collected 
every 1.5 hours. As shown in Figure 3.3D, HER2 expression increased in a time-dependent 
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manner until the 10.5-hour time point, after which it remained constant. This shows that 10.5 
hours of dox induction is sufficient to cause saturation of the cell receptor (HER2). 
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Figure 3.3: Doxycycline induces HER2 over expression. (A and B) HER2 expression analysis by western 
blot and the densitometry analysis of HER2 expression normalised to GAPDH (loading control) using 
Image J (n=1).  (C) RT-PCR in MCF10A cells infected with inducible HER2 lentiviral particles and cultured 
in various concentration of dox (0.01, 0.05, 1.0, 0.5, and 1.0 µg/ml) for 24 hours. 18S was used as 
internal control for RT-PCR (n=2). (D) Fluorescence microscopy performed 24 hours after inducing HER2 
expression by dox. Cells were stained with DAPI and HER2 antibody for nuclear and protein visualisation 
respectively. Alexafluor 555 was used as a secondary antibody. Scale bars represent 100µm. (E and F) 
Western blot analysis of time-dependent HER2 expression for the indicated time points and the 
densitometry analysis of HER2 expression normalised to GAPDH control using Image J (n=1).   
 
3.4 HER2 over expression induces morphological changes 
A key hallmark of transformed cells is the loss of cell organisation, and proliferation, as well as 
cell to cell membrane contact and cell to cell adhesion to their control counterparts (56). In 
monolayer cell culture, un-transduced MCF10A and DOX -ve cells grew in expanding colonies 
with the cobblestone-like structure characteristic of epithelial cells. However, DOX +ve cells 
exhibited a more fibroblastic and spindle-like shape after being in 2-dimensional (2D) culture 
for 7 days (Figure 3.4A). We extended our analysis by studying the morphology of cells in 3-
dimensional (3D) basement membrane cell culture (rBM) in overlay or “on-top” 
matrigel/collagen assay over a period of 9 days. The MCF10A cell morphology progression 
series grown in 3D rBM cultures is a powerful system to study human mammary 
transformation and is simple to track morphological changes compared to 2D cultures. At day 
0, both DOX -ve and DOX +ve cells anchored into the matrix and formed similarly-sized 
spherical masses of cells termed “acini”. After day 3 and until day 9, the acini of DOX -ve cells 
continued to grow in size while retaining their overall spherical structure with smoother outer 
edges. During the same time, the DOX +ve cells became easily distinguishable, as they 
appeared flat and lacked even edges. They not only grew in size, but appeared to have 
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produced a multi-acinar conformation with branched connections. The cells exhibited a more 
irregular, disorganised, arm-protruding, and invasive-like structure as they became denser and 
darker (Figure 3.4B). Moreover, we questioned whether the morphological alterations could 
have been due to the addition of dox and not HER2 over expression. To answer this, we added 
the same amount (1 µg/ml) of dox to an empty vector (GFP) transduced MCF10A cells and DOX 
+ve cells. Indeed, the addition of dox had no impact on GFP-MCF10A cell morphology, as they 
retained circular organised acini conformation similar to DOX -ve cells, but the DOX +ve did not 
(Figure 3.4C). This shows that dox addition is not the cause of morphological changes but HER2 
over expression.  
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Figure 3.4: HER2 over expression disrupts normal MCF10A morphology. (A) HER2 expression was 
maintained for 7 days in monolayer cell culture. Bright-field images of MCF10A and DOX -ve cells show 
normal cobble-stone like morphology. DOX +ve cells show a more spindle-like appearance as a result of 
HER2 expression. Scale bars represent 250µm. (B) DOX -ve and DOX +ve cells were cultured in 3D matrix 
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over 9 days. DOX -ve cells formed spherical acini which increased in size over time. DOX +ve cells formed 
flat projecting cells of complex masses, typical of transformed cells. (C) 1µg/ml dox was added to GFP-
transduced MCF10A and DOX +ve cells. Dox had no effect on MCF10A cell morphology without HER2 
expression. Scale bars represent 50µm. 
 
3.5 Effects of lapatinib and dox absence on HER2 expressing cells 
 
Lapatinib is a dual HER1 and HER2 kinase inhibitor and thus is effective in inhibiting 
downstream signals through the MAPK signalling pathway (233, 234). To explore the effects of 
lapatinib on phosphorylated ERK (phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) in our 
system, cells were acutely treated with four different concentrations of lapatinib for 3 hours. 
Such short-term treatment times have been previously reported and it has been shown that 
even one hour of lapatinib treatment of HER2 over expressing cells may be sufficient to 
decrease HER2 signalling (234, 235). Indeed, lapatinib treatment decreased pERK abundance in 
DOX +ve cells in a dose-dependent manner (Figure 3.5A). Furthermore, to determine if HER2 
activity is required to sustain the aberrant morphological phenotype of DOX +ve acini in 3D, we 
investigated the effect that long-term treatment with lapatinib has on the morphology of 
MCF10A cells. Therefore, we maintained lapatinib treatment of HER2 over-expressing acini for 
5 days. Indeed, cells did not progress to the aberrant morphology, as observed in the 
untreated DOX +ve cells (positive control). At the same time, established aberrant acini formed 
after 4 days were treated with 5µM of lapatinib for 24 hours (Figure 3.5B). This confirmed that 
inhibiting HER2 activity after the formation of invasive morphology induced a significant 
reversal of the aberrant morphology of DOX +ve acini. 
To test whether the induction of HER2 protein expression from the DOX +ve cells is reversible, 
HER2 expression was induced by the addition of dox for 24 hours, followed by the removal of 
dox by three consecutive PBS washes. Western blot analysis at 24, 48 and 72 hours after 
removal of dox showed that HER2 expression decreased over time, but did not reach the basal 
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levels of un-transduced MCF10A or DOX -ve cells within 72 hours (Figure 3.5C). This shows 
that, as expected, this system provides reversible and temporal control of protein expression, 
but may require more time for reversal of HER2 expression to the uninduced state. The HER2 
expression remains at low levels despite dox removal and the half-time of HER2 protein is 
known to be 19.6 hours (236). 
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Figure 3.5: Inhibition of HER2 and its signalling. (A and B) Cells were serum starved for 24 hours and 
treated with various concentrations (0.1, 0.5, 1.0, and 2.0 µM) of lapatinib for three hours. Cells were 
then stimulated with full serum media for 10 minutes before harvesting protein lysates. Western blot 
analysis shows dose-dependent reduction of pERK signalling and the associated densitometry analysis 
normalised to GAPDH control (n=1). (C) DOX +ve cells were treated with 5 µM of lapatinib for 5 days or 
treated on day 4 for 24 hours. DOX -ve and DOX +ve cells served as controls. Scales bars represent 50 
µM (n=1). (D and E) HER2 was induced for 24 hours and cells were washed with PBS three times 
consecutively. Western blot analysis was performed at 24, 48, 72 hours. HER2 levels decreased over 
time but did not reach the basal levels observed in 72 hours as is also shown in the densitometry 
analysis (n=1).  
3.6 HER2 induces invasion of cells and activates associated pathway 
 
An indication of cells progressing towards transformation is their ability to invade the 
surrounding tissue (3, 237). To test the effect of HER2 over expression on the ability of cells to 
invade through matrix barriers, we performed in vitro transwell migration and invasion assays. 
We maintained HER2 over expression in DOX +ve cells for 5 days and plated 150,000 cells in 
parallel to DOX -ve cells on 8µm transwell filters for 16 hours in a low serum media. The 
transwell filters were either matrigel-coated, collagen-coated, or left uncoated to estimate 
migration through the transwell filters. We demonstrated that the DOX +ve cells exhibit 
considerably higher migration and invasion capacity towards the full serum containing media 
compared to the DOX -ve cells (Figure 3.6A). This shows that within 5 days of HER2 over 
expression, cells have acquired an invasive phenotype. 
Previously, microRNAs (miRNAs) such as miR-21 has been shown to enhance invasion and 
metastatic potential in HER2 over expressing cells (238). To confirm the invasive phenotype 
observed through the transwells, we investigated and confirmed a known HER2 signalling 
pathway that induces the expression of miR-21 through the MAPK signalling pathway, which is 
known to contribute to the increased invasive phenotype observed in DOX +ve cells compared 
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to DOX -ve cells. We grew cells in 3D cell culture in a mixture of matrigel/collagen assay for 5 
days to be comparable to the functional invasion assay performed. We determined that HER2 
over expression dysregulates this pathway at gene expression level as it increased the levels of 
a known transcription factor (ETS-1). This upregulates the expression of primary transcript 
coding for miR-21 (pri-miR-21), which is further processed into miR-21. The Pri-miR21 
subsequently decrease the expression of PDCD4 (programmed cell death 4) and/or other 
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unidentified genes allowing active cell invasion relative to control cells (Figure 3.6B) (238). 
 
Figure 3.6: HER2-associated migration and invasion. (A) Cell migration was analysed through the 
transwell membranes over 16-hour period of chemotactic migration towards full serum media. The 
ability of cell invasion was measured in collagen or matrigel coated transwells (n=3). Student’s t-test was 
performed and statistical significance is shown as * for p-value < 0.05, ** for p-value < 0.01. (B) Gene 
expression analysis by RT-PCR of a known pathway associated with HER2-induced invasion. Cells were 
grown in 3D cell culture for 5 days and acini recovered. PDCD4 levels decreases via upregulation of ETS1, 
and primary mir-21 (n=2).  
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3.7 HER2 over expression induces anchorage-independent growth 
Transformed cells have the ability to grow large colonies compared to normal cells in the soft 
agar, a characteristic known as anchorage-independent growth, and a hallmark for in vitro 
transformation (239, 240). The formation of domed-shaped colonies are strongly correlated 
with formation of tumours in experimental mice (241, 242). We tested the anchorage-
independent growth capability of DOX +ve and DOX -ve cells by growing 5000 cells mixed with 
a low percentage (0.3%) of ultra-pure agarose on top of a 0.8% layer of ultra-pure agarose. 
Cells were replenished with fresh media containing dox to maintain HER2 over expression over 
the course of 21 days and colonies were quantified after imaging by a dissecting microscope. 
HER2 over expression in DOX +ve cells induced anchorage-independent growth in the soft 
agar, but the control cells did not (Figure 3.7A). Some DOX +ve cells grew large colonies (above 
100µm perimeter) but DOX -ve cells did not aggregate or form larger colonies after 21 days of 
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being in the soft agar. The DOX +ve cells increased in their sizes and became more 
distinguishable after 10 days, some of which were very large, round structures (Figure 3.7B).  
 
Figure 3.7: HER2 induces MCF10A cell anchorage-independent growth. (A) Colony growth of DOX -ve 
and DOX +ve cells in 0.3% ultra-pure agarose. ImageJ analysis of six different size colonies were 
quantified. Student’s t-test was performed and statistical significance is shown as * for p-value < 0.05, 
** for p-value < 0.01, *** for p-value <0.001. n=3 (B) Representative microscopic images of colonies 
stained with crystal violet after three weeks. Images are at 1.6x magnification. Scale bars represent 
1000µm. 
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3.8 Discussion 
Previously, inducible transformation models have studied various differences occurring 
between normal and transformed cells, for example by inducing over expression of HER2/neu 
in mouse models (243, 244) and primary luminal cells to characterise a phenotype of 
transformation, namely the filling of the lumen (115). Whilst this has been valuable to 
understand the role of HER2 in driving transformation, it has an important limitation in that is 
not suitable to track the alterations that occur at the very outset of transformation with 
physiological levels of HER2 expression. Here, we ectopically generated a stable MCF10A cell 
line transduced with inducible HER2 gene using the Tet-On system that allows for 
characterisation of the earliest changes. The wild type HER2 over expression alone is sufficient 
to transform the immortalised, yet normal MCF10A cell line (245). We anticipate to fully 
exploit this system in understanding the genome-wide early signalling and chromatin structure 
changes upon HER2 induction.  
To work with the successfully transduced HER2 MCF10A cells, we FACS selected only the very 
high 2.3% of cells based on GFP expression, which is expressed from the weak EF1α promoter, 
despite the HER2 being driven by a distinct strong inducible TRE (tetracycline response 
element) promoter. The FACS selection of GFP cells with high fluorescence intensity would 
have ensured that the majority of the transduced cells contained more than one viral 
integration per cell. However, there would still be variation in the HER2 levels among different 
MCF10A cells within the same population as is shown by the IF. This variation in HER2 levels 
could present key caveats due to the rapidly evolving heterogeneity in HER2 expression or due 
to outgrowth of one clone over others in cell culture affecting the inducibility and the overall 
expression of HER2 over time. This limitation of the inducible system cannot be differentiated 
from the response of cells to dox, as it is already known that there is variation in inducibility 
90 
 
over long periods of time, with cells having reduce response to dox, resulting in significantly 
decreased inducibility (246).  
An essential feature of an inducible system is its high inducibility in the presence of an inducing 
agent (dox) and its low background or leakiness in the transduced cells in the absence of dox. 
Our results show tightness of dox-regulation as the DOX -ve cells are identical to the 
untransduced MCF10A cells exhibiting no “leakiness” of HER2 protein in absence of dox. In 
addition, the system displays that HER2 expression is strictly dependent on dox treatment, as 
the plasmid enables the expression of HER2 in a graded fashion by titrating the dox 
concentration. Furthermore, the plasmid encodes GFP as a surrogate marker, which can only 
help to monitor the successful delivery of the plasmid into the target cells. This marker cannot 
be used to monitor the expression of gene of interest (HER2), as both of the genes are driven 
by two different prompters and are therefore, transcribed and expressed at different levels.    
The 3-dimensional basement membrane cell culture offers significant insights compared to 2D 
cultures of normal cells progressing to cancer, making it an ideal system for us to study the 
morphogenesis in a more physiological relevant context. We monitored the morphological 
transformation of cells over a period of 9 days. DOX +ve clearly showed an aberrant 
morphology whereas the DOX -ve did not. The normal MCF10A and DOX -ve cells are known to 
exhibit growth arrest, which appear to be delayed or does not occur in the transformed cells. 
This growth arrest in the DOX -ve cells results in a notable lumen formation after 10 days of 
being in 3D cell culture. Interestingly, the transformed cells demonstrate lack of apoptosis and 
hence the lack of lumen formation. We have not been able to observe this phenotype in our 
experiments since our experimental end point was 9 days, with the lumen formation 
appearing after 10 days. Nevertheless, we show that HER2 over expression disrupts the normal 
MCF10A morphology within 3 days and this invasive morphology is maintained by HER2 
expression, which was the main objective of our experiment. 
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Our results show a marked increase in the ability of DOX +ve cells to form colonies compared 
to DOX -ve cells. Intriguingly, some of the DOX -ve cells also have the ability of colony 
formation. The colony forming ability of normal MCF10A cells to this extent has not been 
reported before. Previous reports show only some colony formation or the complete inability 
of MCF10A cells to grow in the soft agar compared to oncogene-induced transformed MCF10A 
cells (247-250).  However, these reports do not take into consideration the sizes of the 
colonies, whereas we show that approximately 100 colonies were detected in DOX -ve cells 
compared to the 350 colonies in DOX +ve cells when 10µm perimeter size was set as a 
threshold. Moreover, there is an incremental reduction in the number of colonies detected in 
the DOX -ve cells as the size threshold was increased. For example, no colonies were detected 
in the DOX -ve cells when the threshold was increased to 100um perimeter compared to 10 
large colonies detected in the DOX +ve cells. Another explanation that may explain this 
discrepancy is that MCF10A cells are extremely adherent, form round domed-shaped colonies, 
and generally aggregate together and therefore, the colonies observed in the DOX -ve cells are 
a mere characteristic of these cells exhibited in the ultra-pure agarose and are not relevant to 
transformation.  
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Chapter 4 
 
Investigating the dynamics of early signalling changes 
upon HER2 over expression 
 
4.1 Introduction 
 
Signalling pathways convey cellular information into the nucleus in response to external stimuli 
by various post translational modifications (PTMs) to proteins (251). The PTMs contribute to 
vital roles by regulating biological processes such as cell growth, survival, invasion, 
differentiation, and protein turnover. Importantly, reversible phosphorylation events play a 
central role in the growth of tumours. For example, the HER receptor family is activated by 
various ligands, which in turn can initiate a cascade of widespread phosphorylation in 
downstream signalling pathways to promote tumour development (251, 252). Indeed, 
phosphorylation in cancer cell signalling has been actively studied in various biological 
contexts, but there is a need for network-wide analysis of each signalling dynamics to define 
the signalling machinery at the system level. 
To better characterise the phenotypic consequences we have observed through HER2 
mediated cellular neoplastic transformation, we undertook a detailed global study to 
investigate the molecular signalling events in the phosphoproteome driven by HER2 expression 
by an unbiased and comprehensive phosphoproteomic approach. We were particularly 
interested in determining the molecular changes that take place at the very outset of HER2 
protein induction and transformation. We aimed to assess the effect of HER2 over expression 
at short time points after protein induction, in the absence of any other genetic or epigenetic 
alterations except from those already occurring in the immortalised MCF10A cell line. In this 
system, HER2 protein levels increase in a time depend manner upon doxycycline addition. 
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Therefore, the low-level sequential activation of HER2 in early time points may mimic 
physiological signalling events as observed in cancer cells. Indeed, in many different cancers, 
wild type HER2 is over expressed as is the case in this system. 
4.2 Detection of downstream signalling events upon HER2 induction 
 
To establish if the HER2 inducible construct transduced in the MCF10A cells is functioning, we 
first assessed the phosphorylation status of known proteins activated by HER2 protein 
induction. The DOX -ve and DOX +ve cells were cultured in serum free media (by removing EGF 
and horse serum) for 24 hours to lower pathway activities close to basal levels. Cells were then 
stimulated with full media (containing EGF and horse serum) for either 5, 10, 15 minutes or left 
untreated in the serum free media, as a negative control. Western blotting analysis revealed 
notably higher phosphorylation of ERK in DOX +ve cells compared to DOX -ve cells, as is shown 
by the increase in phosphorylation of the activatory modification (ERK[1/2] Thr/202/Tyr204) 
levels upon stimulation with full media, in two biological replicates (Figure 4.1A). Moreover, to 
determine the phosphorylation changes occurring upon the activation of the PI3K-AKT 
signalling pathway, we performed western blotting for AKT activatory modification at serine 
473 (S473). Cells were serum starved for 24 hours and then stimulated with full media for 
either 15, 30, 45 minutes or left untreated in the serum free media. We chose longer time-
points of stimulation compared to ERK phosphorylation as it is known that AKT 
phosphorylation is slower compared to rapid transmission of signalling through the MAPK 
signalling pathway. Interestingly, HER2 over expression did not have an effect on the activation 
of AKT at this specific residue (Figure 4.1B).  
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Figure 4.1: Detection of ERK and AKT activation upon HER2 protein over expression. (A) To detect ERK 
activation DOX -ve and DOX +ve cells were gown in serum starved cell media for 24 hours and then 
stimulated with full media for the indicated time points or left in the serum starved media as a negative 
control. Detection of phospho-ERK (Thr202/Tyr204) is shown. After stripping, the same membrane was 
blotted for total-ERK (ERK 1/2) and GAPDH was used a loading control. n=2. (B) Densitometry analysis of 
pERK expression normalised to GAPDH (loading control) was performed using Image J (n=2). (C) For AKT 
activation DOX -ve and DOX +ve cells were gown in serum starved cell media for 24 hours and then 
stimulated with full media for the indicated time points or left in the serum starved media as a negative 
control. Detection of phospho-AKT (S473) is shown. After stripping, the same membrane was probed 
with a total-AKT antibody and GAPDH was used as a control. n=1. (D) Densitometry analysis of pAKT 
expression normalised to GAPDH (loading control) was performed using Image J (n=1). 
4.3 HER2 over expression increases expression of genes related to 
angiogenesis and adhesion mediators 
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To validate the expression of genes that are known to be enhanced upon HER2 over 
expression and in the presence of exogenous EGF, we performed RT-PCR for 6 different genes 
known to be involved in transcriptional induction of adhesion, morphogenesis and 
angiogenesis (3). HER2 over expression was maintained in DOX +ve cells for 5 days in 2D cell 
culture and RT-PCR was carried out on total RNA from both DOX -ve and DOX +ve cells. We 
found that there was no significant change in the expression of angiogenic and adhesion 
factors including LOX, BMPR2, ILK, VEGFC, BMP6, and LOXL2 when cells are grown in 2D cell 
culture (Figure 4.2A). We thought that this because these genes are relevant to the processes 
of cell adhesion and angiogenesis and there expression may not be directly significant in 2D 
cell culture. Therefore, we extended our analysis to 3-dimensional (3D) cell culture and plated 
DOX -ve and DOX +ve cells in a mixture of matrigel and collagen overlay (“on top”) 3D cell 
culture method for the same number of days (5 days) as the 2D cell culture.  Acini from 3D cell 
culture were recovered and expression of the same genes as above were validated by RT-PCR. 
Intriguingly, HER2 over expression increased the transcription of adhesion and angiogenic 
molecules in the acini of the MCF10A cells (Figure 4.2B).  
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Figure 4.2: Transcriptional effects of HER2 over expression. mRNA expression of genes known to be 
upregulated upon HER2 over expression. (A) Total RNA was isolated after 5 days of HER2 over 
expression in MCF10A cells in 2D cell culture, subjected to reverse transcription and analysed by RT-PCR. 
Light green and bars represent DOX +ve cells and white bars show DOX -ve cells (n=2). (B) HER2 was 
induced in 3D cell culture for 5 days, acini recovered and RT-PCR was performed. Green bars represent 
relative expression of DOX +ve cells compared to DOX -ve cells (n=2). Two-tailed student t-test was 
performed and is depicted as significant [* < 0.05 p-value]. 
4.4 Phospho-proteomic analysis of HER2 activation – an overview of 
experimental design 
 
In order to map the early molecular signalling events induced by HER2 protein over expression 
and cellular transformation, we performed liquid chromatography tandem-mass spectrometry 
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(LC-MS/MS) based phospho-proteomic analysis. To ensure reproducibility of minor 
quantitative changes, the experiment was repeated in 3 biological replicates and each sample 
was analysed twice by mass spectrometry. We selected 4 different time points for DOX -ve 
cells and added doxycycline to induce HER2 protein expression at 0 hours, 0.5 hours, 4 hours, 
and 7 hours to capture signalling dynamics at early and early-immediate points. The decision of 
selecting these time points was based on the western blotting of HER2 over expression in a 
time-dependent manner, and we saw that HER2 is expressed early upon dox addition, we 
wanted to study signalling changes at the very outset of HER2 protein expression (Figure 4.3).  
As a control, we added doxycycline to an empty GFP vector transduced in MCF10A cells at the 
same time points. The analysis compared the signalling changes in a time-dependent manner 
by comparing each time point to the 0 hour time point (0.5 hours vs 0 hours, 4 hours vs 0 
hours, and 7 hours vs 0 hours) to capture the earliest changes during the process of 
transformation (Figure 4.3). To obtain differentially regulated phospho-peptides from our 
dataset, we filtered out background phosphorylation events occurring natively and by the 
addition of dox in the GFP transduced MCF10A cells. We defined a phospho-peptide to be 
significantly differentially regulated if changes in phosphorylation intensity, such as increases 
or decreases in expression had a False Discovery Rate (FDR) corrected p-value of less < 0.05.  
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Figure 4.3: Schematic of experimental outline and phospho-proteome dataset overview. GFP 
transduced MCF10A cells and DOX -ve cells were stimulated by dox and collected at time points labelled. 
Samples were then subjected to mass spectrometry analysis. Collectively, over 4000 unique proteins 
were found to be modified and post our analysis pipeline, more than 1000 phospho-peptides were 
found to have differential phosphorylation levels. 
4.5 Overview of the phosphorylation changes upon HER2 activation 
 
In total, our data analysis workflow revealed changes in 4089 proteins containing one or more 
phosphopeptide. The differentially regulated phosphorylation changes were observed in 800 
proteins, which equalled to 1004 phosphopeptides. From this, 383 proteins were enriched in 
phosphorylation and 417 proteins were depleted of phosphorylation. We also quantified 
phosphorylation changes occurring at each time point upon HER2 activation. We found that 
there were 310 differentially regulated phospho-peptides at 0.5 hours (that may or may not 
also be significantly changing at other time points), 701 at 4 hours and 663 at 7 hours upon 
HER2 induction. The effects of HER2 on all proteins in our experimental setting was also 
quantified (Figure 4.4). Of those proteins that showed increase in phosphorylation, less than 
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15 proteins that contained a phospho-site that showed higher than 5 fold increase in 
phosphorylation abundance at any time point. Fewer than 100 proteins across all time points 
exhibited increase in phosphorylation between 1 to 5 fold intensity. Interestingly, most of the 
affected proteins exhibited a decrease in abundance of phosphorylation because at every time 
point the downregulated phosphorylation sites outnumbered those that were upregulated.   
 
Figure 4.4: Quantification of protein phosphorylation. HER2 effect on phosphorylation of proteins that 
show varying fold changes of phosphorylation. 
To ensure that the experimental design has been correctly executed we first checked if known 
proteins were activated upon HER2 induction. The proteins that should be phosphorylated in 
this model are HER2 and its family member HER1 (EGFR). As expected we observed an increase 
in both the HER2 and HER1 phosphorylation levels at sites T701 and Y1110 in a time-
dependent manner (Figure 4.5).  
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Figure 4.5: An internal quality control (QC) for phospho-proteomic analysis. (A) HER2 phosphorylation 
modification (T701) increases in a time dependent manner. (B) EGFR (Y1110) also becomes marginally 
activated in a time dependent manner compared to control cells. [* FDR corrected p-value of < 0.05. 
4.6 HER2 induced time-dependent differentially regulated phosphorylation 
events 
 
Having screened the phospho-proteome of MCF10A cells upon HER2 activation, we next 
analysed how this phospho-proteome is impacted by cellular transformation induced by HER2 
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protein expression. A volcano plot for the 0.5 hours’ time point is shown in the Figure 4.6A. 
This shows the immediate early phosphorylation events of 310 proteins, which include the 
upregulation of the HER1 (EGFR), the transcription factor JUN, the activation of PAK2, and 
NKTR, but also the downregulation of a novel DNMT1 phospho-peptide amongst many other 
changes. More specifically, of the 310 differentially and significantly changing phospho-
peptides, 153 were significantly depleted (log2 fold change < -0.5, FDR corrected p-value of < 
0.05), whereas 94 were significantly enriched (log2 fold change > 0.5 fold, FDR corrected p-
value < of 0.05). We used the 0.5 log2 fold cut off for upregulation and downregulation 
(represented by the dotted vertical line), since most of these peptides exhibited only marginal 
phosphorylation change. To understand how many phospho-sites are significantly increasing 
with a higher fold change, we picked a 2 log2 fold cut off and found that only 39 phospho-
peptides were changing significantly and 4 phospho-peptides were significantly down-
regulated with a cut off of log2 fold change <-2.  The phospho-peptides that were changing 
(upregulated or downregulated) at 0.5 hours were subjected to ontology enrichment analysis 
(Figure 4.6B). Using the DAVID bioinformatics functional annotation, we identified the 
biological processes that are significantly altered upon HER2 over expression in 0.5 hours. The 
clusters consisted of establishment of RNA localisation (cluster 1), cell-cell adhesion (cluster 4), 
chromosome organisation (cluster 5), and gene silencing (cluster 6). KEGG PATHWAY analysis 
and DISEASE annotations did not reveal any significant terms in any pathway or disease 
clusters, respectively, at the 0.5 hours’ time point.  
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Figure 4.6: Volcano plot of showing the phospho-proteome of HER2 induced changes in MCF10A cells 
at 0.5 hours. The red circles show the significant differential phosphorylation changes and the black 
circles show non-significant changes. The labelled phospho-peptides are indicated by red/black circles. 
The statistical significance was –log10 of the FDR corrected p-values (y axis) and the fold change is 
shown on the x axis. The vertical dotted line indicates a 0.5-fold change. (B) Gene ontology analysis of 
biological processes using DAVID of all the changes occurring at 0.5 hour upon HER2 induction and 
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transformation. The resulting Benjamini p-values for each term were –log10 transformed with a 
threshold of 0.05.  
Next, we assessed the differential phosphorylation changes of 390 phospho-peptides upon 4 
hours of HER2 induction and transformation. These alterations are visualised in a volcano plot 
(Figure 4.7A). There were 125 phospho-peptides significantly depleted (log2 fold change < -0.5, 
FDR corrected p-value of < 0.05) and 168 were significantly upregulated (log2 fold change > 0.5 
fold, FDR corrected p-value < of 0.05). We find the emergence of HER2 phosphorylation, and 
the activation of PAK2 alongside the hyper phosphorylation of a known HER2 interactor, 
EPS8L2. Interestingly, the downregulation of p53 binding protein was noted, and the sustained 
downregulation of the same phospho-site of DNMT1 observed in the earlier 0.5 hours’ time 
point. To investigate how many phospho-sites are significantly increasing with a higher fold 
change, we picked a higher cut off threshold of 2 log2 fold cut off and found that only 35 
phospho-sites were upregulated and 10 were significantly down-regulated with a cut off of 
log2 fold change <-2.  Ontology analysis of these phosphorylated proteins identified biological 
processes enriched for various terms, such as Ras protein signal transduction (cluster 1), cell-
cell adhesion (cluster 5), and the regulation of signalling (cluster 7) (Figure 4.7B). Similar to the 
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0.5 hours’ time point, KEGG PATHWAY and DISEASE annotation analysis did not enrich for any 
significant terms.  
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Figure 4.7: Volcano plot of showing the phospho-proteome of HER2 induced changes in MCF10A cells 
at 4 hours. The red circles show the significant differential phosphorylation changes and the black circles 
show non-significant changes. The statistical significance was –log10 of the FDR corrected p-values (y 
axis) and the fold change is shown on the x axis. The vertical dotted line indicates a 0.5-fold change. (B) 
Gene ontology analysis of biological processes using DAVID of all the changes occurring at 4 hours upon 
HER2 induction and transformation. The resulting Benjamini p-values for each term were –log10 
transformed with a threshold of 0.05.  
We next examined the differential phosphorylation changes upon 7 hours of HER2 induction 
and cellular transformation, which resulted in 455 differentially regulated phospho-peptides, 
visualised by a volcano plot (Figure 4.8A). Of these, 157 phospho-peptides were significantly 
depleted (log2 fold change < -0.5, FDR corrected p-value of < 0.05) and 213 were significantly 
enriched (log2 fold change > 0.5 fold, FDR corrected p-value < of 0.05). Indeed, there is an 
overlap of phospho-peptides that were observed in the 0.5 hours or 4 hours’ time points, as 
the HER2 (T701), DNMT1 (S487), TP53BP1 (S1067), PAK2 (S58), are all maintained indicating 
that these changes are not transient. However, novel changes that were not observed in the 
previous two time points also appear. These include a second HER2 phospho-peptide (HER2 
T1060) as well as the activation of NKTR and PTK2 (FAK2) amongst many other alterations. To 
investigate how many phospho-peptides are significantly upregulated with a higher fold 
change, we picked a higher cut off threshold of 2 log2 fold cut off and found that only 45 
phospho-sites were upregulated and 14 were significantly down-regulated with a cut off of 
log2 fold change <-2. To understand the biological significance of these alterations, we 
performed ontology analysis of the changes occurring at the 7 hours’ time point. There were 
overlapping enrichment of biological processes such as cell-cell adhesion (cluster 1), nuclear 
chromosome segregation (cluster 3), cell projection organisation (cluster 4) and cell 
development (cluster 6), amongst others (Figure 4.8B). Interestingly, KEGG PATHWAY analysis 
107 
 
revealed significant changes in 3 different pathways, including the ErbB (HER) signalling 
pathway (Figure 4.8C).  
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Figure 4.8: Volcano plot of showing the phospho-proteome of HER2 induced changes in MCF10A cells 
at 7 hours. The red circles show the significant differential phosphorylation changes and the black circles 
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show non-significant changes. The statistical significance was –log10 of the FDR corrected p-values (y 
axis) and the fold change is shown on the x axis. The vertical dotted line indicates a 0.5-fold change. (B) 
Gene ontology analysis of biological processes using DAVID of all the changes occurring at 7 hours upon 
HER2 induction and transformation. (C) Pathway enrichment analysis using DAVID. The resulting 
Benjamini p-values for each term were –log10 transformed with a threshold of 0.05.  
4.7 Multisite protein phosphorylation 
 
Multisite protein phosphorylation is a major mechanism of regulating the activity of proteins 
(253). We found that across all time points in the upregulated or the downregulated phospho-
peptides, single phosphorylation sites per protein were strongly represented compared to 
multi-sites phospho-peptides (Figure 4.9A). Approximately 80% of the identified peptides were 
phosphorylated on just one residue, whereas the remaining 20% were phosphorylated at 
multiple sites of 2 or more. As we observed that many proteins could potentially have multi-
site protein phosphorylation, we next asked if they were activatory or inhibitory. We detected 
changes in the phosphorylation status of several regulators and kinases activated upon HER2 
expression with a multitude of phosphorylation modifications. These included HER2, SRC 
substrate cortactin, EGFR, FAK1, and P63 amongst many others (Figure 3.9B). We then 
manually inspected the multiplicity of phospho-peptides of several proteins to assess if they 
are associated with the activation or the inhibition of that protein. Interestingly, out of the 12 
proteins we searched for on PhosphoSitePlus, 5 of them had an activating (inducing) function 
(coloured red) or the function is not yet known. The other 7 phospho-peptide function 
(activatory or inhibitory) is yet to be elucidated (white bars) and no protein was found to have 
an inhibitory effect (Figure 4.9B). Compared to single site phosphorylation, multi-site protein 
phosphorylation maybe considered as an on/off switch for protein function and it increases 
the possibilities for protein regulation, with each phospho-site have a distinct characteristic 
(254).   
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Furthermore, of the 800 differentially regulated proteins we investigated a possible correlation 
with HER2 activity by calculating the Pearson’s correlation coefficient (R²) between the HER2 
phospho-peptide (HER2 T701) and the abundance of other phosphorylated peptides following 
similar intensity as the HER2 T701 modification. By applying a cut off value of 0.8, we identified 
148 proteins strongly following the trend of HER2 fold increase pattern (Figure 4.9C).  
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Figure 4.9: Phospho-proteome identification. (A) Pie charts represent the multi-site protein 
phosphorylation of the identified phospho-peptides. Percentage of phospho-peptides carrying either a 
single (blue), double (orange) or more than three residues (grey) are indicated. (B) Bar chart showing the 
multiplicity of the phosphorylation sites of some proteins. The red bars show the already known 
activating phospho-peptides. The white bars represent the activatory or inhibitory effects that are not 
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yet known. No inhibitory effect was found. (C) Pearson’s ranked phosphorylation changes of phospho-
peptides following the intensity of HER2 T701 residue.  
 
4.8 Quantitative phospho-proteomic analysis of HER2 induced changes 
 
To determine the signalling pathways activated upon HER2 induction at all time points (from 0 
to 7 hours) in the neoplastic transformation, we interrogated our dataset of 1004 differentially 
phosphorylated peptides using DAVID bioinformatics. We found at least 13 terms significantly 
enriched (Benjamini corrected p-value of below 0.05). These included enrichment for ErbB 
(HER) signalling pathway, mTOR signalling pathway, endometrial cancer, and MAPK signalling 
pathway amongst others (Figure 4.10A). To check which components of the HER signalling 
pathway are enriched, a schematic of the canonical KEGG pathway is shown in figure 4.10B. 
The red stars represent the proteins either activated or depleted in our system upon HER2 
over expression at all time points. The data shows the homodimerisation between HER1-HER1 
and HER2-HER2 partners, but also the heterodimerisation between HER1-HER2 family 
members. Interestingly, HER3 and HER4 remain inactive. A novel observation exhibits the 
neuregulin (NRG4) ligand itself is being activated. The predominant pathway that showed 
phosphorylation events was the MAPK signalling pathway, which enriched for SHC, SOS, RAF, 
ERK, and MYC.  However, some proteins of other pathways were also enriched, including FAK, 
PAK, and the activation of AKT and p21, indicating HER2 is able to induce phosphorylation 
changes through many distinct pathways. These changes were only exhibited in the HER2 
transduced cells as none of these changes were significant in the GFP-transduced MCF10A cells 
(Figure 4.10B).   
Furthermore, to understand the biological significance of these results, the same phospho-
peptides were subjected to ontology analysis (Figure 4.10C). Phospho-peptides associated with 
cell-cell adhesion were enriched similarly to the gene ontology (GO) terms we determined for 
each time point, indicating that this cellular process is very sensitive to alterations in the HER 
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signalling. The analysis also revealed the enrichment of a number of other biological processes 
GO terms associated with chromatin organisation, cell projection organisation, cell ageing, and 
regulation of signal transduction pathways amongst other terms.  Lastly, the only disease 
significantly enriched was breast cancer.  
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Figure 4.10: Signalling and biological function analysis of the early immediate changes in 
transformation. (A) Signalling pathway analysis using the DAVID KEGG PATHWAY tools of the 
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differentially phosphorylated events at all time points upon the HER2 protein induction is shown. (B) 
Selection of the canonical ErbB signalling pathway, shown the changes in our system indicated by the 
red stars. (C) Gene ontology analysis of the enrichment biological processes. 
4.9 Time dependent changes upon HER2 over expression 
 
To gain a better understanding of HER2 regulated time-dependent changes, we selected only 
those phospho-peptides that are changing in the 0.5 hour time point and then continuously 
maintained until the final 7 hour time point. We first applied a FDR corrected p-value of at 
least < 0.05 to focus on phospho-peptides that showed statistically significant differential 
regulation (up or down regulation) compared to DOX -ve cells. We found that by applying such 
a stringent threshold it would likely represent fewer but genuine phosphorylation events, thus 
overall only 57 phosphopeptides were differentially regulated, of which 32 phospho-peptides 
were marked as being down regulated and 25 hyper phosphorylated or up regulated. Some of 
the significant down regulated phospho-peptides included DNA methyltransferase (DNMT1 
S387), AKT2 [T451], and ELF4 [S186]. One of the hyper phosphorylated peptides was LAP3 
[R440], which is involved in the turnover of intracellular proteins, but the specific function for 
this phospho-site is not yet known and it has not been associated with breast lesions or HER2 
positive breast cancer.  
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Figure 4.11. Time dependent phosphorylation events. Heatmap displaying differentially regulated 
phosphorylation changes that are time-dependent (significant) that occur in all time points analysed 
upon HER2 over expression but none of these changes are significant in the control cells. [* FDR 
corrected p-value of < 0.05, **FDR corrected p-value of < 0.001, *** FDR corrected p-value of < 0.001]. 
4.10 Activation of chromatin regulators and transcription factors 
 
As we identified various biological processes enriched for proteins associated with 
chromosome organisation, nuclear chromosome segregation, sister chromatid segregation and 
other processes related chromatin, we wanted to assess if there were any transcription factors 
or regulators of chromatin in our dataset that have a molecular effect on transcription of 
genes that are significantly changing upon HER2 over expression that do not alter significantly 
in the GFP transduced cells. We identified 29 phospho-peptides that satisfy those conditions 
by checking their molecular function on PhosphoSitePlus. The alterations included the 
activation of NFkB, JUN, SIRT1, and SOX13 amongst other changes (Figure 4.11). It is 
interesting to note that the majority (72%) of these changes affecting the transcription 
factors/chromatin regulators incidentally occur at the later time points of 4 hours and 7 hours 
and the remaining 28% at 0.5 hours. This is in contrast to the activation of for example, the 
HER signalling pathway, in which the majority (70%) of the proteins become active at either 0.5 
or 4 hours’ time points. These changes were not significant in the GFP transduced cells.  
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Figure 4.12: Identification of transcription factors and chromatin regulators. A list of transcription 
factors and chromatin regulators becoming differentially regulated upon HER2 expression in at least one 
time point is shown. [* FDR corrected p-value of < 0.05, **FDR corrected p-value of < 0.001, *** FDR 
corrected p-value of < 0.001].  
 
Many proteins of the HER signalling pathway and others we have identified here are known to 
directly impact transcription factors, which can ultimately alter chromatin architecture (i.e. its 
accessibility or inaccessibility (255, 256)). Therefore, it would be extremely valuable to 
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understand the association between HER2 induced signalling changes and its effects on 
chromatin organisation, which ultimately plays an important role in transcription. To achieve 
this, we have performed ATAC-seq (Assay for Transposase-Accessible Chromatin using 
sequencing) analysis to interrogate the architectural chromatin alterations upon HER2 over 
expression and during the early stages of cellular transformation. Indeed, we have already 
shown that the components of the HER/MAPK signalling pathway are activated rapidly at 0.5 
and 4 hours’ time points, but the various chromatin regulators become activated at the later 
time points (which can impact chromatin organisation), indicating a series of events in a time-
dependent manner that can ultimately alter chromatin state and contribute to transformation. 
Therefore, performing ATAC-seq alongside our phospho-proteomic data set will help us dissect 
the mechanism(s) by which HER2 induces transformation in an experimental setting and help 
understand the contribution of signalling and chromatin structural changes to transformation 
(Figure 4.12).  
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Figure 4.13: Potential mechanism of HER2 induced transformation in MCF10A cells. The phenotypic 
changes such as morphological alterations, high invasion potential, and anchorage-independent growth 
of HER2 over expressing MCF10A cells will most likely accompany changes at the molecular level. Here, 
we hypothesise that the signalling changes induced by HER2 over expression will result in gross 
chromatin organisational changes. Those changes may include accessible regions of the chromatin at 
where various proto-oncogene reside (potentially activating them) and inaccessible regions of 
chromatin may be enriched where tumour suppressor genes reside (potentially inactivating them), 
contributing the transformative phenotypes we have observed with various functional assays 
performed. 
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4.11 Discussion 
 
In this investigation, we have carried out an in-depth characterisation of the phospho-
proteome of early-immediate signalling changes in the process of cellular transformation. This 
study provides a detailed picture of the downstream consequences (at the phospho-peptide 
level), of neoplastic transformation induced by the activation of a proto-oncogene. The 
phospho-proteomic changes in MCF10A cells upon HER2 protein induction and neoplastic 
transformation of our dataset is in contrast with the other studies that have examined the 
effects of HER2 activation in transformed cells. This is because those systems study already 
transformed cells, or examine the effects of mutations at long time points, when presumably 
other genetic and/or epigenetic aberrations have taken place. To achieve the aim of dissecting 
signalling changes at the very outset of transformation and HER2 expression, our HER2 
inducible MCF10A system provides obvious advantages. The low levels of HER2 activation at 
early time points may closely mimic, to a partial extent, the early signalling changes occurring 
in HER2 positive breast cancer patients. The signalling changes at global scale of low level HER2 
induction has not been performed to date. 
We have previously shown by western blotting that HER2 protein levels increase in a time-
dependent manner by the addition of 1µg/ml of doxycycline, and that the protein levels fully 
saturate after 12 hours in doxycycline containing media. However, our phospho-proteomic 
analysis was performed at the final time point of 7 hours, by which the HER2 expression would 
not be fully induced. Therefore, our phospho-proteomic screen is constrained to the acute 
effects of HER2 activation, since HER2 is not fully expressed; as a result, we have not measured 
the signalling activity of a fully induced HER2 protein. 
Furthermore, MCF10A cells require the addition of ligands to survive, as they induce signalling 
to allow the cells to divide and proliferate. Our simple model requires the exogenous addition 
of a single ligand, which is the epidermal growth factor (EGF). This causes the 
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heterodimerisation between HER1-HER2 or homodimerisation between HER1-HER1, and the 
non-ligand independent homodimerisation between HER2-HER2 receptors. The deprivation of 
additional available ligands in our model results in lack of dimerisation between the other 
HER2 binding partners and family members such as HER3 and HER4. This system is therefore 
restricted in characterising the signalling changes upon just three combinations of 
dimerisation. However, in mammalian cells, 12 different ligands have been identified that can 
induce signalling which would not be reproduced by this system, suggesting the lack of 
complexity in this model to recapitulate the phosphorylation events occurring in HER2 positive 
breast cancer patients. 
Moreover, despite the ectopic over expression of HER2 in cells at early time points, we 
identified less than 2% of phosphotyrosine peptides even though a large number of tyrosine 
kinases are present in the genome and it is known that tyrosine phosphorylation occurs earlier 
on compared to phoshotheronine and phosphoserine. This may be attributed to the technical 
aspect of the experimental setting, such as the use of titanium dioxide (TiO₂), which is known 
to bind to tyrosine phosphorylations less favourably compared to serine and threonine 
modifications, which may explain the lower enrichment of phosphotyrosines (257). There are 
several known biological reasons for the relatively low phosphotyrosine sites identified. Firstly, 
phosphotyrosines become activated only during specific circumstances (258). Secondly, 
phosphotyrosines have a short half-life, due to high levels of activity of phosphotyrosine 
phosphatases or PTPs, unless the phosphotyrosines are protected by the PTP and SH2 domains 
(259). Lastly, since the number of phosphopeptides observed in our system is not high, this 
may correlate to the fewer phosphotyrosines identified. This is because it is known that 
tyrosine phosphorylation occurs on proteins with high abundance. Nevertheless, it appears 
that there is an inherent bias due the method employed for identifying fewer 
phosphotyrosines compared to threonine and serine modifications, but is difficult to dissect if 
that is due to a biological effect, which might be vital or a technical caveat. If technical, then it 
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means that many important phosphopeptides were not identified that may be critical for the 
process of transformation (257). However, since the focus of our study was not only to identify 
phosphotyrosines, but also serine and threonine phosphorylations, the relatively low 
enrichment of tyrosine phosphorylations did not pose a major concern.  
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Chapter 5 
 
Assessing global chromatin accessibility alterations in 
HER2 induced transformation 
 
5.1 Introduction 
 
The opening of chromatin that is accessible for binding by transcription factors is correlated 
with biological activity at a specific genomic region (133). The phenotypic changes induced 
upon HER2 over expression in our model during cellular transformation are likely to be driven 
by alterations in the gene expression, which are themselves governed by the accessibility and 
inaccessibility of chromatin architecture. There are reports that have documented the 
chromatin landscape differences between normal and transformed cells, and have begun to 
define the chromatin state of cancer cell lines (132, 136).  However, the specific changes in 
chromatin state driving the transition from normal to transformed cells are still remaining to 
be explored. More specifically, the over expression of a cell surface receptor and the ensuing 
activation of a plethora of signalling networks and its effects on chromatin landscape is not yet 
elucidated. Here, we attempt to understand the impact of signalling events on the chromatin 
state, and how that contributes to cellular transformation.  
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5.2 ATAC-seq library preparation – attacking the chromatin 
 
To probe for DNA accessibility with a sensitive and fast alternative to other methods such as 
DNase-seq or Mnase-seq, we employed ATAC-seq with next generation sequencing. This 
method uses a hyperactive Tn5 transposase enzyme that inserts sequencing adapters to 
random DNA sequences, but only in accessible regions of the chromatin (260). In an attempt to 
be partially physiologically relevant to the in vivo microenvironment, we prepared DNA 
libraries for ATAC-seq from 50,000 cells from acini grown in 3D cell cultures in contrast to cells 
growing in 2D cell culture. However, the sensitivity of library preparation for ATAC seq from 
acini recovered from 3D cell culture proved challenging initially, because of the difficulty in 
isolating cells that are homogenous population (intact and free from any debris) and also that 
they are the correct number, as the ratio of cell number to transposase enzyme is critical for 
success library preparation.  
50,000 cells were thus recovered from 3D cell culture and libraries prepared as per protocol 
(see 2.13). DNA library profiles were analysed by a bio-analyser, and a representative profile is 
shown in figure 5.1A. At the beginning, it appeared that we were transposing fewer than 
50,000 cells despite counting with a haemocytometer twice and using the average of those 
values, as the fragments appears to be “over-transposed” with a preponderance of shorter 
fragments lacking the periodicity as is generally expected in ATAC-seq libraries. To overcome 
this, we switched to counting the cells with Luna automated cell counter and performed the 
library preparation. The library profile was then as expected for ATAC-seq, and the rest of the 
libraries were prepared in the same manner (Figure 5.1B).  
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Figure 5.1: ATAC-seq library profiles. (A) Library profile for incorrect number of cells, which has been 
over-transposed. (B)  The correct library profile, with periodicity of Tn5 cutting chromatin at different 
fragment lengths.  
5.3 Quality metrics and validation 
 
To identify genome-wide changes in the chromatin accessibility during cellular transformation, 
we analysed 6 different time points. These were 0 hour, 1 hour, 4 hours, 7 hours, 24 hours, 
and 48 hours in two biological replicates, encompassing early and late time points upon HER2 
induction (DOX +ve cells) and their control counterparts, DOX -ve cells. Here, we will confine 
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our analysis to the early time points of transformation only, taking into consideration just the 
first three time points. These are 0 hours DOX -ve, 1 hour DOX +ve, and 4 hours DOX +ve time 
points. For these sample, we obtained on average 57.94% mappability to the human genome.  
We first assessed the fragment length distribution which has 124 base pairs (bp) adapter 
sequence removed, a representative plot is shown in figure 5.2A. This shows more than half of 
the reads tend to be shorter than 150 bp, which are sub-nucleosomal and approximately half 
of the reads appear to be larger than 150 bp. This as it has been previously shown, is an 
expected profile of ATAC-seq library (260). 
To ensure that the biological replicates are reproducible we clustered the samples based on 
Pearson correlation coefficient. The correlation coefficient indicates how strong the 
relationship between two samples is, which consists of numbers from -1 to 1 (where 1 
indicates perfect correlation and -1 indicates perfect anti-correlation). This method is used to 
determine if different samples can be separated. For example, generally it would be expected 
that samples from two biological replicates of the same condition would have greater 
similarity between them, compared to samples from two different conditions.  In our case, it 
appears that the biological replicates are more similar to each other than samples collected at 
different times within the same condition (Figure 5.2B). The PCA plot shows that DOX +ve 
sample cluster together and broadly there is a clear separation between the DOX -ve and DOX 
+ve samples (Figure 5.2C).  
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Figure 5.2: Fragment size and evaluation of reproducibility. (A) Insert size as determined by high 
throughput sequencing, adapter sequences are an additional ~124 base pairs. (B) Correlation heatmap 
using peak caller score data across all the time points in biological replicates. (C) PCA plot showing the 
clustering between DOX -ve and DOX +ve samples and their biological replicates. 
To visualise the enrichment ATAC-seq signal over specific target regions, we plotted heatmaps 
of the signal coverage between the two biological replicates. The y-axis of the heatmap shows 
the regions of accessible chromatin i.e. peaks. The x-axis shows the read counts were 
“centered” on the center of each peak region, which were extended to include 1000 bp of 
upstream of each peak start and 1000 bp downstream of each peak end. This simple peak 
calling with default parameters generated consistent regions between the biological replicates 
(Figure 5.3).  
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Figure 5.3: ATAC-seq quality metrics. Heatmaps showing normalised read coverage for ATAC-seq 
enrichment signal ± 1000 base pairs from the center of the peak for the biological replicates. The scale 
shows highly accessible regions in blue and inaccessible regions in red, based on the fold-change value 
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from each peak. Each row represents one peak. The heatmaps were created using a matrix, which 
requires BigWig files and a BED file. The BigWig file is an indexed, compressed and binary file of the 
genome-wide signal data for various types of calculations. The BED file is a text file format, containing 
the chromosome name, the chromosome start position and end position. Therefore, the matrix used to 
create the heatmaps are all ordered in the same way for the different samples. They rows are ordered 
by the chromosome name, and the start position.   
5.4 Overview of chromatin accessibility landscape 
 
Next, we intersected the two biological replicates and measured the total number of peaks 
(open chromatin regions) in each time point using default MACS2 settings and without 
applying filters or any statistical power. In total we identified dynamic DNA access (71,699 
peaks) at the 0 hour DOX -ve time point, 73,457 peaks in the 1 hour DOX +ve time point, and 
74,375 peaks in the 4 hours DOX +ve point. The majority of the peaks were identified across 
the samples, representing a total of 61,162 shared peaks. However, a number of them were 
also unique to each point (Figure 5.4). It appears that chromatin accessibility between the 
three samples is approximately the same, potentially reflecting that HER2 overexpression does 
not cause large scale changes in chromatin accessibility. 
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Figure 5.4: Quantification of accessible chromatin. Venn diagram shows the peaks that overlap and 
those that are unique to the specific time point. All the samples were downsampled (normalised) to 25 
million reads. Peaks were called by MACS2 and the different number of peaks were counted by 
samtools.  
 The data revealed categories of peaks that are either unique to, or are overlapping between 
the different time points. For instance, a peak associated with SHNG5 is overlapping between 
all the time points and is enriched in all the biological replicates, whereas a peaks associated 
with FAM19A2 and KRT17 are only unique to the time points with HER2 expression, in 1 and 4 
hours DOX +ve time points, with background noise peaks for the DOX -ve replicates (Figure 
5.5). 
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Figure 5.5: Visualising the peaks and associated genes. Integrative Genomics Viewer (IGV) for ATAC-seq 
signal for the indicated genes across the biological replicates and time points. 
To visualise the significant and differential chromatin accessible peaks between the different 
time points and the biological replicates, we generated a heatmap with all the regions that are 
changing (Figure 5.6A). These plots were made after statistically significant peaks were 
selected by setting the threshold with an FDR corrected p-value of 9 and fold-change of at 
least 7. There is a high degree of similarity between the biological replicates and there is a 
distinct pattern in the accessible chromatin from 0h time point to 1 hour time point. The 
heatmap also shows the clustering between the DOX -ve samples and the DOX +ve samples. To 
identify which data points are identified as being differentially chromatin accessible regions, 
we plotted an MA plot (log2 fold change vs. mean average) to visualise changes in chromatin 
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accessibility for all peaks. In total, we identified 22,296 differentially accessible changes (Figure 
5.6B). The MA plot takes into account all the changes between DOX -ve and DOX +ve samples 
at all the time points (0 hour, 1 hour, and 4 hours). Without taking into account the time-
specific changes, there appears to be a decrease in the global chromatin accessibility, since 
more of accessible regions have decrease intensities (< -0.5 fold change) (Figure 5.6B). 
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Figure 5.6: Profiling of chromatin accessibility at early time points upon HER2 over expression. (A) 
Heatmap displaying relative chromatin accessibility. (B) Sites that have differentially accessibility are 
coloured in pink. The differentially accessible regions have an absolute log fold difference of at least 0.5. 
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5.5 Discussion 
 
We provide a non-comprehensive and simple initial quality metrics and visualisation of our 
ATAC-seq data for some of our samples. We performed some very basic tests to check if our 
dataset that has been aligned to human genome meet our expectations.  
A technical aspect of the this ATAC-seq experimental setting included the isolation of acini 
from a 3D matrix at 4°C using the cell recovery solution, to depolymerise the matrigel/collagen 
mixture. Although there is no direct evidence to suggest that such a recovery method would 
impact the chromatin dynamics, the cellular microenvironment between the physiological 
growth conditions at 37 °C and the conditions during the detachment of cells from the matrix 
are quite different. It has been previously shown that the phosphoproteome of cells recovered 
with the recovery solution has significant impact on the phosphoproteomic status of cells 
(261). Therefore, it is conceivable to think that the use of recovery solution may also have an 
effect on the chromatin landscape. 
Furthermore, we used DOX -ve cells as a parental control for ATAC-seq analysis, which does 
not have the addition of dox that is added to the DOX +ve cells for HER2 protein induction. It is 
worth bearing in mind that addition of dox may induce chromatin changes that are not 
associated with HER2 expression. However, there are reports of using dox as an inducing agent 
where a separate control for dox was not performed (262, 263), whereas others have included 
a dox control (264).  
Finally, there is ongoing comprehensive analysis of this dataset across all the time points to 
help understand the impact of HER2 induced transformation on the chromatin architecture, 
with a more specific aim of understanding the effect of HER2 signalling on DNA accessibility.  
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To achieve this we anticipate to address the following:  
1. It will be important to address whether HER2 overexpression creates a chromatin 
accessibility pattern early on after induction, a pattern that is maintained throughout 
the subsequent time points; or is it the case that differential chromatin regions (DCRs) 
are dynamic and time-dependent (i.e specific to time points). 
2. One way of exploring the implication of signalling on chromatin changes is to integrate 
the phosphoproteomic dataset with ATAC-seq data. Accessible chromatin have peaks 
at specific genomic regions and these can be used to identify motifs for transcription 
factor binding. Transcription factors found in the phosphoproteomic data that 
correspond to these genomic motifs could be targets for further investigation as they 
may be involved in regulating chromatin architecture at these regions.  
3. Since transcriptomic changes (chromatin changes) are very closely related to 
epigenetic changes, it would be useful to perform RNA-seq and DNA methylation 
analysis (or use available datasets) to identify chromatin accessibility in differentially 
methylated regions and to correlate the accessible peaks with gene expression by 
RNA-seq. This will give us a combined dataset that could be explored from different 
angles at high temporal resolution. In fact, our collaborators are performing single-cell 
RNA-seq experiments upon HER2 induction and during the transformation process 
with the aim of mapping the transcriptional process of HER2 induced transformation 
and the heterogeneity of the process. 
4. Since the morphological changes take place early upon HER2 induction in our model 
system, it would be interesting to see if the chromatin accessibility changes that occur 
in the early time points play a driving role in the morphological changes we observed, 
or whether these chromatin changes are independent, or facultative, of the process of 
transformation. 
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Chapter 6 
 
Investigating HER2 induced reprogramming associated 
heterogeneity 
 
6.1 Introduction 
 
Breast cancer can originate from different cells in the differentiation hierarchy, and can 
present different survival outcomes, mutational landscapes, and have distinct biological and 
clinical phenotypes (265-267); hence it can be categorised into several distinct subtypes based 
on the genetic and histopathological signatures. An example of this is the classification 
proposed by Perou et al. using microarrays (148), which has led to the formulation of five 
defined intrinsic subtypes, namely luminal A, luminal B, normal-like, HER2 enriched, and basal-
like. The newly diagnosed breast cancers can now be designated to one of these subtypes 
based on the gene expression patterns of the PAM50, which are the 50 informative genes 
(148). However, the model of somatic cells acquiring mutations sequentially may be overly 
simplistic, and the concept of breast cancer stem cells has gained significant attention recently 
(268). These are thought to reside within the basal compartment of the gland because they 
share gene expression profiles and cell surface with the basal cells (269). The heterogeneity in 
cancer incidence, patient prognosis and patient response to therapies can also be ascribed to 
committed cells in the mammary compartment acquiring a stem cell-like phenotype during 
breast tumourigenesis (270-272). 
Aberrant signalling events (273), induction of EMT transition (274), mutations in genes (275), 
and oncogene over expression (276) can induce cells to undergo tumour-reprogramming 
processes and enrich for markers known to be active in stem cells. The acquisition of the stem-
like phenotype is associated with higher transformational potential (277, 278), leading to more 
aggressive forms of cancers because of their ability to self-renew (279, 280). The reason for 
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this is that it allows stem cells to produce a large number of progeny cells, thus increasing the 
probability of cells to acquire further genetic and/or epigenetic aberrations. 
Our first observation was that in the in vitro transformation assays (measuring anchorage-
independent growth of cells) of HER2-induced MCF10A cells, only a small fraction of cells 
plated out of the total population were able to form colonies. This could have been caused by 
cell death that can occur when cells are placed in relatively harsh conditions in this assay. 
Nevertheless, we also considered that perhaps not all cells have the potential to form colonies, 
and that upon induction of HER2 overexpression, a subset of cells would acquire markers 
associated with breast stem cells, which would increase their ability to form colonies. We 
therefore investigated the “stemness” of MCF10A cells upon HER2 protein induction and its 
control counterparts and hypothesised that the sub-population of cells with enrichment of 
stem-like markers will exhibit a higher transformative potential compared to bulk population 
or those that have non-stem like markers. 
6.2 Identification of stem cell markers upon HER2 protein induction 
 
To investigate if HER2 protein over expression induces reprogramming-associated 
heterogeneity in early cellular transformation, we tested the expression of proteins associated 
with breast stem-like phenotype. As a starting reference into identifying possible stem cell 
proteins that may be differentially expressed in DOX +ve cells compared to DOX -ve cells, we 
explored existing literature and investigated the cell surface markers proposed in the 
mammary epithelial cell hierarchy (154), as well as markers associated with embryonic stem 
cells, and cancer stem cells. We induced HER2 over expression for 72 hours and used DOX -ve 
parental population as control. Firstly, we began by performing immunofluorescence analysis 
to check for the expression of stem markers such as SOX2 (SRY-Box 2) and KLF4 (kruppel-like 
factor 4), which are enriched in pluripotent stem-like cells, and the expression of MUC1 
(CD227), which is depleted in breast stem cells (154). We found that there was no difference in 
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the protein expression of SOX2 and KLF4 between DOX -ve and DOX +ve cells, with both cell 
types exhibiting homogenous and depleted levels of the cell surface proteins (Figure 6.1). 
Therefore, SOX2 and KLF4 were disqualified from our panel of markers for identifying the 
stemness of cells due the lack of differential expression between DOX -ve and DOX +ve cells. 
However, we observed heterogeneous expression of the MUC1 protein (Figure 6.1). MUC1 is a 
type I transmembrane, which is normally expressed at low levels in the luminal epithelial cells 
of the mammary gland, and its expression is low or negative in normal breast stem cells (154, 
281, 282). DOX -ve cells showed no variability in its protein expression as most cells were 
expressing similar levels of MUC1. On the other hand, DOX +ve cells (72 hours after induction 
of HER2) exhibited heterogeneous expression of MUC1, with some cells being negative for 
MUC1 expression or below the detection threshold of immunofluorescence analysis. 
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Figure 6.1: Investigating the acquisition of stem-like phenotypic features. DOX +ve and DOX -ve cells 
were grown for 3 days, fixed and subjected to staining by the indicated antibodies to stain for 
stem/progenitor cells using immunofluorescence assay. DAPI was used as a nuclear stain. Magnification: 
20X for SOX2 and KLF4 images and 40X for MUC1 images. Scale bars represent 50µm in MUC1 images 
and 100µm for KLF4 and SOX2 images. 
 
We moved on from using immunofluorescence analysis, which gives us a static image of 
protein expression, to flow cytometry to quantitatively measure the protein abundance. We 
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further investigated the protein expression of CD44 (cluster of differentiation 44) and CD49F 
(α6-Integrin subunit), both of which are highly expressed in mammary stem cells (283). 
Mammary cancer stem cells have been previously isolated by high expression of CD44 
alongside CD24 -ve and Lin -ve markers (155). The co-expression of CD49F +ve with EpCAM -ve 
(epithelial cellular adhesion molecule) expression have also been used as prognostic markers 
for breast cancer (284). As with the previous experiment, HER2 expression was maintained for 
72 hours, and flow cytometry analysis for the two proteins performed. Interestingly, flow 
cytometry analysis confirmed the high expression of CD44 and CD49F in both DOX -ve and DOX 
+ve cells in two independent biological replicates (Figure 6.2). For this reason, we also 
disqualified these markers of heterogeneity from our system, despite them being detected at 
high levels in both cell types as is seen in breast stem cells. 
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Figure 6.2: Determining the expression of stem markers. Flow cytometric analysis of single stains of 
CD44 and CD49F in in two independent biological replicates of DOX -ve and DOX +ve cells. The gating 
was based on the negative control. 
6.3 Characterising HER2 induced MCF10A cells for stemness 
 
We continued our investigation to identify stem markers that may be heterogeneously 
expressed upon HER2-induced transformation, and have differential expression between DOX 
+ve and DOX -ve cells. It has been shown that decreased expression of MUC1 and the EpCAM 
is associated with the most primitive cells in the mammary epithelial stem cell hierarchy (154). 
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We confirmed our previous observation by flow cytometry that MUC1 has decreased 
expression in DOX +ve cells compared to DOX -ve cells (Figure 6.3). 
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Figure 6.3: Relative abundance of MUC1 protein expression. Flow cytometry analysis of single stains of 
MUC1 in two independent biological replicates of DOX -ve and DOX +ve cells. The negative gating was 
based on unstained cells. 
 
Additionally, we found that EpCAM has decreased expression upon HER2 over expression, 
resulting in a subpopulation of cells exhibiting a stem-like phenotype (“stemness”). We verified 
the expression of MUC1 and EpCAM in two independent biological replicates and found 
variable percentage of MUC1 -ve and EpCAM -ve cells in both DOX +ve and DOX -ve cells, with 
consistently higher enrichment of MUC1 -ve and EpCAM -ve population in the DOX +ve cells 
relative to DOX -ve cells. The variability in MUC1 and EpCAM expression may show that 
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acquisition of the stem-like phenotype is a stochastic process or is a result of technical aspects 
of the experiment (Figures 6.3 and 6.4).  
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Figure 6.4: Relative abundance of EpCAM protein expression. Flow cytometric analysis of single stains 
of EpCAM in two independent biological replicates of DOX -ve and DOX +ve cells. The gating strategy 
was based on unstained cells. 
To find out if the identified stem markers are co-expressed and co-localised as a result of HER2 
over expression we carried out flow cytometry for the expression of MUC1, EpCAM, and added 
CD24 (cluster of differentiation 24), which is absent in breast cancer stem cells (285). The lack 
of CD24 expression alongside CD44 +ve expression in breast cells have been associated with 
enhanced tumourigenicity, and the conclusions from several investigations have shown a role 
in cancer initiation and metastasis (285-287). We identified that in the DOX +ve cells there 
were approximately 60% of cells expressing HER2 protein. Of these, we found 19.4% MUC1 -ve 
cells, of which 26.2% were EpCAM -ve cells. All of the MUC1 -ve/EpCAM -ve cells were also 
CD24 -ve (Figure 6.5). This was in contrast to the DOX -ve cells, which had depleted levels of 
stem markers. We identified 5.45% MUC1 -ve cells, of which 2.93% were EpCAM -ve. All of the 
MUC1 -ve/EpCAM -ve cells were also CD24 -ve (Figure 6.5). This suggests that in vitro 
transformation of MCF10A cells upon HER2 protein over expression favours/selects a 
subpopulation of cells enriched for cells with proteins expressed in stem cells based on the 
MUC1/EpCAM/CD24 -ve phenotype. 
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Figure 6.5: Outline of flow cytometry strategy of identifying the MUC1/EpCAM/CD24 co-expression in 
DOX +ve and DOX -ve cells. HER2 was induced for 72 hours and cells were treated with the combination 
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of antibodies as labelled. Cells were gated on HER2 expressing cells, which were further gated for the 
absence of MUC1, and thereafter for the absence of EpCAM and CD24. The negative gates were set on 
relative fluorescence minus one (FMO) controls whereby at least 99% of cells were selected. 
We further wanted to know if variable HER2 expression (HER2 biomarker heterogeneity) 
induces differential expression levels of stem markers. At this point, we hypothesised that 
increased HER2 expression, more specifically the highest HER2 expressing cells in this 
experiment, would drive a more rapid acquisition of the stem state. We therefore selected the 
top 20% of HER2 expressing cells, and surprisingly, the stem-like markers were less enriched 
compared to the bulk HER2 positive population (6.6). This is because the enrichment of the 
stemness MUC1 -ve (11.6%) and EpCAM -ve (16.1%) had decreased compared to the bulk 
HER2 over expressing cells. Next, we selected the lowest 20% of HER2 expressing cells, and 
unexpectedly, we found that the stem cell markers have enriched in this population (Figure 
6.6). There was an enrichment of stem markers, as MUC1 -ve (24.4%) and EpCAM -ve (30.1%) 
expression was higher compared to the high HER2 expressing cells, but also higher than the 
bulk HER2 positive cells (Figure 6.6).  
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Figure 6.6: Identification of stemness based on HER2 biomarker heterogeneity. Of the DOX +ve cells, 
cells were gated based on 20% highest HER2 expression and 20% lowest HER2 expression. Cells were 
thereafter gated on the absence of MUC1, followed by the absence of EpCAM and CD24. The negative 
gates were set on relative fluorescence minus one (FMO) controls whereby at least 99% of cells were 
selected.  
To enquire the stem-like phenotype of the medium HER2 expressing cells, we selected the 
middle 30% of HER2 expressing cells juxtaposed between the high and low HER2 positive cells. 
The resulting marker enrichment was the intermediate of the high HER2 and low HER2 
expressing cells, with MUC1 -ve (23.4%) and EpCAM -ve (28.8%) (Figure 6.7). 
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Figure 6.7: Enrichment of stem markers based on “intermediate” expression of HER2. ~About 30% of 
HER2 medium expressing cells were first gated and thereafter on MUC1 –ve cells, which were further 
gated for EpCAM -ve and CD24 -ve cells. The negative gates were set on relative fluorescence minus one 
(FMO) controls whereby at least 99% of cells were selected. 
To find out the percentage of stem cell markers based on the co-expression of 
MUC1/EpCAM/CD24 -ve proteins in the different subtypes of cells present in the total 
population, we plotted the enrichment of stem cell markers as a percentage value for simple 
visualisation. We see as previously shown that the low HER2 expressing cells have the most 
pronounced stem-like phenotype, followed by cells expressing “medium” HER2 expression.  
 
Figure 6.8: Determining enrichment of stem cell markers in subpopulations of HER2 positive cells. Cells 
were analysed by flow cytometry and HER2 positive cells were divided into three subpopulations of low, 
medium and higher HER2 expression as described above. The enrichment of stem markers is shown as a 
proportion of the total number of cells exhibiting MUC1 -ve, EpCAM -ve, and CD24 -ve phenotype. 
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6.4 Cells enriched for breast stem cell markers are associated with 
increased colony formation in vitro 
 
As different HER2 expression levels correlate with distinct stem cell markers in our model 
based on the three proteins (MUC1, EpCAM, and CD24), where the expression of stem markers 
is especially enriched in the low HER2 expressing cells, we investigated the differences in the 
transformational potential between cells based on HER2 biomarker heterogeneity. The 
expression of HER2 was maintained for 72 hours in the DOX +ve cells and then cells were flow 
sorted based on the expression of HER2 protein. We sorted cells into three groups: the highest 
~20% of HER2 expressing cells, the lowest ~20% of HER2 expressing cells, and the intermediate 
~35% of cells, whilst using DOX -ve and DOX +ve cells as negative and positive controls (Figure 
6.9A). To assess the ability to form colonies of the three sorted cell populations and associated 
controls, we performed soft agar colony formation assay by plating 5000 cells from each group 
in each well containing ultra-pure agarose. Interestingly, we found that the low HER2 
expressing cells had a greater anchorage-independent growth capacity relative to the high or 
medium HER2 protein expressing cells, as they grew more colonies in the semi-solid media 
(Figure 6.9B). 
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Figure 6.9. Anchorage-independent growth of cells based on stem-like phenotype. (A) HER2 expression 
was induced for 3 days and cells were sorted based on HER2 expression into low, medium and high 
HER2 expression. (A) 5000 cells from each condition were plated into ultra-pure agarose to investigate 
their transformational potential over 21 days. N=2. 
In the above experiment, we can see that DOX +ve cells have an enhanced colony formation 
ability compared to the low HER2 expressing cells or the others. However, the DOX +ve and 
DOX -ve cells were not flow sorted again in this experiment. We only FACS separated the DOX 
+ve cells into low, medium and high HER2 expressing cells. However, to make appropriate 
comparisons between the different types of cells, all of them must be subjected to the same 
procedures. To satisfy this, we FACS selected the cells into low, medium and high HER2 
expressing cells, but also sorted the DOX +ve and DOX -ve cells. As previously, 5000 cells were 
then plated onto ultra-pure agarose to measure the anchorage-independency. Similar results 
to the previous experiments were observed. This is because the DOX +ve cells formed the 
highest number of colonies followed by the cells expressing low levels of HER2 (Figure 6.10).    
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Figure 6.10: Measuring transformational potential of cells based on stem-like phenotype. As above, 
HER2 expression was induced for 3 days and cells were separated based on HER2 expression and then 
subjected to soft agar colony formation assay for 21 days. This experiment was performed in 3 technical 
replicates. 
6.5 Investigating oncogene-induced senescence 
 
Our results thus far indicate that high HER2 expressing cells form fewer colonies relative to the 
low and medium HER2 expressing cells. To understand why this was the case, we hypothesised 
that the cells with high HER2 expression undergo senescence, due to a phenomenon known as 
oncogene-induced senescence or OIS. Indeed, OIS has been previously observed with other 
oncogenes, such as Ras (288, 289). The high expression of HER2 is known to drive 
tumourigenesis, but paradoxically can also induce senescence (290). It has been found to 
induce senescence by upregulating various tumour suppressor proteins such as p16 (291). OIS 
is known to upregulate other tumour suppressor proteins such as p53, p27, and p21 (292). To 
test if high HER2 over expression leads to senescence, we carried out western blot analysis on 
proteins known to be upregulated in senescence. We investigated the senescence protein 
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expression in DOX -ve, low HER2, medium HER2, high HER2 expressing and DOX +ve cells. As 
positive controls we used DLD1 (colorectal cell line), expressing p53 and p27 and HCT166 cell 
line (human colon cancer cell line) expressing p53, p27, and p21. Another positive control was 
Naïve hESC (naïve human embryonic stem cells), which are also positive for p53, and NALM6 
(acute lymphoblastic leukaemia (ALL) cell line) which is positive for p27 and p53. From this 
preliminary analysis, we concluded that there was no difference in the expression of proteins 
implicated in OIS. Therefore, high HER2 expressing cells do not induce OIS and so another 
mechanism may be responsible for the low colony growth in agarose. However, the loading 
controls (GAPDH and tubulin) are not equal as the high HER2 expressing have less protein 
loaded compared to other cell types. This analysis requires further attention to ensure 
appropriate conclusions are made (Figure 6.11). 
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Figure 6.11: Investigating oncogene-induced senescence. (A and B) Western blot and densitometry 
analysis of the indicated proteins known to have higher expression in cells that have undergone OIS. 
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Protein lysates were prepared from cells sorted based on HER2 expression as previously (Figure 4.9). 
HER2 was induced in cells for 3 days (DOX +ve cells) and then FACS separated based on HER2 expression 
into three different subtype (low, medium, and high HER2 expressing cells). Cells were grown in culture 
and protein lysates were prepared. DOX -ve and DOX +ve cells were used as controls. DLD1, HCT116, 
Naïve hESC, and NALM6 protein lysates were used as positive controls (n=2).  
As a way to explain why low HER2 expressing cells have a higher anchorage-independent 
growth compared to cells with medium or high HER2 expression, we hypothesised that 
medium and high HER2 expressing cells may have lower signalling activity of the MAPK 
signalling network relative to low HER2 expressing cells, which could be contributing to their 
weakened ability to form colonies. This could be caused by negative feedback loops acting to 
limit MAPK signalling in cells expressing very high levels of HER2 protein. To determine if there 
are differences in signalling between cells expressing varying levels of HER2, we as previously 
induced HER2 protein expression for 72 hours. Cells were serum starved for 24 hours (whilst 
maintaining HER2 expression). Cells were then stimulated for 5 minutes with full growth media 
to activate the signalling and protein lysates were prepared for western blot analysis. The 
preliminary western blot shows that there is no difference in the activation of ERK activity as 
the expression of phospho-ERK remained the same across the different populations. It appears 
that high HER2 expressing cells have lower ERK activation, but that is likely due to the lower 
protein loading as indicated by the lower total-ERK, tubulin and GAPDH protein expression 
(Figure 6.12). However, we consistently observed low levels of protein abundance in the high 
HER2 expressing cells based on the loading controls, despite multiple repeats of protein 
quantifications. This possibly indicates to a biological effect in high HER2 expressing cells, 
potentially during FACS selection, when cells are under stress, with high HER2 cells being more 
affected than other subpopulation of cells.    
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Figure 6.12: ERK phosphorylation in cells expressing differential levels of HER2 protein. (A and B) 
Western blot and densitometry analysis for HER2, phosphorylated-ERK, total-ERK, loading controls 
(GAPDH and tubulin) in cells expressing varying levels of HER2 protein (n=1).  
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One of the earliest and consistent phenotypic alterations observed upon HER2 induction in 
MCF10A cells in this system is the aberrant morphological changes in 3D cell culture. To assess 
this phenotype we cultured the DOX -ve, DOX +ve low HER2, medium HER2, and high HER2 
expressing cells in 3D culture for 3 days. We found that all cell populations were characterised 
by flattened morphology with protrusions, expect for DOX -ve cells that formed normal round 
conformation as previously shown. However, the extent of protrusions was variable between 
the cell types. The DOX +ve cells had the most pronounced invasive morphology, followed by 
the low HER2 expressing cells. To a large extent, the medium and high HER2 expressing cells 
also form aberrant structures, but there were also some normal, round acini as observed in the 
DOX -ve cells, which were absent in the DOX +ve and low HER2 expressing cells (6.13).  
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Figure 6.13: Morphology observed for the labelled cell populations grown in matrigel/collagen. 
Representative fluorescence images of cells cultured in overlay 3D cell culture method for 3 days. Blue: 
nuclear staining with DAPI. Red: Actin staining by phalloidin dye. Magnification: 10X. n=1. 
6.6 Discussion  
 
Our results indicate that in vitro transformation of MCF10A cells as a result of HER2 protein 
over expression results in generation of markers present in stem cells. We find that there is an 
emergence of a subset of cells that have enrichment for markers of stem cells, which may have 
a higher transformational potential. Interestingly, these subpopulation of stem cells marked by 
the decreased levels of MUC1, EpCAM, and CD24 are counterintuitively enriched for low HER2 
protein abundance compared to cells expressing high HER2 protein levels.  
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Since independent clones of HER2 transduced cells resulted in different percentages of cells 
giving rise to the stem-like subpopulation may suggest that the emergence of the stem-like 
phenotype in this model is a stochastic transition, indicating that the behaviours of the cells 
may partly be due the over expression of HER2 but also other unknown intrinsic and/or 
extrinsic factors. This results points to heterogeneous cancer stem cell population as distinct 
subset of cells acquires the capability to present the stem cell phenotype. 
In this system, we have observed that the enrichment for stem-like cells arises three days after 
HER2 protein induction. However, this is an arbitrary time-point we had chosen and have 
continued our subsequent experiments at the three day time point, and we do not know 
precisely when exactly these stem-like cells are emerging. It may be that it arises much earlier 
than the three day time point such as at 24 hours or 48 hours and those time points may be 
associated with a more expanded stem-like phenotype. In that case, we would have missed 
the most critical stage of the transition to stem-like phenotype. Our work so far does not show 
the plasticity of these cells to reprogram back to dedifferentiated cells and cannot yet 
ascertain if these cells expand the stem cell population, or if the transition is static or is 
decreased as the HER2 over expression is maintained for longer. 
As for the high HER2 expressing cells that grow fewer colonies in the ultra-pure agarose, we 
reject our hypothesis based on high HER2 cells inducing OIS. It is conceivable think that 
because there is lack of growth in high HER2 expressing cells, they might be undergoing 
apoptosis as high HER2 expressing cells in isolation may be toxic. It would be interesting to 
study the expression of markers associated with apoptosis such as caspase and PARP. 
Furthermore, it has been shown that non-malignant cells upregulates IRF6 (Interferon 
Regulatory Factor 6) (293), which leads to the blockage of anoikis. Since low HER2 expressing 
cells would -at first thought- be considered closer to normal cells than high HER2 expressing 
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cells, it could be that the low HER2 expressing cells are blocking cell death by the upregulation 
of IRF6 and eventually growing more colonies. However, this remains to be studied. 
Furthermore, we have not yet elucidated the reason why the DOX +ve cells have an increased 
anchorage-independent growth compared to low HER2 expressing cells, despite having 
restricted stem-like phenotype. It may be that when there is a heterogeneous cell population 
(i.e. low, medium, high HER2 expressing cells), they conform to a more aggressive behaviour as 
compared to a more homogeneous cell population (low HER2 expressing cells only). The EMT 
transition between low, med, high HER2 expressing cells will also need to be compared to DOX 
+ve cells, since it could be that the DOX +ve cells undergo EMT to a higher extent than low 
HER2 expressing cells, making them more transformative. Indeed, other characteristics of 
heterogeneity would also need to be studied to understand the true nature of aggressiveness 
between low HER2 cells and the bulk (DOX +ve) cells. It could be that the DOX +ve despite 
forming more colonies would be easily eliminated because it has lower percentage of stem 
cells, whereas the low HER2 expressing cells have fewer colonies, but because of higher 
number of stem cells, would be resistant to therapies. 
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Chapter 7 
 
Discussion 
 
7.1 MCF10A cells – controversial model for breast cancer progression 
 
The MCF10A human breast epithelial cell line provides an opportunity to investigate the 
initiation, development, and progression of breast cancer systematically. This cell line is 
arguably the most commonly used non-malignant breast cell model, as it exhibits 
characteristics of normal breast epithelium, such as dependency on growth factors for survival, 
lack of anchorage-independent growth and formation of acini in 3D cell culture (294, 295). 
These features render MCF10A cells a good model to study the effects of oncogene-induced 
transformation. However, despite not being transformed, the molecular features of MCF10A 
cells include the inactivation of p16 and p14ARF genes, which has allowed spontaneous 
immortalisation of these cells (294). The main objective of our system was to characterise the 
early events in transformation; however, several lines of evidence have shown that 
immortalisation is a prerequisite for transformation (296-298). Immortalisation of cells, which 
disrupts the physiological mechanisms regulating normal proliferation and cell growth, is a 
hallmark of cancer. To achieve the state of immortality, cells must gain additional genetic 
and/or epigenetic alterations, and since MCF10A cells are established to proliferate without 
limit in vitro (298) (by the inactivation of p16 and p14ARF), the initial phase of transformation 
has indeed already taken place before HER2 expression could be induced in our system.  
As a consequence, our model is limited in that it is not possible to characterise the events at 
the very onset of transformation. To overcome this challenge, an alternative model may be 
proposed. Transformation of primary human breast cells can be generated by using an 
inducible oncogene in 3D cell culture to be more physiologically relevant to the human 
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context, which will allow the most appropriate characterisation in vitro of the early events 
upon an oncogenic insult. Indeed, primary breast epithelial cells have been previously 
oncogenically transformed (299-301). However, the accompanying molecular changes using an 
inducible oncogene that has been implemented in breast cancer to transform primary breast 
cells are not yet elucidated.  
Nevertheless, it is recognised that HER2 over expression is not the only aberrant lesion in HER2 
positive breast cancer and other changes such as p53 mutations are observed alongside HER2 
over expression (91). However, p16 inactivation, as is the case in MCF10A cell line, is not an 
early event in HER2 positive breast cancer. This is because HER2 is over expressed in most 
cases of DCIS, but only about 20-30% of invasive ductal carcinomas (IDCs) exhibit over 
expression. These observations establish that HER2 over expression acts as an early event, or 
even as a first hit, which may be followed by a secondary hit – an invasion promoting hit – 
which impacts only a fraction of DCIS cases, and ultimately gives rise to IDCs. In the context of 
MCF10A cells, impaired HER2 expression cannot be the first hit as it is already established that 
MCF10A cell line’s first hit is the inactivation of p16 and p14 ARF locus. Thus, this cell line does 
not follow the canonical progression of breast cancer as is seen in HER2 positive breast cancer 
patients and, therefore, many of the associated molecular events occurring in our model 
system cannot fully recapitulate those observed in patients. 
7.2 Conditional oncogene expression – taking advantage of inducibility 
 
By applying a tightly controlled doxycycline-inducible gene expression model to MCF10A cell 
line, we have further contributed to the improvement of this system, which is commonly used 
to characterise the early carcinogenic alterations and to understand the luminal epithelial cell 
biology. The main advantage of this model lies in the feature that it is inducible, allowing for 
high resolution analysis at the earliest time-points upon HER2 over expression. In our model, 
we introduced the pINDUCER21 (inducible) vector into MCF10A cells, which allow examination 
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of early transformational changes at a high temporal resolution. However, a key caveat when 
transducing cells with an inducible vector is the heterogeneous expression levels of transgene 
within the cell population, due to differences in the position of viral integration (116). Yet, in 
our model system the differences in gene expression levels were not an issue as the 
heterogeneity recapitulates the HER2 positive breast cancer patients better, since HER2 
biomarker heterogeneity has been observed in clinical samples. Furthermore, this allows us to 
compare cells expressing high or low levels of HER2 protein with those cells that do not 
express the HER2 transgene at all, within the same genetic background.  
The pINDUCER21 vector tightly controls HER2 expression under the control of TRE promoter, 
but the GFP is driven by a weak EF1α promoter, which we used to flow-sort cells to obtain only 
those cells that have the vector successfully transduced. However, since the GFP driven 
promoter is weak, we FACS-selected only the 2.3% cells based on GFP expression at high purity 
(approximately 90%), despite the fact that many cells would have had successful transduction. 
MCF10A cells are known to be heterogeneous, expressing various markers for breast stem 
cells, myoepithelial cells, and luminal cells (55), and the decision to select based on such a low 
percentage of cells poses the risk that the native heterogeneity may not be captured. This 
might have a profound effect on the subsequent experiments, making it difficult to make 
meaningful conclusions or comparisons with other systems employing MCF10A cells, especially 
comparisons to clinical samples as the heterogeneity observed in patients may not be 
replicated. 
Although inducible systems allow for stringent control for characterising gene function, cells 
can lose over time the fraction of cells that have been successfully transduced. We found that 
when we cultured cells for an additional 8 passages, the GFP expression was reduced by up to 
30 percent as measured by flow cytometry (Figure 3.2C). This would mean that the expression 
of HER2 is also reduced. Although we have not directly measured the inducibility of HER2 
174 
 
transgene over time, we can indirectly see from our experiments that not all cells express 
HER2 (Figure 3.3). It is documented that tetracycline inducible system gradually lose 
inducibility over time (246). Two possible explanations may be considered: firstly, it could be 
that the 10% non-transduced cells clonally outgrow and outcompete the transduced cells over 
time, and the cells with the successful transduction are progressively lost. Secondly, epigenetic 
silencing may act to inactivate the inducible promoter (tetracycline response element), 
resulting in decreased number of cells with the vector (246). 
Finally, inducible systems require mediators such as tetracycline or its derivative doxycycline to 
induce the expression of the gene of interest. However, the use of these antibiotics can have 
confounding off targets effects at concentrations commonly used in inducible systems, from 
100ng/ml to 5µg/ml. It has been identified that the use of dox in cell lines, including the 
MCF10A cell line, can decrease the proliferation of cells and induce metabolic gene expression 
alterations (302). This could have notable effects on the various phenotypic changes we have 
observed to characterise transformation. For instance, upon HER2 over expression, we have 
seen morphological changes in 3D cell culture, higher migration and invasion potential, and the 
formation of colonies in agarose, which all rely on proliferation to a partial extent. We would 
assume that the addition of dox may have significantly reduced the extent of the phenotypes 
observed. This is because these phenotypes – without dox addition and with sole HER2 over 
expression – would be more pronounced and with the introduction of dox have been 
decreased to a certain level. Therefore, the true extent of HER2 transformational drive may 
not be appropriately characterised. 
7.3 HER2 induced phenotypic alterations  
 
Using wild-type HER2 over expression as a model oncogene, we have further confirmed that 
aberrant ectopic expression of HER2 in MCF10A cells can alter the morphology, 
migration/invasion potential, and their ability to carry out metastatic properties by growing in 
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the semi-solid media (3, 239). These features can only be exhibited by cells that have 
undergone transformation. MCF10A cells cultured in matrigel/collagen develop important 
characteristics of normal mammary tissue, which can be manipulated by HER2 over 
expression. We provide evidence of the dramatic disruption of the normal architecture of 
MCF10A cells to produce morphological protrusions similar to the ones observed in early pre-
malignant mammary lesions by means of HER2 over expression alone. However, 3D cell 
cultures are simplified microenvironments with reduced complexity compared to in vivo 
models, but they are still useful for mechanistic studies in transformation. Our observations 
are in full agreement with previous reports showing the elongated, larger and less cohesive 
features of MCF10A acini upon oncogene expression, whereas normal cells retain organised, 
spherical conformation (55, 295, 303-306). An essential feature of early breast cancer is the 
repopulation of the lumen with cancer cells (57). It would have been useful to allow the DOX -
ve cells to form the lumen as it occurs in normal MCF10A cells after day 10. This could have 
been followed by the induction of HER2 to study if the lumen formation occurs as a result of 
HER2 expression. This phenotype would be useful to have been seen by a live imaging system 
such as an incuCYTE microscope to pinpoint the time it takes for HER2 to induce this 
phenotype.  
Another neoplastic characteristic of transformed cells is the induction of migration and 
invasion of cells into the surrounding tissues. Likewise, the migratory and invasive features are 
in line with previous studies that show that constitutive expression of HER2 results in higher 
migration and invasion potential (48, 307, 308). We have shown that MCF10A cells with HER2 
over expression (DOX +ve cells) are able to grow colonies in semi-solid media, which to an 
extent represents metastasis in vivo as cells are moved from their normal microenvironment 
to reside in an unsuitable one. However, the variation in performing the technical aspects of 
the assay and the individual quantification methods employed make it challenging to draw 
comparisons between our results and of the previous studies. For instance, in our experiments 
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we used 0.3% ultra-pure agarose to measure anchorage-independent growth of cells, whereas 
the type of matrix and its percentage can vary between different experiments, such as the use 
of noble agar (ultra-pure gelling agent) in this study (53). Another variation involves methods 
introduced to count the number of colonies. This could be overcome by the incorporation of 
fluorescent dye to enable high throughput counting. Furthermore, specialised soft agar or 
agarose solution could be used to facilitate the isolation of viable cells for easy counting after 
the assay end point to allow for protein, DNA and RNA samples to be prepared if required. 
Although the assays we have performed show the transformative behaviour of cells as a result 
of HER2 over expression, there are other aspects of transformed cells that could also be 
investigated such as foci formation capability of cells and the ability of cells to survive and 
proliferate in reduced growth factor media (6). 
One of the most fundamental and useful piece of information missing from transformational 
models in general is the question; how long does it take for cells to become fully transformed 
upon induction of an oncogene? The inability to answer this question may largely be attributed 
to the use of non-inducible systems and of normal versus cancer cells, because the timing of 
gene induction is not known. However, it appears that even inducible gene expression systems 
cannot answer this difficulty properly. For instance, we have seen in our model that the 
morphological alterations occur within three days of HER2 over expression, that the cells can 
migrate/invade after five days of HER2 induction, and that the anchorage-independency is 
acquired within the 21 days. However, this does not inform when cells attain full 
transformation in vitro, even though we know that by day 21 the cells have transformed 
relative to the normal cells according to the soft agar assay. It could be that cells gain 
migratory and invasive phenotype earlier than 5 days, it is just that we measured 
migration/invasion of cells at 5 day time point, and that the cells gain anchorage independency 
earlier than 21 days. However, we do not yet know if this phenotype is attained earlier in 
177 
 
transformation. The advantage of knowing when full transformation is achieved in cells could 
give us clues to perform the molecular analysis at the right and most relevant time points. For 
example, if complete transformation was reached by day 5, then the molecular analysis time 
points could be spread out to encompass full transformation without uncertainty, preventing 
the characterisation of molecular analysis from time points that are not in our objectives. 
Nevertheless, cellular transformation could sometimes be an ambiguous term and its proper 
definition is important in understanding what can be classified as transformed or not. For 
example, overexpression of cyclooxygenase 1 in spontaneously immortalized human umbilical 
vein endothelial cells were not anchorage-independent but grow tumours in vivo aggressively 
(309). These cells would be classified as transformed despite not growing colonies in soft agar 
because they are able to induce a more significant event, which is to grow tumours in mice. In 
another case, human primary foreskin fibroblasts attained anchorage-independent and grew 
tumours in vivo but were able to indefinitely proliferate in cell culture (310). Moreover, the 
human papilloma virus 16 E6 oncogene was sufficient to induce anchorage-independent 
growth but did not generate tumours when injected into mice (311). Therefore, 
transformation of cells is dependent on a number of factors and experimental settings, such as 
in vivo or in vitro work, the types of analysis performed, relative controls, and the types of 
analysis performed.  
7.4 The signalling dynamics – taking a global approach 
 
Our global phosphoproteomic study extends the knowledge of signalling induced by HER2 over 
expression by identifying previously uncharacterised downstream signalling proteins. In this 
experimental setting, we carried out a mass spectrometry screen under standard growth 
conditions as opposed to in response to acute external stimuli to faithfully mimic the 
physiological impact of HER2 expression at short time points after induction. We have also 
identified previously unknown phospho-peptides which include LAP3 (R440), HIPK1 (Y352), and 
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GPX1 (S153). Whilst it is extremely valuable to understand the early signalling changes upon 
HER2 protein over expression and cellular transformation, the screen is restricted to the short 
term effects of HER2 expression and may overlook the secondary effects which could rely on 
the transcription and translation of regulatory proteins.  
A limitation of our investigation is the identification of a relatively modest number of 
phosphopeptides from our analysis. Our dataset shows approximately 4000 proteins with one 
or more phosphosite, which is lower than published reports of 7500 and 7214 phosphosites 
respectively (312-315). Furthermore, another limitation of this study is the reliance on the 
phosphoproteome of cells, without focusing on changes in protein abundance. In the absence 
of in-depth proteomic analysis, we cannot distinguish if the alterations in the 
phosphoproteome of our cells are a result of the protein phosphorylation stoichiometry or due 
to differential levels of total protein expression. However, it could be that it is primarily the 
activation of proteins (via phosphorylation) rather than total protein expression that may be 
vital for the regulation of molecular mechanisms involved in transformation (316). 
Our phosphoproteomic analysis finds that, upon HER2 over expression in all the time points we 
have studied, approximately 20% of the phosphoproteome is significantly changed. Although 
not directly relevant, this is in contrast to the gastric cell line which displayed that 5% of the 
phosphoproteome was significantly altered compared to the parental cell line (317). In 
another case, GIST cell line showed approximately 75% of the phosphoproteome altered 
versus the parental cell line (318). One reason for these differences could be the underlying 
genomic drivers introduced between different cell lines. Another contributing factor may be 
that the depth of the phosphoproteome coverage is less comprehensive in our study and that 
we are only examining the phosphopeptides with the highest abundance in our cells. Finally, it 
could be that receptor tyrosine kinases (such as HER2), reprogramme signalling networks to 
achieve transformation using distinct set of mechanisms.  
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As expected, one the largest increases of phosphorylation was seen in the HER2 (at T701 and 
T1060) itself, because as we add dox, the levels of HER2 proteins increase and hence a higher 
fold change was observed. The fold change was some 6-fold more in the 7 hour time point 
compared to the 0.5h one. This is because the longer the cells were cultured in dox-containing 
media, the higher the time-dependent expression of HER2. This may mean that with higher 
protein abundance, HER2 can increasingly homodimerise and transmit potent signals 
downstream, as they do not rely on a ligand to induce active signalling due to their open 
extracellular conformation. Furthermore, as HER2 expression increased, counterintuitively 
there was a higher number of differentially regulated phosphopeptides observed. For instance, 
phosphopeptides that had differential levels of phosphorylation at the 0.5h time point were 
310, at 4h time point they were 390, which increased to 455 at the 7h time point. This shows 
that higher HER2 expression is likely to change phosphorylation status of an increasing number 
of proteins. A rather simple observation maybe put forward: it is well known that the higher 
grade tumours (3+) of HER2 positive breast cancers are more aggressive due to the higher 
expression of HER2 protein expression as assessed by IHC. It is therefore conceivable to think 
that one of the reasons why they behave aggressively is the result of widespread activity in the 
signalling networks amongst other changes. 
Amongst the earliest changes detected at the 0.5h time point upon HER2 protein over 
expression are the downregulation of phosphopeptides involved in cell-cell junction and 
adherens junctions, these phosphopeptides include: LMO7 (S988), which is downregulated at 
all time points, but also include CTND1 (T869), AKT2 (T451), and TLN1 (S488), amongst other 
changes. This is consistent with the observed phenotypic alterations, such as the 
morphological changes in 3D cell culture and anchorage-independent growth of cells. 
To capture the dynamics and complexity of the signalling networks upon HER2 over 
expression, a cocktail of ligands should be used which could include heregulin (HRG), neregulin 
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(NRG), TGFα, EGF, and epiregulin. These would induce dimerisation of all possible 
combinations between the various family members of HER receptors. This is unlike the 
addition of EGF ligand alone, as in our case, which induces homodimerisation between HER1-
HER1 and heterodimerisation between HER1-HER2. Notably, it is already known that 
stimulation by HRG activates a specific subset of the migration signalling network that is not 
induced by EGF (319). Nevertheless, the advantage of introducing a single ligand, such as EGF 
allows us to attribute the signalling changes to one factor without ambiguity from other 
ligands.   
While the phosphoproteomic layer of protein regulation provides valuable and descriptive 
insight to the process of transformation, the challenge is that the results are not readily 
interpretable or actionable. For instance, we identified that a handful of signalling cascades are 
affected upon HER2 protein over expression, which may suggest that administration of specific 
kinase inhibitors could be used as a therapy, it does not reveal the complete mechanism of 
transformation. Nevertheless, there have been successful instances such as in Zeevi et al (320), 
where they employed an ‘-omics’ dataset, patient data, and machine learning to implement a 
change in nutrition to regulate glucose levels, without deep insight of the mechanism. 
However, in the majority of cases, the absence of mechanistic information of disease 
progression makes it challenging to find targets for therapeutics with reliability. In order to 
move away from the ‘big picture’ provided by the phosphoproteomic data to investigate a 
testable hypothesis, it is documented that signal transduction pathways can modulate 
chromatin structure. To study the relationship between important signal transduction 
pathways and the chromatin architectural landscape in transformation, we have performed 
ATAC-seq analysis at similar time points to our phosphoproteomic study to analyse the link 
between cell signalling and chromatin structure. Interestingly, we have seen that in our system 
the MAPK signalling pathway, which is known to regulate gene expression at multiple levels, is 
the dominant cascade by which signalling is transduced. Among the downstream targets of the 
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MAPK signalling pathway, the MAPK5 and MAPK1 are of interest as they are able to directly 
target several transcription factors such as NFkB and ELK-1, which can in turn induce 
phosphorylation of Histone 3 and HMG-like proteins known to have an effect on chromatin 
accessibility (321, 322). We have observed from our dataset that various transcription factors 
and chromatin regulators become phosphorylated, and these include NFkB at (T811) and 
phosphorylation changes in various HMG phosphosites (such as HMG4BX [S497] and HMGA1 
[T53 and S36]) amongst many others, which could potentially have an effect on the chromatin 
architecture. 
7.5 Multiple layers of heterogeneity in breast cancer 
 
We have shown that a sub-population of potentially cancer stem cells can emerge during the 
processes of cellular transformation by inducing the expression of HER2 protein. This subset of 
cells is uniquely marked by the absence of markers known to be either low or absent in breast 
stem cells, which include MUC1, EpCAM and CD24. Interestingly, we also identified that 
different HER2 expression levels coincide with distinct expression of stem markers, with the 
low HER2 expressing cells, unexpectedly, being the most enriched for stem cell markers 
compared to medium or high HER2 expressing cells. 
We used a combination of well-known cell surface markers of MUC1/EpCAM/CD24 
low/negative that is associated with stem cells (154, 323, 324). These markers individually 
have been implicated in stem and cancer stem cells, but their co-expression to identify stem-
like phenotype to date has not yet been investigated. Nevertheless, there are other (cancer) 
stem markers known to be associated with stem-like phenotype, such as the high expression 
of ALDH1 (325, 326), high expression of CD44 and low expression of CD24, which together 
have been used as cancer stem cell markers in mammary cells (327-329). 
Our findings are in line with previous investigations that have shown that EpCAM and CD24 
negative or low-expressing cells are associated with mammary stem cells (330, 331). However, 
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it is the over expression of MUC1, rather than its decrease in protein abundance, that has been 
associated with worse prognosis in breast cancer (332). The upregulation of MUC1-C subunit is 
known to increase phospho-AKT and results in resistance to tamoxifen in breast cancer (333). 
Elevated expression of MUC1 has also been shown to be preserved in cancer stem cell 
population in luminal breast cancer cell lines (334). It seems that MUC1 has a multifaceted role 
in transformation, being associated with higher transformational potential when over 
expressed, but also, in our case, found to be associated with enhanced in vitro 
transformational properties when lowly expressed, jointly with EpCAM and CD24. 
Interestingly, reduced EpCAM expression is not only found in stem cells, but also in cells that 
display EMT phenotype (335). 
In our experimental setting thus far, our approach to identifying stem-like phenotypic features 
was confined to considering the expression of markers enriched in stem cells. However, other 
potential mechanisms could be applied to identify, or at least confirm, the cells acquiring 
stemness. For instance, it is known that the rate of cell cycle of stem cells versus differentiated 
cells is different (336). It is identified that stem cells have a faster G1 phase of the cell cycle 
compared to differentiated cells (336). Furthermore, it would be useful to identify epigenetic 
signatures of stem cells compared to differentiated cells. It has already been found that the 
expression of EZH2, a core subunit of the PRC2 complex, can activate NOTCH1 signalling by 
binding to the NOTCH1 promoter and activating its signalling, which enhances the stem cell 
phenotype of cells (337). This is unprecedented, since EZH2 is normally known to have a 
suppressive role rather than activating one. 
The identification of an expanded stem-like phenotype based on the MUC1/EpCAM/CD24 -ve 
expression and its association with low HER2 expressing cells in our system is a novel finding. 
This is because in HER2 positive cancers, high HER2 expression is associated with higher 
tumour grade and aggressive disease, and in turn worse prognosis and survival (338, 339). 
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Since it is known that the upregulation of stemness in cancer cells is associated with higher 
transformational potential (340), we would have expected that stem-like phenotype would be 
more highly enriched in the high HER2 expressing cells compared to the low or medium HER2 
expressing cells. However, an observation may be made here; it is known that patients with 
high HER2 expressing cells (tumour grade 3+) tend to respond better to anti-HER2 therapy 
(341) compared to patients expressing borderline HER2 expression (tumour grade 2+) (342). 
This is partly attributed to HER2 regional biomarker heterogeneity. However, since cancers 
with upregulated stem-like phenotype are at the forefront of resistance to therapies, it is 
conceivable to think that part of the reason why the borderline HER2 positive breast cancer 
patients do not respond well to treatment is their expanded stemness, just as we have 
observed in our system compared to high expressing cells. To test this hypothesis, low, 
medium and high HER2 expressing cells could be separated and treated with trastuzumab or 
lapatinib to study what levels of HER2 confer higher levels of resistance to inhibition. 
Furthermore, if the low HER2 expressing cells have more stemness – and considering that 
normal MCF10A cells have even lower levels of HER2 expression than the low HER2 expressing 
cells in the DOX +ve cells – it is logical to assume that MCF10A cells would have an even higher 
stem-like phenotype. However, the normal MCF10A cells (or the DOX -ve cells) did not have a 
MUC1/EpCAM/CD24 -ve phenotype. This shows that the low HER2 expressing cells have co-
occurring aberrant alterations that make the cells acquire the stem-like phenotype. 
7.6 HER2 over expression – what does it mean in the context of patients? 
 
In the context of HER2 positive breast cancer patients, protein and gene expression levels 
provide critical information, as they act as predictive markers to diagnose patients based on 
biomarker expression. It is not clear, for example, whether the borderline (2+ grade) tumours 
have undergone complete neoplastic transformation or whether only the patients with 3+ 
grade tumours have full malignant transformation. Although not directly comparable to the 
184 
 
context and complexity observed in patients, a minimal and consistent increase in HER2 
expression, as shown in our study, seems sufficient to induce transformation as measured by 
our in vitro assays. This raises the possibility of 3+ grade tumours undergoing additional 
changes (such as further HER2 amplification) that make them more aggressive. Nevertheless, 
the prognostic significance of the low-expressing HER2 positive cancers, such as 1+ grade 
tumours, which are generally regarded as HER2 negative alongside 0 grade tumours as 
assessed by IHC, have not yet been properly evaluated. One of the main reasons for not 
appropriately evaluating the prognostic value of low level HER2 expression is because the 
investigators generally group the 0+ and 1+ tumours categories together, assuming in advance 
that low level HER2 expression may not be clinically significant, despite systems such as ours 
showing that it may be sufficient to progress cancer. Additionally, many of these studies were 
published before the 0-3+ scoring system was clinically established by IHC. The HER2 positivity 
was defined by protein expression or by gene amplification above a given threshold by 
western blotting, or by immunostaining (343-349). Furthermore, it has been assumed that 
patients with low levels of HER2 expression many not benefit from targeted treatments such 
as trastuzumab, but existing data with regards to the low levels HER2 expression and their 
response to trastuzumab are contradictory and limited in number. For instance, in an 
evaluation by the National Surgical Breast and Bowel Project (NSABP) B-31, which looked at 
161 patients found to be negative for HER2 expression by IHC and FISH. In this group of 
patients, the rate of relapse in patients treated with chemotherapy and trastuzumab versus 
chemotherapy alone was 8% and 21% respectively (350). In another similar study, in patients 
that were classified as HER2 negative both by IHC and FISH, the relapse rate of patients treated 
with chemotherapy and trastuzumab compared to chemotherapy alone was 15% and 30% 
respectively (348). However, the HER2 negative patients in the CALGB 9840 trial had a better 
response rate to chemotherapy and trastuzumab versus chemotherapy alone (35% versus 
29%), but that was not significant (103). This points to the potential for low HER2 expressing 
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patients – generally thought as being negative – also benefitting from anti-HER2 therapy. 
Therefore, low levels of HER2 expression, in an in vitro system as we describe here, are critical 
in understanding how we define HER2 positivity and could provide us with a useful 
understanding of how low HER2 expressing breast cancer behaves. However, it should be 
emphasised that our investigation is at the hypothesis-generating stage, and should be 
extended further in order to aid our understanding of HER2 positive breast cancer. 
Our model presented here is yet to be tested alongside primary HER2 positive breast cancer 
patient samples. Since the HER2 over expression in our system is low, it would valuable to test 
the HER2 gene and protein expression are similar to clinical samples from HER2 breast cancer 
patients with 0, 1+, 2+, and 3+ graded tumours. I would hypothesise that the HER2 expression 
levels would be similar to those observed in 1+ graded tumours. Based on the current HER2 
assessments performed by IHC, the HER2 protein expression would be classified as normal in 
our system. However, as we have shown that such low levels of HER2 expression is sufficient 
to induce transformation and global changes in the signalling network as well as genome-wide 
changes in the epigenome. Another layer of complexity arises when such patients are not 
considered to be treated with HER2 targeted therapy, as the 1+ graded patients are seen as 
the “bystanders”. If some of the work presented here could be replicated in a more 
physiologically relevant setting, such as in vivo work or the same levels of HER2 expression in 
primary breast cells, we could present a case for questioning the current practice of not 
treating 1+ graded tumours with anti-HER2 therapies. Especially when drug related toxicities of 
treating low HER2 expressing patients with anti-HER2 therapies are mild (351). This would be 
particularly useful for patients that present heterogeneous population of HER2 positivity. If 
potentially clear significant and compelling evidence is found that low HER2 expressing cells do 
not indeed benefit from anti-HER2 therapies, then at least an alternative method of 
therapeutics may be suggested for the 1+ scored tumours.  
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